STAT6 inhibitors and methods of use thereof

Abstract

The present invention relates to novel compounds (I') which inhibit the Signal Transducer and Activator of Transcription protein 6 (STAT6). This invention also relates to pharmaceutical compositions containing them, processes for their preparation and their use in the treatment of several disorders.

Description

[0001] STAT6 INHIBITORS AND METHODS OF USE THEREOF FIELD OF THE INVENTION The present invention relates to novel compounds which inhibit the Signal Transducer and Activator of Transcription protein 6 (STAT6). This invention also relates to pharmaceutical compositions containing them, processes for their preparation and their use in the treatment of several disorders. BACKGROUND OF THE INVENTION Signal Transducers and Activators of Transcription (STAT) are a family of transcription factors regulated by phosphorylation which play a key role in the signaling of several cytokines dependent on Janus kinases (JAK) activity. Cytokine-dependent JAK phosphorylation of STAT induces STAT homodimerization through SH2 domains and nuclear translocation to the nucleus where they regulate gene transcription through binding to the promoters of specific target genes. Although JAK play an important role in STAT activation, additional mechanisms also can play a key role in STAT regulation including phosphorylation by alternative protein kinases, acetylation, methylation, or ubiquitination among other mechanisms. STAT6 is activated by interleukin-4 (IL-4) and IL-13 cytokines which mediate STAT6 phosphorylation and translocation to the nucleus where it can bind to specific DNA sequences, thereby regulating the expression of target genes. Other cytokines such as IL-3, IL-15, interferon α (IFNα), growth factors such as platelet-derived growth factor (PDGF) or stimulator of interferon genes (STING) agonists can also activate STAT6. STAT6-mediated signaling pathway is required for the development of T-helper type 2 (Th2) cells and type II immune responses. Expression of Th2 cytokines, including IL-4, IL-13, and IL-5 is reduced in STAT6-deficient mice in comparison to wild-type mice. In preclinical models of allergic skin inflammation, STAT6-defient mice show inflammation amelioration, decreased expression of type II cytokines such as IL-4 or IL-5, lower immunoglobulin E (IgE) levels and preserved skin barrier function. STAT6 also plays a key role in preclinical models of asthma, and STAT6- / -mice are protected against developing lung inflammation and express lower levels of IL-4 and IL-5 than STAT6+ / +mice. In humans, STAT6 gain of function mutations (for instance p.D419H, p.E377K or p.D419N mutations) are associated with severe atopic dermatitis, food allergy and eosinophilic asthma highlighting the role of STAT6 in type II immunity. In addition, different polymorphisms of the STAT6 gene are associated to a higher risk of suffering atopic diseases. STAT6 controls different pathophysiological mechanisms key for the development of atopic and allergic diseases such as Th2 differentiation through controlling the expression of GATA3 gene, Ig class switching to IgE, macrophage polarization to M2 macrophages, differentiation of cytotoxic T cells type 2 (Tc2) for Tc2 cell production of IL-4, IL-13 and IL-5 and production of pro-inflammatory cytokines such as TARC by dendritic and monocytes / macrophages. STAT6 expression is also dysregulated in certain forms of lymphomas such as in the Hodgkin lymphoma group, primary mediastinal and primary central nervous system lymphoma, as well as some follicular and T cell lymphomas, and mutations in STAT6 gene have been shown in some of these patients. High levels of P-STAT6 are also found in cutaneous cell lymphomas (CTCL) and in CD4+Sezary syndrome (SS) T cells, and STAT6 regulates several common pathways in CTCL / SS malignant lymphocytes that are associated with control of cell-cycle progression and genomic stability as well as production of Th2 cytokines. SUMMARY OF THE INVENTION The present inventors have identified novel compounds which are inhibitors of STAT6. Such compounds typically exhibit low lipophilicity, and good permeability. The present invention therefore provides a heterocyclic compound, which heterocyclic compound is a compound of formula (I') or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof, for use as a medicament, (I') wherein • R1is C1-C6haloalkyl, −L'−Z, −L'−C(O)Ry, −L'−C(O)NRiRy, −L'−C(O)OH, −L'−C(O)ORy, −L'−NRiC(O)Ry, −L'−SO2NRiRy, or −L'−Het, wherein Het is 4- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl, wherein said heterocyclyl is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, oxo, C1- C6alkyl, C1-C6haloalkyl, −L'−ORiand −L'−NRiRii, and said heteroaryl is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, C1-C6alkyl, C1-C6haloalkyl, −L'−ORiand −L'−NRiRii; Z is selected from −ORi, −NRiRyand −SRi; Ryis C1-C6alkyl, C1-C6haloalkyl, phenyl, 3- to 7-membered carbocyclyl, 5- to 7-membered heteroaryl or 4- to 7-membered heterocyclyl, wherein said carbocyclyl and heterocyclyl are unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, oxo, C1- C6alkyl, C1-C6haloalkyl, −L'−ORiand −L'−NRiRii, and said phenyl and heteroaryl are unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, C1-C6alkyl, C1-C6haloalkyl, −L'−ORiand −L'−NRiRii; Riand Riiare the same or different and are selected from hydrogen, C1-C6alkyl and C1-C6haloalkyl; and L' is a direct bond, C1-C6alkylene or C1-C6haloalkylene; • R2is hydrogen, C1-C6alkyl, C1-C6haloalkyl, −L''−Z', −L''−C(O)Rz, −L''−C(O)ORz, −L''−C(O)NRiiiRz, −L''−C(O)NH2, −L''−NRiiiC(O)Rz, −L''−NRiiiC(O)ORz, −L''−NRiiiC(O)NRivRz, −L''−NRiiiC(O)C(O)NRivRz, −L''−NRiiiSO2Rz, −L''−(4- to 10- membered heterocyclyl), or −L''−(5- to 7-membered heteroaryl), wherein said heterocyclyl is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, oxo, C1-C6alkyl, C1-C6haloalkyl, −L''−ORiiiand −L''−NRiiiRiv, and wherein said heteroaryl is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, C1-C6alkyl, C1- C6haloalkyl, −L''−ORiiiand −L''−NRiiiRiv; wherein Z' is selected from −OH, −ORiii, −NH2, −NRiiiRzand −SRiii; Rzis C1-C6alkyl, C1-C6haloalkyl, −Q''−Z', −A−A', −Q'−A−A', or −A−Q''−A, wherein A is phenyl, 3- to 7-membered carbocyclyl, 5- to 7-membered heteroaryl or 4- to 10-membered heterocyclyl, wherein said carbocyclyl and heterocyclyl are unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, oxo, cyano, C1-C6alkyl, C1-C6haloalkyl, −L''−ORiii, −L''−NRiiiRiv, and −L''−C(O)NRiiiRiv, and said phenyl and heteroaryl are unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, cyano, C1-C6alkyl, C1-C6haloalkyl, −L''−ORiii, −L''−NRiiiRiv, and −L''−C(O)NRiiiRiv; A' is hydrogen, phenyl or 4- to 8-membered heterocyclyl, wherein said phenyl is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, C1-C6alkyl, C1-C6haloalkyl, 3- to 7-membered carbocyclyl, 4- to 7-membered heterocyclyl, −L''−ORiii, and −L''−NRiiiRiv, and said heterocyclyl is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, oxo, C1-C6alkyl, C1-C6haloalkyl, 3- to 7-membered carbocyclyl, 4- to 7-membered heterocyclyl, −L''−ORiii, and −L''−NRiiiRiv; Q' is C1-C6alkylene, C1-C6haloalkylene, or −Q''−O−L''−; Q'' is C1-C6alkylene or C1-C6haloalkylene; L'' is a direct bond, C1-C6alkylene or C1-C6haloalkylene; Riiiand Rivare the same or different and are selected from hydrogen, C1-C6alkyl and C1-C6haloalkyl; or R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety; and • G1and G2are the same or different and are selected from phenyl, naphthyl, 4- to 10- membered heterocyclyl, 5- to 10-membered heteroaryl, or 4- to 10-membered carbocyclyl, wherein said heterocyclyl and carbocyclyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1- C4haloalkyl, oxo, and −LG−ORG, and wherein said phenyl, naphthyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, and −LG−ORG, wherein LGis a direct bond, C1-C6alkylene or C1-C6haloalkylene; and RGis selected from hydrogen, C1-C6alkyl and C1-C6haloalkyl; • Y is methylene or −C(O)−, wherein said methylene is unsubstituted or substituted by C1-C4alkyl, C1-C4haloalkyl, halogen or hydroxy; • X1is C or N; m is 0 or 1; X2and X3are the same or different and are selected from N, NR' and CR'', and X4is selected from N, NR' and CR'''; provided that when m is 0, either (a) at least one of X2and X4is NR', and X1is C, or (b) X2is selected from N and CR'' and X4is selected from N and CR''', and X1is N; and when m is 1, X1is C, X2and X3are the same or different and are selected from N and CR'', and X4is selected from N and CR'''; wherein R' is hydrogen or C1-C4alkyl; R'' is hydrogen, C1-C4alkyl or halogen; and R''' is hydrogen, C1-C4alkyl, halogen, C1-C4haloalkyl, cyano or 3- to 5-membered carbocyclyl; • L1is −C(O)NRv−Q−, −L1'−NRv−Q−, or −Het'−Q−, wherein Q is a direct bond, linear or branched C1-C6alkylene, or linear or branched C1-C6haloalkylene, wherein said alkylene and haloalkylene are unsubstituted or substituted by a hydroxy group; L1' is a direct bond, linear or branched C1-C2alkylene, linear or branched C1- C2haloalkylene or 4- to 6-membered heterocyclylene; Het' is a 4- to 6-membered heterocyclylene group or a 5- to 6-membered heteroarylene group, which group is unsubstituted or substituted by one, two or three C1-C3alkyl groups which are the same or different; and Rvis hydrogen or C1-C3 alkyl; • Raand Rbare the same or different and are selected from C1-C4alkyl or C1-C4haloalkyl; or Raand Rbtogether with the carbon to which they are attached form a 3- to 7- membered carbocyclyl moiety or 4- to 7-membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl; • Rc and Rd are the same or different and are selected from hydrogen and C1-C4 alkyl, or Rcand Rdtogether are oxo; • Reand Rfare the same or different and are selected from hydrogen, halogen, C1-C4alkyl and C1-C4haloalkyl; and • n is 0 or 1. The invention also provides a compound which compound is (a) a heterocyclic compound of formula (I'), wherein R1, R2, G1, G2, Y, X1, X2, X3, X4, L1, Ra, Rb, Rc, Rd, Re, Rf, m and n are as defined herein; or (b) a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative of said heterocyclic compound, provided not: [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5- fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [3-[[5-Fluoro-2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5- dimethyl-1-piperazinyl]methanone; [3-[(2-Ethyl-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[(2-Ethyl-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(2-methoxyethyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[[5-Fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(2- ethyl-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[[5- fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(2- ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[[2- (ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl][3-[(2-ethoxy- 5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol- 5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl][3-[[2- (ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [4,6-Dihydro-6,6-dimethyl-3-[[4-(trifluoromethyl)-2-pyrimidinyl]amino]pyrrolo [3,4-c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1- piperazinyl]methanone; [4,6-Dihydro-6,6-dimethyl-3-[(4-methyl-2-pyrimidinyl)amino]pyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1- piperazinyl]methanone; [4,6-Dihydro-6,6-dimethyl-3-[(4-methyl-2-pyrimidinyl)amino]pyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1- piperazinyl]methanone; [4,6-Dihydro-3-[(4-methoxy-2-pyrimidinyl)amino]-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1- piperazinyl]methanone; [3-[[2-(Ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5- dimethyl-1-piperazinyl]methanone; [3-[[2-(Ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethyl pyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5S)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[(5-Fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo [3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-hydroxypropyl)-2,5-dimethyl-1-piperazinyl] methanone; [3-[(5-Fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo [3,4-c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl] methanone; [3-[(5-Fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4- dimethyl-1-piperazinyl]methanone; [3-[[2-(Ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(2-methoxyethyl)-2,5- dimethyl-1-piperazinyl]methanone; [3-[(4-Ethoxy-2-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[(5-Fluoro-2-methoxy-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl- 1-piperazinyl]methanone; [3-[(5-Fluoro-2-methoxy-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4- dimethyl-1-piperazinyl]methanone; [3-[[5-Fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl- 1-piperazinyl]methanone; [3-[[5-Fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4- dimethyl-1-piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [(2S,5R)-2,5-Dimethyl-4-(3,3,3-trifluoropropyl)-1-piperazinyl][3-[(2-ethyl-5- fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol- 5(1H)-yl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][1-(3,3,3-trifluoropropyl)-4-piperidinyl]methanone; [(2S,5R)-2,5-Dimethyl-4-(3,3,3-trifluoropropyl)-1-piperazinyl][3-[[2-(ethylamino)- 5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol- 5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(3,3,3-trifluoropropyl)-1-piperazinyl][3-[(2-ethoxy-5- fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol- 5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl][3-[(5-fluoro-2- methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol- 5(1H)-yl]methanone; Methanone, bis[3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]-, hydrate (1:1); Methanone, bis[3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]-, with 2-propanol (1:1); [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-1- piperazinyl][3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-1- piperazinyl][3-[(2-ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [3-[(4,6-Dimethyl-2-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1- piperazinyl]methanone; [4,6-Dihydro-3-[(4-methoxy-2-pyrimidinyl)amino]-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1- piperazinyl]methanone; Methanone, [3-[[2-(ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5- dimethyl-1-piperazinyl]-, acetate (1:1); [3-[(2-Ethoxy-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]methanone; [2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5-fluoro-2- methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol- 5(1H)-yl]methanone; Methanone, [3-[(2,5-difluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl pyrrolo[3,4-c]pyrazol-5(1H)-yl][(2R,5S)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4- yl)methyl]-1-piperazinyl]-, relative stereochemistry; Bis[3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo [3,4- c]pyrazol-5(1H)-yl]methanone; or [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S)-2-methyl-4-[(tetrahydro-4-hydroxy-2H-pyran-4- yl)methyl]-1-piperazinyl]methanone. DETAILED DESCRIPTION OF THE INVENTION When describing the compounds, compositions, combinations and methods of the present invention, the following terms have the following meanings, unless otherwise indicated. Definitions The term "therapeutically effective amount" refers to an amount sufficient to effect treatment when administered to a patient in need of treatment. The term "treatment" as used herein refers to the treatment of a disease or medical condition in a human patient which includes: (a) preventing the disease or medical condition from occurring, i.e., prophylactic treatment of a patient; (b) ameliorating the disease or medical condition, i.e., causing regression of the disease or medical condition in a patient; (c) suppressing the disease or medical condition, i.e., slowing the development of the disease or medical condition in a patient; or (d) alleviating the symptoms of the disease or medical condition in a patient. As used herein, the term “pharmaceutically acceptable salt” refers to a salt prepared from a base or acid which is acceptable for administration to a patient, such as a mammal. Such salts can be derived from pharmaceutically-acceptable inorganic or organic bases and from pharmaceutically-acceptable inorganic or organic acids. As used herein, a N-oxide is formed from the tertiary basic amines or imines present in the molecule, using a convenient oxidising agent. As used in the present invention, the term tautomer means two or more forms or isomers of an organic compound that readily could be interconverted into each other via a common chemical reaction called tautomerization. This reaction commonly results in the formal migration of a hydrogen atom or proton, accompanied by a switch of a single bond and adjacent double bond. The concept of tautomerizations is called tautomerism. Because of the rapid interconversion, tautomers are generally considered to be the same chemical compound. In solutions in which tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent and pH. The compounds of the invention may exist in both unsolvated and solvated forms. The term solvate is used herein to describe a molecular complex comprising a compound of the invention and an amount of one or more pharmaceutically acceptable solvent molecules. The term hydrate is employed when said solvent is water. Examples of solvate forms include, but are not limited to, compounds of the invention in association with water, acetone, dichloromethane, 2-propanol, ethanol, methanol, dimethylsulfoxide (DMSO), ethyl acetate, acetic acid, ethanolamine, or mixtures thereof. The invention also includes isotopically-labelled compounds of the invention, wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as2H and3H, carbon, such as11C,13C and14C, chlorine, such as36CI, fluorine, such as18F, iodine, such as123I and125I, nitrogen, such as13N and15N, oxygen, such as15O,17O and18O, phosphorus, such as32P, and sulfur, such as35S. Preferred isotopically-labelled compounds include deuterated derivatives of the compounds of the invention. As used herein, the term deuterated derivative embraces compounds of the invention where in a particular position at least one hydrogen atom is replaced by deuterium. Deuterium (D or2H) is a stable isotope of hydrogen which is present at a natural abundance of 0.015 molar %. Isotopically-labelled compounds derivatives of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labelled reagent in place of the non-labelled reagent otherwise employed. In the case of compounds of the invention that are solids, it is understood by those skilled in the art that the inventive compounds and salts may exist in different crystalline or polymorphic forms, or in an amorphous form, all of which are intended to be within the scope of the present invention. Compounds of the present invention containing one or more chiral centre may be used in enantiomerically or diastereoisomerically pure form, or in the form of a mixture of isomers. As used herein, "alkyl" or "alkylene" is intended to include both branched and linear (straight-chain) saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, "C1-C6alkyl" (or alkylene), is intended to include C1, C2, C3, C4, C5and C6alkyl groups. "C1-C3alkyl" (or alkylene), is intended to include C1, C2and C3alkyl groups. Additionally, for example, "C1-C6alkyl" denotes alkyl having 1 to 6 carbon atoms. "C1-C3alkyl" denotes alkyl having 1 to 3 carbon atoms. Typically, C1-C6alkyl is preferably C1-C4alkyl, more preferably C1-C3alkyl, and is more preferably methyl. Examples of alkyl include, but are not limited to, methyl, ethyl, propyl (for example n- propyl, i-propyl, preferably i-propyl) and butyl (for example n-butyl, i-butyl, sec-butyl and t-butyl, preferably t-butyl). Typically, C1-C6alkylene is preferably C1-C4alkylene, more preferably C1-C3alkylene, and is more preferably methylene. Examples of alkylene include, but are not limited to, methylene, ethylene and propylene (for example n-propylene, i- propylene, preferably i-propylene). For the avoidance of doubt, where two alkyl moieties are present in a group, the alkyl moieties may be the same or different. As used herein, a halogen is typically chlorine, fluorine, bromine or iodine and is preferably chlorine, bromine or fluorine, more preferably chlorine or fluorine, and most preferably fluorine. As used herein, the term “haloalkyl” or “haloalkylene” is intended to include both branched and linear (straight-chain) saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, and which contains at least one halogen atom. The halogen is typically chlorine, fluorine, bromine or iodine, and is preferably chlorine, fluorine or bromine, more preferably chlorine or fluorine, and most preferably fluorine. Typically, C1-C6haloalkyl is preferably C1-C4haloalkyl, and more preferably C1-C3haloalkyl, for example C1-C3fluoroalkyl. The term "carbocyclyl" (or “carbocyclylene”) refers to a monocyclic or polycyclic (e.g., bicyclic or tricyclic), non-aromatic, saturated or partially unsaturated ring system whose ring atoms consist of carbon atoms. Preferably, the carbocyclyl is a saturated ring system (i.e. in which all ring bonds between adjacent carbon atoms are single bonds), which is referred to herein as “cycloalkyl”. A polycyclic carbocyclyl may comprise fused rings (where a first ring and a second ring share two adjacent ring carbon atoms), bridged rings (where two non-adjacent ring carbon atoms of a first ring are shared with a second ring) and / or spirocyclic rings (where a first ring shares only a single ring carbon atom with a second ring). A tricyclic or higher order polycyclic cycloalkyl may comprise a mixture of fused, bridged and spirocyclic relationships between its constituent rings. Preferably, the carbocyclyl is a monocyclic or bicyclic carbocyclyl, more preferably a monocyclic or bicyclic bridged carbocyclyl. A typical carbocyclyl (or carbocyclylene) is 3- to 7-membered carbocyclyl, 4- to 10-membered carbocyclyl or 5- to 10-membered carbocyclyl, for example 5- to 7-membered carbocyclyl, 4- to 6-membered carbocyclyl, or 3- to 5-membered carbocyclyl. Example carbocyclyl groups include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, bicyclo[1.1.1]pentyl, and bicyclo[2.2.2]octanyl and the like. Typically, carbocylyl is preferably cyclopropyl, cyclobutyl, cyclopentyl or bicyclo[1.1.1]pentyl. A particularly preferred example of a carbocyclyl or cycloalkyl is cyclobutyl. As used herein, "heterocyclyl”, “heterocycle” or "heterocyclic” (or “heterocyclylene”) refers to a monocyclic or polycyclic (e.g., bicyclic or tricyclic), non- aromatic, saturated or partially unsaturated ring system whose ring atoms consist of carbon atoms and at least one heteroatom selected from O, S and N. The at least one heteroatom is commonly 1-3 heteroatoms, for instance 1-2 heteroatoms or 1 heteroatom. Preferably, the at least one heteroatom ring atom is selected from N and O, more preferably N. Preferably, the heterocyclyl is monocyclic or bicyclic. More preferably, the heterocyclyl is monocyclic. In one embodiment, the heterocyclyl is saturated. In one embodiment, the heterocyclyl is unsaturated. Preferably, the heterocyclyl is saturated. Typical examples of heterocycles include 4- to 10-membered heterocycles, wherein “X-membered” means that the total number of ring atoms in the heterocycle is X. Preferred heterocycles are 4- to 10-membered heterocycles, 9- to 10-membered heterocycles, 4- to 7- membered heterocycles, 4- to 6-membered heterocycles, 4- to 5-membered heterocycles and 5- to 6-membered heterocycles. Examples of heterocycles include, but are not limited to, azetidinyl, pyrrolidinyl, piperazinyl, pyrazolidinyl, piperadinyl, oxetanyl, dihydrotriazolyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, indolinyl, imidazolidinyl, tetrahydro- 1H,3H-5l2-furo[3,4-c]pyrrole, 2-oxa-5-azabicyclo[2.2.1]heptane, oxa-8-azabicycloctane, 2- oxa-6-azaspiro[3.4]octane, 7-oxa-azaspiro[3.5]nonane, 6-oxa-3l2-azabicyclo[3.1.1]heptane, 2-oxazaspiro[3.5]nonane, 2-oxa-azaspiro[3.3]heptane, 1,2,3,4-tetrahydroquinoline, benzo[d][1,3]dioxole, and tetrahydropyrazolo[1,5-a]pyrazinyl. Preferred examples of heterocycles include azetidinyl, oxetanyl, piperidinyl, morpholinyl and pyrrolidinyl. As described herein, a heterocycle may be substituted by one or more oxo groups, typically one oxo group. Examples of heterocycles substituted by one oxo group include oxadiazolonyl, benzoxazolonyl, morpholinonyl, dihydrotriazolonyl, dihydroquinolinonyl, imidazolidinone, pyrimidinonyl, pyrrolidinonyl and oxoindolinyl. As used herein, “heteroaryl” (or “heterarylene”) refers to a monocyclic or polycyclic (e.g., bicyclic or tricyclic), aromatic ring system whose ring atoms consist of carbon atoms and at least one heteroatom selected from O, S and N. The at least one heteroatom is commonly 1-3 heteroatoms, for instance 1-2 heteroatoms or 1 heteroatom. Preferably, the at least one heteroatom ring atom is selected from N and O. More preferably, the at least one heteroatom ring atom is N. Preferably, the heteroaryl is monocyclic or bicyclic, more preferably monocyclic. Typical examples of heteroaryls include 5- to 10-membered heteroaryls, wherein “X- membered” means that the total number of ring atoms in the heteroaryl is X. Preferred heteroaryls are 5- to 7-membered heteroaryls, 5-membered heteroaryls and 6-membered heteroaryls. Examples of heteroaryl groups include, without limitation, furanyl, thiophenyl, imidazolyl, thiazolyl, isothiazolyl, indolyl, benzimidazolyl, pyrrolyl (pyrryl), oxazolyl, indazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5- oxadiazolyl, 1,3,4-oxadiazolyl, thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5- thiadiazolyl, 1,3,4-thiadiazolyl, triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, tetrazolyl, and the like. Preferred examples of heteroaryls include imidazolyl, triazolyl, pyrazolyl, oxadiazolyl, oxazolyl, pyridinyl and tetrazolyl. A particularly preferred example of a heteroaryl is pyrazolyl. The term “aryl” (or “arylene”) is intended to mean an aromatic moiety containing, if specified, the specified number of carbon atoms. For example, C6-C10aryl is preferably phenyl or naphthyl. Preferably, C6-C10aryl is phenyl. As used herein, a PROTAC refers to a proteolysis targeting chimera. PROTACs are heterobifunctional molecules that degrade a target protein by hijacking the ubiquitin– proteasome system, and are well-known to the person skilled in the art. In particular, PROTACs consist of two covalently linked protein-binding molecules: one capable of engaging an E3 ubiquitin ligase, and another that binds to a target protein meant for degradation (such as STAT6). Through binding to both the E3 ubiquitin ligase and the target protein in a cell, the PROTAC recruits the target protein to a ternary complex with the E3 ligase. The E3 ligase itself is in complex with an activated Ub-loaded E2 ligase, and the ternary complex formation brings the ensemble into close proximity with the target protein. This induces the (poly)-ubiquitination of the target protein at lysine residues, marking it for degradation by the 26S proteasome. This mechanism is catalytic, and PROTAC molecules freed from the ternary complex can elicit degradation of the target protein at multiple sites. Compounds The invention relates to compounds of formula (I') or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: (I') In one aspect, the heterocyclic compound is a compound of formula (I) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof, wherein: • R1, Y, L1, Ra, Rb, Rc, Rd, Re, Rf, and n are as defined above for formula (I'); • R2is hydrogen, C1-C6alkyl, C1-C6haloalkyl, −L''−Z', −L''−C(O)Rz, −L''−C(O)ORz, −L''−C(O)NRiiiRz, −L''−NRiiiC(O)Rz, −L''−NRiiiC(O)ORz, −L''−NRiiiC(O)NRivRz, −L''−NRiiiSO2Rz, or −L''−(4- to 10-membered heterocyclyl), wherein said heterocyclyl is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, oxo, C1- C6alkyl, C1-C6haloalkyl, −L''−ORiiiand −L''−NRiiiRiv; wherein Z' is selected from −OH, −ORiii, −NH2, −NRiiiRzand −SRiii; Rzis C1-C6alkyl, C1-C6haloalkyl or −A−A', wherein A is phenyl, 3- to 7-membered carbocyclyl, 5- to 7-membered heteroaryl or 4- to 10-membered heterocyclyl, wherein said carbocyclyl and heterocyclyl are unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, oxo, C1-C6alkyl, C1-C6haloalkyl, −L''−ORiii, and −L''−NRiiiRiv, and said phenyl and heteroaryl are unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, C1-C6alkyl, C1-C6haloalkyl, −L''−ORiii, and −L''−NRiiiRiv; A' is hydrogen or 5- to 7-membered heterocyclyl which is unsubstituted or substituted by one, two or three C1-C3alkyl groups which are the same or different; L'' is a direct bond, C1-C6alkylene or C1-C6haloalkylene; Riiiand Rivare the same or different and are selected from hydrogen, C1-C6alkyl and C1-C6haloalkyl; or R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety; and • G1and G2are the same or different and are selected from phenyl, naphthyl, 4- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, and 4- to 10- membered carbocyclyl, wherein said heterocyclyl and carbocyclyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, oxo and hydroxy, and wherein said phenyl, naphthyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, and hydroxy; and • X1is C or N; m is 0 or 1; and X2, X3and X4are the same or different and are selected from N, NR' and CR''; provided that when m is 0, either (a) at least one of X2and X4is NR', and X1is C, or (b) X2and X4are selected from N and CR'', and X1is N; and when m is 1, X1 is C and X2, X3 and X4 are the same or different and are selected from N and CR''; wherein R' is hydrogen or C1-C4alkyl, and R'' is hydrogen, C1-C4alkyl or halogen. In one aspect, the compound is a compound which is (a) a heterocyclic compound of formula (I'), wherein R1, R2, G1, G2, Y, X1, X2, X3, X4, L1, Ra, Rb, Rc, Rd, Re, Rf, m and n are as defined herein; or (b) a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative of said heterocyclic compound, (I') provided that said compound is not: [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5- fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol- 5(1H)-yl]methanone; [3-[[5-Fluoro-2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[(2-Ethyl-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1-piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1-piperazinyl]methanone; [3-[(2-Ethyl-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(2-methoxyethyl)-2,5-dimethyl-1-piperazinyl]methanone; [3-[[5-Fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(2- ethyl-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol- 5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[[5- fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(2- ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol- 5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[[2- (ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl][3-[(2-ethoxy- 5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl][3-[[2- (ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [4,6-Dihydro-6,6-dimethyl-3-[[4-(trifluoromethyl)-2-pyrimidinyl]amino]pyrrolo [3,4-c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1- piperazinyl]methanone; [4,6-Dihydro-6,6-dimethyl-3-[(4-methyl-2-pyrimidinyl)amino]pyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1- piperazinyl]methanone; [4,6-Dihydro-6,6-dimethyl-3-[(4-methyl-2-pyrimidinyl)amino]pyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1- piperazinyl]methanone; [4,6-Dihydro-3-[(4-methoxy-2-pyrimidinyl)amino]-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1- piperazinyl]methanone; [3-[[2-(Ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[[2-(Ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethyl pyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5S)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[(5-Fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo [3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-hydroxypropyl)-2,5-dimethyl-1-piperazinyl] methanone; [3-[(5-Fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo [3,4-c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl] methanone; [3-[(5-Fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[[2-(Ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(2-methoxyethyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[(4-Ethoxy-2-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1-piperazinyl]methanone; [3-[(5-Fluoro-2-methoxy-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[(5-Fluoro-2-methoxy-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[[5-Fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[[5-Fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl]methanone; [(2S,5R)-2,5-Dimethyl-4-(3,3,3-trifluoropropyl)-1-piperazinyl][3-[(2-ethyl-5- fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][1-(3,3,3-trifluoropropyl)-4-piperidinyl]methanone; [(2S,5R)-2,5-Dimethyl-4-(3,3,3-trifluoropropyl)-1-piperazinyl][3-[[2-(ethylamino)- 5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(3,3,3-trifluoropropyl)-1-piperazinyl][3-[(2-ethoxy-5- fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl][3-[(5-fluoro-2- methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; Methanone, bis[3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]-, hydrate (1:1); Methanone, bis[3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]-, with 2-propanol (1:1); [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-1- piperazinyl][3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-1- piperazinyl][3-[(2-ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [3-[(4,6-Dimethyl-2-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1- piperazinyl]methanone; [4,6-Dihydro-3-[(4-methoxy-2-pyrimidinyl)amino]-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1- piperazinyl]methanone; Methanone, [3-[[2-(ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]-, acetate (1:1); [3-[(2-Ethoxy-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1-piperazinyl]methanone; [2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5-fluoro-2- methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; Methanone, [3-[(2,5-difluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl pyrrolo[3,4-c]pyrazol-5(1H)-yl][(2R,5S)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4- yl)methyl]-1-piperazinyl]-, relative stereochemistry; Bis[3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo [3,4- c]pyrazol-5(1H)-yl]methanone; or [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S)-2-methyl-4-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-1- piperazinyl]methanone. Preferably, the heterocyclic compound of the invention is a compound as described herein or a pharmaceutically acceptable salt, or a solvate, or a tautomer, or a stereoisomer thereof. Preferably, in formula (I') or formula (I), R1is −C1-C4haloalkyl, −L'−Z, −L'−C(O)Ry, −L'−C(O)NRiRy, −L'−C(O)OH, −L'−C(O)ORy, −L'−NRiC(O)Ry, −L'−SO2NRiRy, or −L'−Het. In this embodiment, R1is preferably −L'−Z, −L'−C(O)Ry, −L'−C(O)NRiRy, −L'−C(O)OH, −L'−C(O)ORy, −L'−NRiC(O)Ry, or −L'−Het. Typically, R1is −L'−C(O)NRiRy. More preferably, R1is −C1-C4haloalkyl, −SRi, –(C1-C4alkylene)−ORi, −C(O)Ry, −C(O)NRiRy, −C(O)OH, −C(O)ORy, −NRiC(O)Ry, −SO2NRiRy, or −Het. In this embodiment, R1is more preferably –(C1-C4alkylene)−ORi, −C(O)Ry, −C(O)NRiRy, −C(O)OH, −C(O)ORy, −NRiC(O)Ry, or −Het. More typically, R1is −C(O)NRiRy. Yet more preferably, R1is −C1-C3haloalkyl, −SRi, −(C1-C4alkylene)−OH, −C(O)Ry, −C(O)NRi(C1- C3alkyl), −C(O)OH, −C(O)O(C1-C3alkyl), −NRiC(O)(C1-C3alkyl), −SO2NRi(C1-C3alkyl), 4- to 5-membered heterocyclyl which is unsubstituted or substituted by one oxo group, one C1-C3alkyl group or one −N(C1-C3alkyl)2group, or which is substituted by one oxo group and one C1-C3alkyl group; or a 5-membered heteroaryl group which is unsubstituted or substituted with one or two C1-C3alkyl. In this embodiment, R1is yet more preferably (C1- C4alkylene)−OH, −C(O)Ry, −C(O)NRi(C1-C3alkyl), −C(O)OH, −C(O)O(C1-C3alkyl), −NRiC(O)(C1-C3alkyl), 4- to 5-membered heterocyclyl which is unsubstituted or substituted by one oxo group, one C1-C3alkyl group or one −N(C1-C3alkyl)2group; or a 5-membered heteroaryl group which is unsubstituted or substituted with one C1-C3alkyl. Yet more typically, R1is −C(O)NRi(C1-C3alkyl). Further preferably, R1is −CF2CH3, −SCH3, C4alkylene−OH, −C(O)Ry, −C(O)NHCH3, −C(O)N(CH3)2, −C(O)N(CH3)(C3alkyl), −C(O)N(CH2CH3)2,−C(O)OH, −C(O)OCH3, −NHC(O)CH3, −N(CH3)C(O)CH3, −SO2NH(CH3), or unsubstituted pyrrolidinone, or an oxetanyl moiety which is unsubstituted or substituted by one methyl group or one −N(CH3)2group, or a triazolyl moiety which is unsubstituted, substituted with one methyl group, or substituted with one oxo group and one methyl group, or an imidazolyl moiety which is unsubstituted, substituted with one or two methyl groups, or substituted with one oxo group and one methyl group, or a pyrazolyl moiety which is unsubstituted or substituted by one methyl group, or unsubstituted oxadiazolyl, or an oxazolyl moiety which is unsubstituted or substituted by one methyl group, or a furanyl moiety which is substituted with two methyl groups, or unsubstituted tetrahydrofuranyl, or unsubstituted tetrazolyl. In this embodiment, R1is further preferably C4alkylene−OH, −C(O)Ry, −C(O)NHCH3, −C(O)N(CH3)2, −C(O)N(CH3)(C3alkyl), −C(O)OH, −C(O)OCH3, −NHC(O)CH3, −N(CH3)C(O)CH3, unsubstituted pyrrolidinone, an oxetanyl moiety which is unsubstituted or substituted by one methyl group or one −N(CH3)2group, or an imidazolyl or triazolyl moiety which is unsubstituted or substituted with one methyl group, or unsubstituted pyrazolyl, or unsubstituted oxadiazolyl, or unsubstituted oxazolyl. In this embodiment, R1is most preferably −C(O)−(unsubstituted pyrrolidinyl), −C(O)N(CH3)2, an imidazolyl or triazolyl moiety which is unsubstituted or substituted with one methyl group, or unsubstituted pyrazolyl, or unsubstituted oxadiazolyl, or unsubstituted oxazolyl. Most typically, R1is −C(O)N(CH3)2. Preferably, in formula (I') or formula (I), Het is 4- to 7-membered heterocyclyl or 5- to 7-membered heteroaryl, wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1- C4alkyl, C1-C4haloalkyl, and −N(C1-C4alkyl)2, and said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, and −N(C1-C4alkyl)2. More preferably, Het is 4- to 6-membered heterocyclyl or 5- to 6-membered heteroaryl, wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from oxo, C1-C4alkyl, and −N(C1-C4alkyl)2, and said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from C1-C4alkyl. Yet more preferably, Het is 4- to 5-membered heterocyclyl which is unsubstituted or substituted by one oxo group, one C1-C3alkyl group or one −N(C1-C3alkyl)2group, or which is substituted by one oxo group and one C1-C3alkyl group; or a 5- membered heteroaryl group which is unsubstituted or substituted with one or two C1-C3alkyl. In this embodiment, yet more preferably, Het is 4- to 5-membered heterocyclyl which is unsubstituted or substituted by one oxo group, one C1-C3alkyl group or one −N(C1-C3alkyl)2group; or a 5-membered heteroaryl group which is unsubstituted or substituted with one C1-C3alkyl. Further preferably, Het is unsubstituted pyrrolidinone, or an oxetanyl moiety which is unsubstituted or substituted by one methyl group or one −N(CH3)2group, or a triazolyl moiety which is unsubstituted, substituted with one methyl group, or substituted with one oxo group and one methyl group, or an imidazolyl moiety which is unsubstituted, substituted with one or two methyl groups, or substituted with one oxo group and one methyl group, or a pyrazolyl moiety which is unsubstituted or substituted by one methyl group, or unsubstituted oxadiazolyl, or an oxazolyl moiety which is unsubstituted or substituted by one methyl group, or a furanyl moiety which is substituted with two methyl groups, or unsubstituted tetrahydrofuranyl, or unsubstituted tetrazolyl. In this embodiment, further preferably, Het is unsubstituted pyrrolidinone, an oxetanyl moiety which is unsubstituted or substituted by one methyl group or one −N(CH3)2group, an imidazolyl or triazolyl moiety which is unsubstituted or substituted with one methyl group, or unsubstituted pyrazolyl, unsubstituted oxadiazolyl, or unsubstituted oxazolyl. Most preferably, Het is an imidazolyl or triazolyl moiety which is unsubstituted or substituted with one methyl group, or unsubstituted pyrazolyl, or unsubstituted oxadiazolyl, or unsubstituted oxazolyl. Preferably, in formula (I') or formula (I), Z is −ORior −SRi. In this embodiment, preferably Z is −ORi. More preferably, Z is −OH or −S(C1-C3alkyl). Most preferably, Z is −OH or −SCH3. In this embodiment, most preferably Z is −OH. In one embodiment, Z is selected from −ORior −NRiRy. Preferably, in formula (I') or formula (I), Ryis C1-C4alkyl, C1-C4haloalkyl, phenyl, 3- to 7-membered cycloalkyl, 5- to 7-membered heteroaryl or 4- to 7-membered heterocyclyl, wherein said cycloalkyl and heterocyclyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl, and C1-C4haloalkyl, and said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, and C1-C4haloalkyl. More preferably, Ryis C1-C4alkyl, 3- to 7- membered cycloalkyl or 4- to 7-membered heterocyclyl, wherein said cycloalkyl and heterocyclyl are unsubstituted or substituted by one C1-C4alkyl group. Typically, Ryis C1- C4alkyl. Yet more preferably, Ryis C1-C3alkyl, or unsubstituted 4- to 6-membered heterocyclyl. More typically, Ryis C1-C3alkyl. Further preferably, Ryis methyl, ethyl, i- propyl, unsubstituted azetidinyl, unsubstituted pyrrolidinyl, unsubstituted piperidinyl, or unsubstituted morpholinyl. In this embodiment, further preferably Ryis i-propyl, unsubstituted azetidinyl, unsubstituted pyrrolidinyl, unsubstituted piperidinyl, or unsubstituted morpholinyl. In this embodiment, further preferably Ryis unsubstituted pyrrolidinyl. Most typically, Ryis methyl. Preferably, in formula (I') or formula (I), Riand Riiare the same or different and are selected from hydrogen and C1-C4alkyl. More preferably, Riand Riiare the same or different and are selected from hydrogen and C1-C3alkyl. Most preferably, Riand Riiare the same or different and are selected from hydrogen and methyl. Yet further preferably, Riand Riiare methyl. Preferably, in formula (I') or formula (I), L' is a direct bond, C1-C4alkylene or C1-C4haloalkylene. More preferably, L' is a direct bond or C1-C4alkylene. When R1is −L'−Z, preferably L' is a direct bond or C4alkylene (propylene). Typically, when R1is −L'−Z and Z is −ORi, preferably L' is C4alkylene (propylene), more preferably i-propylene. Typically, when R1is −L'−Z and Z is −NRiRyor −SRi, preferably L' is a direct bond. In one embodiment when R1is −L'−Z, preferably L' is C4alkylene (propylene), more preferably i- propylene. When R1is −L'−C(O)Ry, −L'−C(O)NRiRy, −L'−C(O)OH, −L'−C(O)ORy, −L'−NRiC(O)Ry, −L'−SO2NRiRy, or −L'−Het, preferably L' is a direct bond. Preferably, in formula (I'), R2is hydrogen, C1-C4alkyl, C1-C4haloalkyl, −L''−Z', −L''−C(O)Rz, −L''−C(O)ORz, −L''−C(O)NRiiiRz, −L''−C(O)NH2, −L''−NRiiiC(O)Rz, −L''−NRiiiC(O)ORz, −L''−NRiiiC(O)NRivRz, −L''−NRiiiC(O)C(O)NRivRz, −L''−NRiiiSO2Rz, −L''−(4- to 7-membered heterocyclyl), or −L''−(5- to 7-membered heteroaryl), wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl, and C1-C4haloalkyl, and wherein said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, and C1-C4haloalkyl; or R2is −L2- LBM, wherein L2is a linker and LBM is a ligase binding moiety. In this embodiment, in formula (I') or formula (I), R2is preferably hydrogen, C1-C4alkyl, −L''−Z', −L''−C(O)Rz, −L''−C(O)NRiiiRz, −L''−NRiiiC(O)Rz, −L''−NRiiiC(O)ORz, −L''−NRiiiC(O)NRivRz, −L''−NRiiiSO2Rz, or −L''−(4- to 7-membered heterocyclyl), wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl, and C1-C4haloalkyl; or R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety. Alternatively, in formula (I'), preferably, R2is hydrogen, C1-C4alkyl, C1-C4haloalkyl, −L''−Z', −L''−C(O)Rz, −L''−C(O)ORz, −L''−C(O)NRiiiRz, −L''−C(O)NH2, −L''−NRiiiC(O)Rz, −L''−NRiiiC(O)ORz, −L''−NRiiiC(O)NRivRz, −L''−NRiiiC(O)C(O)NRivRz, −L''−NRiiiSO2Rz, −L''−(4- to 7- membered heterocyclyl), or −L''−(5- to 7-membered heteroaryl), wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl, and C1-C4haloalkyl, and wherein said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, and C1-C4haloalkyl. In this embodiment, in formula (I') or formula (I), R2is preferably hydrogen, C1-C4alkyl, −L''−Z', −L''−C(O)Rz, −L''−C(O)NRiiiRz, −L''−NRiiiC(O)Rz, −L''−NRiiiC(O)ORz, −L''−NRiiiC(O)NRivRz, −L''−NRiiiSO2Rz, or −L''−(4- to 7-membered heterocyclyl), wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl, and C1-C4haloalkyl. Typically, in formula (I') or formula (I), R2is −L''−NRiiiC(O)Rz. More preferably, in formula (I'), R2is hydrogen, C1-C4alkyl, C1-C4haloalkyl, −Z', −C(O)Rz, −C(O)ORz, −C(O)NRiiiRz, −C(O)NH2, −NRiiiC(O)Rz, −NRiiiC(O)ORz, −NRiiiC(O)NRivRz, −NRiiiC(O)C(O)NRivRz, −NRiiiSO2Rz, −(4- to 7-membered heterocyclyl) which is unsubstituted or substituted by one oxo group, or −(5- to 7-membered heteroaryl) which is unsubstituted or substituted with one C1-C3alkyl group; or R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety. In this embodiment, in formula (I') or formula (I), R2is more preferably hydrogen, C1-C4alkyl, −Z', −C(O)Rz, −C(O)NRiiiRz, −NRiiiC(O)Rz, −NRiiiC(O)ORz, −NRiiiC(O)NRivRz, −NRiiiSO2Rz, or −4- to 7-membered heterocyclyl which is unsubstituted or substituted by one oxo group; or R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety. Alternatively, more preferably in formula (I'), R2is hydrogen, C1-C4alkyl, C1-C4haloalkyl, −Z', −C(O)Rz, −C(O)ORz, −C(O)NRiiiRz, −C(O)NH2, −NRiiiC(O)Rz, −NRiiiC(O)ORz, −NRiiiC(O)NRivRz, −NRiiiC(O)C(O)NRivRz, −NRiiiSO2Rz, −(4- to 7- membered heterocyclyl) which is unsubstituted or substituted by one oxo group, or −(5- to 7-membered heteroaryl) which is unsubstituted or substituted with one C1-C3alkyl group. In this embodiment, in formula (I') or formula (I), R2is more preferably hydrogen, C1-C4alkyl, −Z', −C(O)Rz, −C(O)NRiiiRz, −NRiiiC(O)Rz, −NRiiiC(O)ORz, −NRiiiC(O)NRivRz, −NRiiiSO2Rz, or −4- to 7-membered heterocyclyl which is unsubstituted or substituted by one oxo group. More typically, in formula (I') or formula (I), R2is −NRiiiC(O)Rz. Yet more preferably, in formula (I'), R2is hydrogen, C1-C3alkyl, C1-C3haloalkyl, −Z', −C(O)(C1-C3alkyl), −C(O)O(C1-C4alkyl), −C(O)NRiii(C1-C3alkyl), −C(O)NRiii(−A−A'), −C(O)NH2, −NRiiiC(O)Rz, −NRiiiC(O)O(C1-C4alkyl), −NRiiiC(O)O(−A−A'), −NRiiiC(O)NRiv(C1-C3alkyl), −NRiiiC(O)C(O)NRiv(C1-C3alkyl), −NHSO2(C1-C3alkyl), 5-membered heterocyclyl which is unsubstituted or substituted with one oxo group, or 5-membered heteroaryl which is unsubstituted or substituted with one C1-C3alkyl group; or R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety. In this embodiment, in formula (I') or formula (I), R2is more preferably hydrogen, C1-C3alkyl, −Z', −C(O)(C1-C3alkyl), −C(O)NRiii(C1- C3alkyl), −NRiiiC(O)Rz, −NHC(O)O(C1-C4alkyl), −NHC(O)N(C1-C3alkyl)2, −NHSO2(C1- C3alkyl), or 5-membered heterocyclyl which is unsubstituted or substituted with one oxo group; or R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety. Alternatively, yet more preferably in formula (I'), R2is hydrogen, C1-C3alkyl, C1-C3haloalkyl, −Z', −C(O)(C1-C3alkyl), −C(O)O(C1-C4alkyl), −C(O)NRiii(C1-C3alkyl), −C(O)NRiii(−A−A'), −C(O)NH2, −NRiiiC(O)Rz, −NRiiiC(O)O(C1-C4alkyl), −NRiiiC(O)O(−A−A'), −NRiiiC(O)NRiv(C1-C3alkyl), −NRiiiC(O)C(O)NRiv(C1-C3alkyl), −NHSO2(C1-C3alkyl), 5-membered heterocyclyl which is unsubstituted or substituted with one oxo group, or 5-membered heteroaryl which is unsubstituted or substituted with one C1- C3alkyl group. In this embodiment, in formula (I') or formula (I) R2is yet more preferably hydrogen, C1-C3alkyl, −Z', −C(O)(C1-C3alkyl), −C(O)NRiii(C1-C3alkyl), −NRiiiC(O)Rz, −NHC(O)O(C1-C4alkyl), −NHC(O)N(C1-C3alkyl)2, −NHSO2(C1-C3alkyl), or 5-membered heterocyclyl which is unsubstituted or substituted with one oxo group. Further preferably, in formula (I'), R2is hydrogen, methyl, −CH2F, −Z', −C(O)CH3, −C(O)O(tert-butyl), −C(O)NH(CH3), −C(O)N(CH3)2, −C(O)NH(−A−A'), −C(O)NH2, −N(CH3)C(O)CH3, −NHC(O)Rz, −NHC(O)O(C3-C4alkyl), −NHC(O)O(unsubstituted phenyl), −NHC(O)N(CH3)2, −NHC(O)N(CH3)(CH2CH3), −NHC(O)NH(CH3),−NHC(O)C(O)N(CH3)2, −NHSO2(CH3), unsubstituted pyrrolidinone, unsubstituted dihydrotriazolone, unsubstituted oxadiazolone, imidazolyl which is unsubstituted or substituted with one methyl group, triazolyl which is unsubstituted or substituted with one methyl group, or unsubstituted tetrazolyl; or R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety. In this embodiment, in formula (I') or formula (I), R2is further preferably hydrogen, methyl, −Z', −C(O)CH3, −C(O)NH(CH3), −C(O)N(CH3)2, −N(CH3)C(O)CH3, −NHC(O)Rz, −NHC(O)O(C4alkyl), −NHC(O)N(CH3)2, −NHSO2(CH3), or unsubstituted pyrrolidinone; or R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety. Alternatively, in formula (I'), further preferably R2is hydrogen, methyl, −CH2F, −Z', −C(O)CH3, −C(O)O(tert-butyl), −C(O)NH(CH3), −C(O)N(CH3)2, −C(O)NH(−A−A'), −C(O)NH2, −N(CH3)C(O)CH3, −NHC(O)Rz, −NHC(O)O(C3-C4alkyl), −NHC(O)O(unsubstituted phenyl), −NHC(O)N(CH3)2, −NHC(O)N(CH3)(CH2CH3), −NHC(O)NH(CH3),−NHC(O)C(O)N(CH3)2, −NHSO2(CH3), unsubstituted pyrrolidinone, unsubstituted dihydrotriazolone, unsubstituted oxadiazolone, imidazolyl which is unsubstituted or substituted with one methyl group, triazolyl which is unsubstituted or substituted with one methyl group, or unsubstituted tetrazolyl. In this embodiment, in formula (I') or formula (I), R2is further preferably hydrogen, methyl, −Z', −C(O)CH3, −C(O)NH(CH3), −C(O)N(CH3)2, −N(CH3)C(O)CH3, −NHC(O)Rz, −NHC(O)O(C4alkyl), −NHC(O)N(CH3)2, −NHSO2(CH3), or unsubstituted pyrrolidinone. Most preferably, in formula (I') or formula (I), R2is −NHC(O)Rz, −NHC(O)O(tert-butyl), or −NHC(O)N(CH3)2; or R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety. Alternatively, most preferably in formula (I') or formula (I), R2is −NHC(O)Rz, −NHC(O)O(tert-butyl), or −NHC(O)N(CH3)2. In one embodiment, R2is not hydrogen. Typically, in formula (I') or formula (I), R2is −NRiiiC(O)Rz. In this embodiment, in formula (I'), R2is typically −NRiiiC(O)(−A−A'), −NRiiiC(O)(C1-C5alkyl), −NRiiiC(O)(C1- C3haloalkyl), −NRiiiC(O)−Q''−ORiii, −NRiiiC(O)−Q''−OH, or −NRiiiC(O)−Q''−NRiii(C1-C3alkyl). More typically, R2is −NHC(O)Rz. In this embodiment, in formula (I'), R2is more typically −NHC(O)(−A−A'), −NHC(O)(C1-C5alkyl), −N(CH3)C(O)(C1-C3alkyl), −NHC(O)(C1-C3haloalkyl), −NHC(O)−(C1-C2alkylene)−OCH3, −NHC(O)−(C1-C2alkylene)−OH, or −NHC(O)CH2CH2N(C1-C3alkyl)2.Yet more typically, in formula (I') or formula (I), R2is −NHC(O)(−A−A'). Even further typically, in formula (I'), R2is −NHC(O)((5- to 7-membered heteroaryl which is unsubstituted or substituted with one C1- C3alkyl group)−(4- to 7-membered heterocyclyl which is unsubstituted or substituted with one 3- to 5-membered carbocyclyl group or one C1-C3haloalkyl group)), or −NHC(O)((unsubstituted phenyl)−(4- to 6-membered heterocyclyl which is unsubstituted or substituted with one −ORiiigroup)). Yet further typically, in formula (I'), R2is −NHC(O)((5- membered heteroaryl which is substituted with one methyl group)−(6-membered heterocyclyl which is substituted with one cyclobutyl group or one C2haloalkyl group)), or −NHC(O)((unsubstituted phenyl)−(4-membered heterocyclyl which is substituted with one methoxy group)), or −NHC(O)((unsubstituted phenyl)−(unsubstituted 6-membered heterocyclyl)). Most typically, in formula (I'), R2is −NHC(O)((pyrazolyl which is substituted with one methyl group)−(piperidinyl which is substituted with one cyclobutyl group or one −CH2CHF2group)), or −NHC(O)((unsubstituted phenyl)−(azetidinyl which is substituted with one methoxy group)), or −NHC(O)((unsubstituted phenyl)−(unsubstituted morpholinyl)). When R2contains or is L2-LBM in formula (I') or formula (I), the compound of the invention may be used as a PROTAC. L2is any linker which is suitable for covalently linking the ligase binding moiety LBM to the remainder of the compound of the invention. Suitable L2groups are known to the person skilled in the art and include alkylene groups, polyethylene glycol chains, other glycol chains and triazolylene moieties. For example, L2may comprise a C2to C20alkylene group and / or a polyethylene glycol (PEG) chain with a molecular weight of from 50 g / mol to 500 g / mol. Preferably, L2is −NHC(O)−L2'−ZL−, wherein L2' is selected from C2-C20alkylene, − L2''−(HetL)−L2''−, and −L2'''–(OCH2CH2)p−; ZLis a direct bond or −NH−L2'''−; each L2'' is the same or different and is a direct bond or C1-C10alkylene; L2''' is a direct bond or C1-C3alkylene; HetLis 5- to 7-membered heterocyclylene or 5- to 7-membered heteroarylene; and p is from 1 to 20. Preferably, HetLis 6-membered heterocyclylene. More preferably, HetLis piperazinylene. Preferably, p is from 1 to 10. LBM is a ligase binding moiety which binds to the E3 ubiquitin (Ub) ligase, preferably at the substrate binding domain of the E3 Ub ligase. Suitable LBM moieties are known the person skilled in the art and include any moiety which is suitable for binding to one of the human proteome’s E3 ligases. Preferably, LBM is selected from formulae (a) to (f) below, where * represents the point of attachment to L2: (d) * wherein R is F or CN; Y2 is O or CH2; X is NH, O or −NHC(O)−; and W is −C(O)NH− or −C(O)−. Preferably, in formula (I') or formula (I), Z' is selected from −OH, −ORiii, −NH2, and −NRiiiRz. In this embodiment, Z' is preferably selected from −NH2or −NRiiiRz. More preferably, Z' is selected from −OH, −O(C1-C3alkyl), −NH2, −NRiii(C1-C3alkyl), −NRiii(C1- C3haloalkyl), a −NH−(5- to 6-membered heteroaryl) group which is unsubstituted, and a −NH−(4- to 6-membered heterocyclyl) group which is unsubstituted or substituted with one C1-C3alkyl group, or one C1-C3alkyl group and one oxo group. In this embodiment, Z' is more preferably selected from −NH2, −NRiii(C1-C3alkyl), a −NH−(5- to 6-membered heteroaryl) group which is unsubstituted, or a −NH−(4- to 6-membered heterocyclyl) group which is unsubstituted or substituted with one C1-C3 alkyl group. Yet more preferably, Z' is −NH2, −NRiii(C1-C3alkyl), −NRiii(C1-C3haloalkyl), a −NH−(6-membered heteroaryl) group which is unsubstituted, a −NH−(4-membered heterocyclyl) group which is unsubstituted or substituted with one C1-C3alkyl group, or a −NH−(6-membered heterocyclyl) group which is substituted with one C1-C3alkyl group and one oxo group. In this embodiment, Z' is yet more preferably −NH2, −NRiii(C1-C3alkyl), a −NH−(6-membered heteroaryl) group which is unsubstituted, or a −NH−(4-membered heterocyclyl) group which is unsubstituted or substituted with one C1-C3alkyl group. Most preferably, Z' is −NH2, −NH(CH3), −N(CH3)2, −NHCH2CF3, a −NH−pyridinyl group which is unsubstituted, a −NH−oxetanyl group which is unsubstituted or substituted with one methyl group, or a −NH−(unsubstituted pyrimidinone) group. In this embodiment, Z' is most preferably −NH2, −NH(CH3), −N(CH3)2, a −NH−pyridinyl group which is unsubstituted, or a −NH−oxetanyl group which is unsubstituted or substituted with one methyl group. Preferably, in formula (I'), Rzis C1-C6alkyl, C1-C6haloalkyl, −(C1-C3alkylene)−Z', −A−A', −(C1-C3alkylene)−A−A', −(C1-C3alkylene−O−C1-C3alkylene)−A−A', or −A−(C1- C3alkylene)−A. In this embodiment, in formula (I') or formula (I), Rzis preferably C1-C6alkyl or −A−A'. Typically, in formula (I') or formula (I), Rzis −A−A'. More preferably, in formula (I'), Rzis C1-C5alkyl, or 3- to 5-membered cycloalkyl which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, cyano, and −ORiii, or 4- to 10 membered heterocyclyl which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, cyano, C1-C3alkyl, and oxo, or phenyl−A' wherein said phenyl is unsubstituted or substituted with one substituent selected from C1-C3alkyl, halogen, −N(C1-C3alkyl)2, and – (C1-C3alkylene)−C(O)NRiii(C1-C3alkyl), or (5- to 6-membered heteroaryl)−A' wherein said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C3alkyl. In this embodiment, in formula (I') or formula (I), Rzis more preferably C1-C5alkyl, unsubstituted 3- to 5-membered cycloalkyl, unsubstituted 6-membered heteroaryl, unsubstituted 4-membered heterocyclyl, 9- to 10- membered heterocyclyl which is unsubstituted or substituted with one C1-C3alkyl group, or phenyl−A' wherein said phenyl is unsubstituted or substituted with one C1-C3alkyl group. More typically, in formula (I'), Rzis phenyl−A' wherein said phenyl is unsubstituted or substituted with one substituent selected from C1-C3alkyl, halogen, −N(C1-C3alkyl)2, and – (C1-C3alkylene)−C(O)NRiii(C1-C3alkyl), or (5- to 6-membered heteroaryl)−A' wherein said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C3alkyl. Yet more preferably, in formula (I'), Rzis methyl, tert-butyl, iso-butyl, −CH2−(tert-butyl), cyclopropyl which is unsubstituted or substituted with one halogen group, cyclobutyl which is unsubstituted or substituted with one cyano group or one methoxy group, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted cyclohexyl, oxadiazolyl which is substituted with one methyl group, unsubstituted thiazolyl, benzodioxazolyl which is unsubstituted or substituted with one or two halogen groups, oxetanyl which is unsubstituted or substituted with one methyl group, azetidinyl which is unsubstituted or substituted with one cyano group or one methoxy group, unsubstituted pyrrolidinyl, pyrimidinonyl which is unsubstituted or substituted with one methyl group, indolinyl which is unsubstituted or substituted with one methyl group, morpholinyl which is unsubstituted or substituted with one methyl group, piperidinyl which is unsubstituted or substituted with one methyl group, piperazinyl which is unsubstituted or substituted with one methyl group, tetrahydroquinoline which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and methyl, unsubstituted tetrahydrofuranyl, unsubstituted tetrahydropyranyl, tetrahydropyrazolo[1,5- a]pyrazinyl which is unsubstituted or substituted with one methyl group, tetrahydro-1H,3H- 5l2-furo[3,4-c]pyrrole which is substituted with one or two methyl groups, unsubstituted oxa-azaspiroheptane, unsubstituted oxa-azaspirooctane, unsubstituted oxa-azaspirononane, unsubstituted oxa-azabicycloheptane, unsubstituted oxa-azabicycloctane, or phenyl−A' wherein said phenyl is unsubstituted or substituted with one substituent selected from methyl, propyl, halogen, −N(CH3)2, and –(ethylene)−C(O)NH(CH3), or (imidazolyl)−A' wherein said imidazolyl is unsubstituted or substituted with one methyl group, or (pyrazolyl)−A' wherein said pyrazolyl is unsubstituted or substituted with one or two methyl groups, or (pyridinyl)−A' wherein said pyridinyl is unsubstituted or substituted with one C1- C3alkyl group or one halogen group, or (pyrimidinyl)−A' wherein said pyrimidinyl is unsubstituted or substituted with one methyl group. In this embodiment, in formula (I') or formula (I), Rzis yet more preferably methyl, tert-butyl, −CH2−(tert-butyl), unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted pyridinyl, unsubstituted oxetanyl, indolinyl which is unsubstituted or substituted with one methyl group, tetrahydropyrazolo[1,5-a]pyrazinyl which is unsubstituted or substituted with one methyl group, or phenyl−A' wherein said phenyl is unsubstituted or substituted with one propyl group. In this embodiment, in formula (I') or formula (I), Rzis most preferably methyl, tert-butyl, −CH2−(tert-butyl), unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted pyridinyl, or phenyl−A' wherein said phenyl is unsubstituted. Yet more typically, in formula (I') or formula (I), Rzis (unsubstituted phenyl)−A', or (pyrazolyl)−A' wherein said pyrazolyl is substituted with one methyl group. Most typically, in formula (I'), Rzis (pyrazolyl which is substituted with one methyl group)−(piperidinyl which is substituted with one cyclobutyl group or one −CH2CHF2group), or (unsubstituted phenyl)−(azetidinyl which is substituted with one methoxy group), or (unsubstituted phenyl)−(unsubstituted morpholinyl). Preferably, in formula (I'), A is phenyl, 3- to 7-membered cycloalkyl, 5- to 7- membered heteroaryl or 4- to 10-membered heterocyclyl, wherein said cycloalkyl and heterocyclyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, cyano, −ORiii, oxo, C1-C4alkyl and C1-C4haloalkyl, and said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, −N(C1-C3alkyl)2, –(C1-C3alkylene)−C(O)NRiii(C1-C3alkyl), C1-C4alkyl and C1-C4haloalkyl. In this embodiment, in formula (I') or formula (I), A is preferably phenyl, 3- to 7-membered cycloalkyl, 5- to 7-membered heteroaryl or 4- to 10-membered heterocyclyl, wherein said cycloalkyl and heterocyclyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl and C1-C4haloalkyl, and said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl. More preferably, in formula (I'), A is a phenyl moiety which is unsubstituted or substituted with one substituent selected from C1-C3alkyl, halogen, −N(C1- C3alkyl)2, and –(C1-C3alkylene)−C(O)NRiii(C1-C3alkyl), a 3- to 7-membered cycloalkyl moiety which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from C1-C3alkyl, halogen, cyano, and −ORiii, a 5- to 7- membered heteroaryl moiety which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C3alkyl, or a 4- to 10- membered heterocyclyl moiety which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, cyano, C1-C3alkyl, and oxo. In this embodiment, in formula (I'), A is more preferably a phenyl moiety, a 3- to 7-membered cycloalkyl moiety, a 5- to 7-membered heteroaryl moiety or a 4- to 10- membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one C1-C3alkyl group. Typically, in formula (I'), A is a phenyl moiety which is unsubstituted or substituted with one substituent selected from C1-C3alkyl, halogen, −N(C1-C3alkyl)2, and – (C1-C3alkylene)−C(O)NRiii(C1-C3alkyl), or a 5- to 7-membered heteroaryl moiety which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C3alkyl. Yet more preferably, in formula (I'), A is a 3- to 6-membered cycloalkyl moiety which moiety is unsubstituted or substituted with one halogen group, one cyano group or one methoxy group, a 5- to 6- membered heteroaryl moiety which moiety is unsubstituted or substituted with one or two substituents which are the same or different and are selected from C1-C3alkyl and halogen, a 4- to 5-membered heterocyclyl moiety which moiety is unsubstituted or substituted with one methyl group, one cyano group, or one methoxy group, a 6-membered heterocyclyl moiety which moiety is unsubstituted or substituted with one methyl group and one oxo group, or one methyl group, a 7- to 10-membered heterocyclyl moiety which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C3alkyl, or phenyl which is unsubstituted or substituted with one substituent selected from C1-C3alkyl, halogen, −N(CH3)2, and –(ethylene)−C(O)NH(CH3). In this embodiment, in formula (I') or formula (I), A is yet more preferably unsubstituted 3- to 5-membered cycloalkyl, unsubstituted 6-membered heteroaryl, unsubstituted 4-membered heterocyclyl, 9- to 10-membered heterocyclyl moiety which moiety is unsubstituted or substituted with one C1-C3alkyl group, or phenyl which is unsubstituted or substituted with one C1-C3alkyl group. Yet more typically, in formula (I'), A is phenyl which is unsubstituted or substituted with one substituent selected from C1-C3alkyl, halogen, −N(CH3)2, and – (ethylene)−C(O)NH(CH3), or a 5- to 6- membered heteroaryl moiety which moiety is unsubstituted or substituted with one or two substituents which are the same or different and are selected from C1-C3alkyl and halogen. Further preferably, in formula (I'), A is cyclopropyl which is unsubstituted or substituted with one halogen group, cyclobutyl which is unsubstituted or substituted with one cyano group or one methoxy group, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted cyclohexyl, oxadiazolyl which is substituted with one methyl group, unsubstituted thiazolyl, benzodioxazolyl which is unsubstituted or substituted with one or two halogen groups, oxetanyl which is unsubstituted or substituted with one methyl group, azetidinyl which is unsubstituted or substituted with one cyano group or one methoxy group, unsubstituted pyrrolidinyl, pyrimidinonyl which is unsubstituted or substituted with one methyl group, indolinyl which is unsubstituted or substituted with one methyl group, morpholinyl which is unsubstituted or substituted with one methyl group, piperidinyl which is unsubstituted or substituted with one methyl group, piperazinyl which is unsubstituted or substituted with one methyl group, tetrahydroquinoline which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and methyl, unsubstituted tetrahydrofuranyl, unsubstituted tetrahydropyranyl, tetrahydropyrazolo[1,5-a]pyrazinyl which is unsubstituted or substituted with one methyl group, tetrahydro-1H,3H-5l2-furo[3,4-c]pyrrole which is substituted with one or two methyl groups, unsubstituted oxa-azaspiroheptane, unsubstituted oxa- azaspirooctane, unsubstituted oxa-azaspirononane, unsubstituted oxa-azabicycloheptane, unsubstituted oxa-azabicycloctane, phenyl which is unsubstituted or substituted with one substituent selected from methyl, propyl, halogen, −N(CH3)2, and – (ethylene)−C(O)NH(CH3), imidazolyl which is unsubstituted or substituted with one methyl group, pyrazolyl which is unsubstituted or substituted with one or two methyl groups, pyridinyl which is unsubstituted or substituted with one C1-C3alkyl group or one halogen group, or pyrimidinyl which is unsubstituted or substituted with one methyl group. In this embodiment, in formula (I') or formula (I), A is further preferably unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted pyridinyl, unsubstituted oxetanyl, indolinyl moiety which is unsubstituted or substituted with one methyl group, tetrahydropyrazolo[1,5-a]pyrazinyl moiety which is unsubstituted or substituted with one methyl group, or phenyl which is unsubstituted or substituted with one propyl group. In this embodiment, in formula (I') or formula (I), A is most preferably unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted pyridinyl, or phenyl which is unsubstituted. Further typically, in formula (I'), A is phenyl which is unsubstituted or substituted with one substituent selected from methyl, propyl, halogen, −N(CH3)2, and –(ethylene)−C(O)NH(CH3), or pyrazolyl which is unsubstituted or substituted with one or two methyl groups. Most typically, in formula (I') or formula (I), A is unsubstituted phenyl or pyrazolyl which is substituted with one methyl group. In formula (I'), where a compound contains two A groups, for the avoidance of doubt the two A groups may be the same or different. Preferably, in formula (I'), A' is hydrogen, a phenyl moiety which moiety is unsubstituted or substituted with −(C1-C3alkylene)−NRiiiRiv, or a 4- to 8-membered heterocyclyl moiety which moiety is unsubstituted or substituted by one substituent selected from C1-C3alkyl, C1-C3haloalkyl, oxo, 3- to 5-membered carbocyclyl, 4- to 5-membered heterocyclyl, and −ORiii. In this embodiment, in formula (I') or formula (I), A' is preferably hydrogen or 5- to 7-membered heterocyclyl which is unsubstituted or substituted by one C1- C3alkyl group. Typically, in formula (I'), A' is a 4- to 8-membered heterocyclyl moiety which moiety is unsubstituted or substituted by one substituent selected from C1-C3alkyl, C1-C3haloalkyl, oxo, 3- to 5-membered carbocyclyl, 4- to 5-membered heterocyclyl, and −ORiii. More preferably, in formula (I'), A' is hydrogen, phenyl which is substituted with −(C1-C3alkylene)−NH(CH3), a 4-membered heterocyclyl which is unsubstituted or substituted with one substituent selected from methyl, cyclopropyl, cyclobutyl, and methoxy, a 5-membered heterocyclyl which is unsubstituted or substituted with one methoxy group, a 6-membered heterocyclyl which is unsubstituted or substituted with one substituent selected from methyl, ethyl, C2haloalkyl, cyclopropyl, cyclobutyl, oxetanyl, oxo, and methoxy, or an unsubstituted 7- to 8-membered heterocyclyl. In this embodiment, in formula (I') or formula (I), A' is more preferably hydrogen or 6-membered heterocyclyl which is unsubstituted or substituted with one methyl group. More typically, in formula (I'), A' is a 4-membered heterocyclyl which is unsubstituted or substituted with one substituent selected from methyl, cyclopropyl, cyclobutyl, and methoxy, or a 6-membered heterocyclyl which is unsubstituted or substituted with one substituent selected from methyl, ethyl, C2haloalkyl, cyclopropyl, cyclobutyl, oxetanyl, oxo, and methoxy. Most preferably, in formula (I'), A' is hydrogen, phenyl which is substituted with −(CH2)−NH(CH3), azetidinyl which is substituted with one substituent selected from methyl, methoxy, cyclopropyl, and cyclobutyl, piperidinyl which is substituted with one substituent selected from methyl, ethyl, cyclopropyl, cyclobutyl, −CH2CH2F, −CH2CHF2, methoxy, and oxetanyl, morpholinyl which is unsubstituted or substituted with one methyl group or one oxo group, piperazinyl which is substituted with one substituent selected from methyl, cyclopropyl, and cyclobutyl, tetrahydropyridinyl which is substituted with one methyl group, pyrrolidinyl which is substituted with one methoxy group, or unsubstituted oxazaspiroheptane, unsubstituted oxazaspirooctane, or unsubstituted tetrahydropyranyl. In this embodiment, in formula (I') or formula (I), A' is most preferably hydrogen, piperidinyl which is unsubstituted or substituted with one methyl group, or unsubstituted tetrahydropyranyl. Yet more typically, in formula (I'), A' is piperidinyl which is substituted with one substituent selected from methyl, ethyl, cyclopropyl, cyclobutyl, −CH2CH2F, −CH2CHF2, methoxy, and oxetanyl, or azetidinyl which is substituted with one substituent selected from methyl, methoxy, cyclopropyl, and cyclobutyl, or morpholinyl which is unsubstituted or substituted with one methyl group or one oxo group. Most typically, in formula (I'), A' is piperidinyl which is substituted with one substituent selected from cyclobutyl and −CH2CHF2, or azetidinyl which is substituted with one methoxy group, or unsubstituted morpholinyl. Preferably, in formula (I'), Q' is C1-C6alkylene or –(C1-C6alkylene)−O−L''−. More preferably, Q' is C1-C3alkylene or –(C1-C3alkylene)−O−(C1-C3alkylene)−. Most preferably, Q' is methylene or –(CH2)−O−(CH2)−. Preferably, in formula (I'), Q'' is C1-C6alkylene. More preferably, Q'' is C1-C3alkylene. Most preferably, Q'' is C1-C2alkylene. Preferably, in formula (I') or formula (I), L'' is a direct bond, C1-C3alkylene or C1- C3haloalkylene. More preferably, L'' is a direct bond or C1-C3alkylene. Most preferably, L'' is a direct bond. Preferably, in formula (I') or formula (I), Riiiand Rivare the same or different and are selected from hydrogen and C1-C4alkyl. More preferably, Riiiand Rivare the same or different and are selected from hydrogen and C1-C3alkyl. Most preferably, Riiiand Rivare the same or different and are selected from hydrogen and methyl. Preferably, in formula (I'), G1is selected from phenyl, 4- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl, and 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, oxo, −ORGand –(C1-C3alkylene)−ORG, and wherein said phenyl, and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, −ORGand –(C1-C3alkylene)−ORG. In this embodiment, in formula (I') or formula (I), G1is preferably selected from phenyl, 4- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl, and 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1- C4haloalkyl and oxo, and wherein said phenyl, and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl. In this embodiment, in formula (I') or formula (I), more preferably G1is selected from a phenyl moiety, a 4- to 7-membered heterocyclyl moiety, a 5- to 7-membered heteroaryl moiety, or a 4- to 7-membered cycloalkyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl. More preferably, in formula (I') or formula (I), G1is selected from a phenyl moiety, a 5- to 7-membered heterocyclyl moiety, a 5- to 7-membered heteroaryl moiety, or a 5- to 7-membered cycloalkyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl. Yet more preferably, in formula (I') or formula (I), G1is unsubstituted 5- to 6- membered heterocyclyl, unsubstituted 5- to 6-membered cycloalkyl, 5- to 6-membered heteroaryl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine, chlorine and C1-C3alkyl, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine, chlorine and C1-C3alkyl. In this embodiment, in formula (I') or formula (I), G1is yet more preferably unsubstituted 5- to 6-membered heterocyclyl, unsubstituted 5- to 6-membered heteroaryl, unsubstituted 5- to 6-membered cycloalkyl, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine and C1-C3alkyl. Yet more typically, in formula (I') or formula (I), G1is phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine, chlorine and C1- C3alkyl. Further preferably, in formula (I') or formula (I), G1is unsubstituted piperidinyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted cyclohexyl, unsubstituted pyrimidinyl, pyridinyl which is unsubstituted or substituted with one methyl group, one fluorine group, or one chlorine group, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine, chlorine and methyl. In this embodiment, in formula (I') or formula (I), G1is further preferably unsubstituted piperidinyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted pyridinyl, or phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl. Most preferably, in formula (I') or formula (I), G1is phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl. Most typically, in formula (I') or formula (I), G1is unsubstituted phenyl. In formula (I') or formula (I), when G1is a 6-membered monocyclic ring (such as phenyl, 6-membered monocyclic heterocyclyl, 6-membered monocyclic heteroaryl or 6- membered carbocyclyl), the R1moiety is preferably at the para position in relation to moiety Y. Preferably, in formula (I'), G2is selected from phenyl, 4- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, and 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, −LG−OH and oxo, and wherein said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, −O−(C1-C4alkyl), C1-C4alkyl and C1-C4haloalkyl. In this embodiment, in formula (I') or formula (I), G2is preferably selected from phenyl, 4- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, and 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl and oxo, and wherein said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl. More preferably, in formula (I'), G2is selected from phenyl, 4- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, and 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one substituent selected from C1-C4alkyl, −(C1-C4alkylene)−OH and oxo, and wherein said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, −O−(C1-C4alkyl), C1-C4alkyl and C1-C4haloalkyl. In this embodiment, in formula (I') or formula (I), G2is more preferably selected from phenyl, 4- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, and 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one substituent selected from C1-C4alkyl and oxo, and wherein said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl. Yet more preferably, in formula (I'), G2is 5- to 10- membered heterocyclyl which is unsubstituted or substituted with one oxo group; 5- to 6- membered cycloalkyl which is unsubstituted or substituted with one hydroxy group; 5- to 10- membered heteroaryl which is unsubstituted or substituted with one halogen group, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from halogen, −O−(C1-C3alkyl) and C1-C3alkyl. In this embodiment, in formula (I') or formula (I), G2is yet more preferably G2is 5- to 10- membered heterocyclyl which is unsubstituted or substituted with one oxo group; unsubstituted 5- to 6- membered cycloalkyl; unsubstituted 5- to 10- membered heteroaryl, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine and C1-C3alkyl. Yet more typically, in formula (I'), G2is phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from halogen, −O−(C1-C3alkyl) and C1-C3alkyl. Further preferably, in formula (I'), G2is unsubstituted piperidinyl, unsubstituted benzimidazolyl, unsubstituted pyrrolidinyl, unsubstituted tetrahydropyranyl, unsubstituted bicyclo[1.1.1]pentyl, cyclohexyl which is unsubstituted or substituted with one hydroxy group, unsubstituted indolinyl, unsubstituted oxoindolinyl, unsubstituted benzoxazolonyl, unsubstituted dihydroquinolinonyl, pyridinyl which is unsubstituted or substituted with one chlorine group, unsubstituted pyrimidinyl, unsubstituted indolyl, unsubstituted oxazolyl, unsubstituted thiazolyl, or phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine, chlorine, methoxy and methyl. In this embodiment, in formula (I') or formula (I), G2is further preferably unsubstituted piperidinyl, unsubstituted benzimidazolyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted indolinyl, unsubstituted oxoindolinyl or unsubstituted pyridinyl, or phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl. Most preferably, in formula (I') or formula (I), G2is phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl. Most typically, in formula (I') or formula (I), G2is unsubstituted phenyl. In formula (I') or formula (I), when G2is a 6-membered monocyclic ring (such as phenyl, 6-membered monocyclic heterocyclyl, 6-membered monocyclic heteroaryl or 6- membered carbocyclyl), the R2moiety is preferably at the para position in relation to moiety L1. Preferably, in formula (I'), LGis a direct bond, C1-C4alkylene or C1-C4haloalkylene. More preferably, LGis a direct bond or C1-C3alkylene. Yet more preferably, LGis a direct bond or methylene. Most preferably, LGis a direct bond. Preferably, in formula (I'), RGis selected from hydrogen, C1-C4alkyl and C1-C4haloalkyl. More preferably, RGis selected from hydrogen and C1-C3alkyl. Yet more preferably, RGis selected from hydrogen and methyl. In one preferred embodiment, RGis hydrogen. In an alternative preferred embodiment, RGis methyl. Preferably, in formula (I') or formula (I), Y is methylene or −C(O)−. Most preferably, Y is methylene. In formula (I') or formula (I), X1, X2, X3, X4and m together define a monocyclic, 5- or 6-membered aromatic ring, preferably a monocyclic 5-membered heteroaryl ring. For example, the ring defined by X1, X2, X3, X4and m may be pyrrolyl, imidazolyl, pyrazolyl, 1,2,4-triazolyl, phenyl, or pyridinyl. Preferably, the ring defined by X1, X2, X3, X4and m is pyrrolyl, imidazolyl, pyrazolyl, or 1,2,4-triazolyl. More preferably, the ring defined by X1, X2, X3, X4and m is pyrrolyl or imidazolyl. In this embodiment, more preferably, the ring defined by X1, X2, X3, X4and m is pyrrolyl. In one embodiment, more preferably, the ring defined by X1, X2, X3, X4and m is imidazolyl. In formula (I') or formula (I), preferably, m is 0. In formula (I') or formula (I), preferably, X1is N. In formula (I') or formula (I), preferably, X2is CR''. In one preferred embodiment in formula (I') or formula (I), X2is N. In formula (I'), preferably, X4is CR'''. In this embodiment, in formula (I') or formula (I), preferably X4is CR''. In one preferred embodiment in formula (I') or formula (I), X4is N. Preferably, in formula (I'), m is 0, X1is N, X2is selected from N and CR'' and X4is selected from N and CR'''. In this embodiment, in formula (I') or formula (I), preferably m is 0, X1is N and X2and X4are selected from N and CR''. More preferably, in formula (I'), m is 0, X1is N, X2is N or CR'', and X4is CR'''. In this embodiment, in formula (I') or formula (I), more preferably, m is 0, X1is N and X2and X4are CR''. Yet more preferably, in formula (I'), m is 0, X1is N, X2is N, CH, CF or C(CH3) and X4is CR'''. In this embodiment, in formula (I') or formula (I), yet more preferably, m is 0, X1is N, X2is CH and X4is CR''. Further preferably, in formula (I'), m is 0, X1is N, X2is N, CH, CF or C(CH3) and X4is CH, CF, CCl, CBr, C(CH3), C(cyclopropyl), or C(CN). In this embodiment, in formula (I') or formula (I), further preferably, m is 0, X1is N, X2is CH and X4is CH or CF. Most preferably, in formula (I') or formula (I), m is 0, X1is N, X2is CH and X4is CH. Alternatively, most preferably in formula (I') or formula (I), m is 0, X1is N, X2is N and X4is CH or C(CH3). Preferably, in formula (I') or formula (I), R' is hydrogen or methyl. More preferably, R' is hydrogen. Preferably, in formula (I') or formula (I), R'' is hydrogen, methyl or fluorine. More preferably, R'' is hydrogen or fluorine. Most preferably, R'' is hydrogen. Preferably, in formula (I'), R''' is hydrogen, halogen, methyl, trifluoromethyl, cyano or 3-to 4-membered carbocyclyl. More preferably, R''' is hydrogen, fluorine, chlorine, bromine, methyl, trifluoromethyl, cyano, or cyclopropyl. Most preferably, R''' is hydrogen or methyl. Preferably, the ring defined by X1, X2, X3, X4and m contains no more than two R', R'' or R''' groups which are not hydrogen. More preferably, the ring defined by X1, X2, X3, X4and m contains no more than one R', R'' or R''' groups which are not hydrogen. Preferably, in formula (I') or formula (I), L1is −C(O)NRv−Q−, −L1'−NRv−Q−, or – (5- to 6-membered heteroarylene)−Q−. In this embodiment, preferably L1is −C(O)NRv−Q−, or −L1'−NRv−Q−. More preferably, L1is −C(O)NRv−Q−, –(4-membered heterocyclylene)−NRv−Q−, −NRv−Q− or –(5-membered heteroarylene)−Q−. In this embodiment, more preferably L1is −C(O)NRv−Q−, or −NRv−Q−. Yet more preferably, L1is −C(O)NRv−Q−, –(oxetanylene)−NRv−Q−, or –(triazolylene)−Q−. In this embodiment, yet more preferably L1is −C(O)NRv−Q−. Most preferably, L1is −C(O)NH−CH2−, −C(O)N(CH3)−CH2−, −C(O)NH−, −C(O)NH−CH(CH3)–, −C(O)NH−C(2H)2−, (oxetanylene)−NH−CH2−, or –(triazolylene)−CH2−. In this embodiment, most preferably, L1is −C(O)NH−CH2−. In one embodiment, L1is not −NH−. Preferably, in formula (I') or formula (I), Q is a direct bond, linear or branched C1- C4alkylene, or linear or branched C1-C4haloalkylene, wherein said alkylene and haloalkylene are unsubstituted. More preferably, Q is a direct bond, or unsubstituted C1-C2alkylene. Yet more preferably, Q is a direct bond or methylene. Most preferably, Q is methylene. Preferably, in formula (I') or formula (I), L1' is a direct bond, linear or branched C1- C2alkylene, linear or branched C1-C2haloalkylene or 4- to 5-membered heterocyclyene. More preferably, L1' is a direct bond, linear or branched C1-C2alkylene, linear or branched C1-C2haloalkylene or 4-membered heterocyclyene. Yet more preferably, L1' is a direct bond, linear or branched C1-C2alkylene, linear or branched C1-C2haloalkylene or oxetanylene. In this embodiment, further preferably, L1' is a direct bond, linear or branched C1-C2alkylene, or linear or branched C1-C2haloalkylene. In this embodiment, more preferably, L1' is a direct bond. More preferably, L1' is oxetanylene. Preferably, in formula (I') or formula (I), Het' is a 5- to 6-membered heteroarylene group which is unsubstituted or substituted by one, two or three C1-C3alkyl groups which are the same or different. More preferably, Het' is a 5- to 6-membered heteroarylene group which is unsubstituted or substituted by one C1-C3alkyl group. Further preferably, Het' is an unsubstituted 5- to 6-membered heteroarylene group. Most preferably, Het' is an unsubstituted triazolylene group. Preferably, in formula (I') or formula (I), Rvis hydrogen or methyl. More preferably, Rvis hydrogen. Preferably, in formula (I') or formula (I), Raand Rbare the same or different and are selected from C1-C4alkyl or C1-C4haloalkyl; or Raand Rbtogether with the carbon to which they are attached form a 3- to 7-membered cycloalkyl moiety or 4- to 7-membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl. More preferably, Raand Rbare the same or different and are C1-C4alkyl; or Raand Rbtogether with the carbon to which they are attached form a 3- to 7-membered cycloalkyl moiety or 4- to 6-membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C4alkyl. In this embodiment, more preferably, Raand Rbare the same or different and are C1-C4alkyl; or Raand Rbtogether with the carbon to which they are attached form a 4- to 6-membered cycloalkyl moiety or 4- to 6-membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C4alkyl. More typically, Raand Rbtogether with the carbon to which they are attached form a 3- to 7-membered cycloalkyl moiety or 4- to 6-membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C4alkyl. Yet more preferably, Raand Rbare the same or different and are C1-C3alkyl, or Raand Rbtogether with the carbon to which they are attached form an unsubstituted 4- to 6-membered heterocyclyl, or a 3- to 7-membered cycloalkyl which is unsubstituted or substituted by one or two substituents selected from fluorine and C1-C3alkyl. In this embodiment, yet more preferably, Raand Rbare the same or different and are C1-C3alkyl, or Raand Rbtogether with the carbon to which they are attached form an unsubstituted 4- to 6-membered heterocyclyl, or a 4- to 6-membered cycloalkyl which is unsubstituted or substituted by two substituents selected from fluorine and C1-C3alkyl. Yet more typically, Raand Rbtogether with the carbon to which they are attached form an unsubstituted 4- to 6-membered heterocyclyl, or a 3- to 7-membered cycloalkyl which is unsubstituted or substituted by one or two substituents selected from fluorine and C1-C3alkyl. Yet further typically, Raand Rbtogether with the carbon to which they are attached form an unsubstituted 4-membered heterocyclyl, or an unsubstituted 4-membered cycloalkyl. Further preferably, Raand Rbare the same or different and are methyl, or Raand Rbtogether with the carbon to which they are attached form unsubstituted oxetanyl, unsubstituted tetrahydrofuranyl, unsubstituted cyclopropyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or a cyclobutyl group which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl. In this embodiment, further preferably, Raand Rbare the same or different and are methyl, or Raand Rbtogether with the carbon to which they are attached form unsubstituted oxetanyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or a cyclobutyl group which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl. Yet further preferably, Rais methyl and Rbis methyl; or Raand Rbtogether with the carbon to which they are attached form unsubstituted oxetanyl, unsubstituted tetrahydrofuranyl, unsubstituted cyclopropyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or a cyclobutyl group which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl. In this embodiment, yet further preferably, Rais methyl and Rbis methyl; or Raand Rbtogether with the carbon to which they are attached form unsubstituted oxetanyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or a cyclobutyl group which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl. Most preferably, Raand Rbtogether with the carbon to which they are attached form unsubstituted oxetantyl, or a cyclobutyl group which is unsubstituted or substituted by two substituents selected from fluorine and methyl. In this embodiment, most preferably, Raand Rbtogether with the carbon to which they are attached form a cyclobutyl group which is unsubstituted or substituted by two substituents selected from fluorine and methyl. Typically, Raand Rbtogether with the carbon to which they are attached form unsubstituted oxetanyl or unsubstituted cyclobutyl. Preferably, in formula (I') or formula (I), Rcand Rdare the same or different and are selected from hydrogen and C1-C4alkyl. More preferably, Rcand Rdare the same or different and are selected from hydrogen and methyl. Most preferably, Rcand Rdare hydrogen. Preferably, in formula (I') or formula (I), Reand Rfare the same or different and are selected from hydrogen and C1-C4alkyl. More preferably, Reand Rfare the same or different and are selected from hydrogen and methyl. Most preferably, Reand Rfare hydrogen. Preferably, in formula (I') or formula (I), n is 1. Preferably, the heterocyclic compound is a compound of formula (I'i) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: wherein R1, R2, G1, G2, Y, X1, X2, X4, L1, Ra, Rb, Rc, Rd, Reand Rfare as defined above for formula (I'). In this embodiment, preferably the heterocyclic compound is a compound of formula (Ii) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: wherein R1, R2, G1, G2, Y, X1, X2, X4, L1, Ra, Rb, Rc, Rd, Reand Rfare as defined above for formula (I). More preferably, the heterocyclic compound is a compound of formula (I'ii(a)) or (I'ii(b)) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: (I'ii(b)) wherein R1, R2, G1, G2, Y, L1, R''', Ra, Rb, Rc, Rd, Reand Rfare as defined above for formula (I'). In this embodiment, more preferably, the heterocyclic compound is a compound of formula (Iii) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: wherein R1, R2, G1, G2, Y, L1, R'', Ra, Rb, Rc, Rd, Reand Rfare as defined above for formula (I). Yet more preferably, the heterocyclic compound is a compound of formula (I'iii(a)) or (I'iii(b)) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof:

[0002] (I'iii(b)) wherein R1, R2, G1, G2, Y, L1, R''', Ra, and Rbare as defined above for formula (I'). In this embodiment, yet more preferably, the heterocyclic compound is a compound of formula (Iiii) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: wherein R1, R2, G1, G2, Y, L1, R'', Ra, and Rbare as defined above for formula (I). Further preferably, the heterocyclic compound is a compound of formula (I'iv(a)) or (I'iv(b)) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: wherein R1, R2, G1, G2, R''', Ra, and Rbare as defined above for formula (I'). In this embodiment, further preferably, the heterocyclic compound is a compound of formula (Iiv) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: wherein R1, R2, G1, G2, R'', Ra, and Rbare as defined above for formula (I). In one preferred embodiment, the heterocyclic compound is a compound of formula (I'i) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof:

[0003] wherein • R1is C1-C4haloalkyl, −L'−Z, −L'−C(O)Ry, −L'−C(O)NRiRy, −L'−C(O)OH, −L'−C(O)ORy, −L'−NRiC(O)Ry, −L'−SO2NRiRy, or −L'−Het, wherein Het is 4- to 7-membered heterocyclyl or 5- to 7-membered heteroaryl, wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl, C1- C4haloalkyl, and −N(C1-C4alkyl)2, and said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, −N(C1-C4alkyl)2; Z is selected from −ORi, −NRiRyand −SRi; Ryis C1-C4alkyl, C1-C4haloalkyl, phenyl, 3- to 7-membered cycloalkyl, 5- to 7-membered heteroaryl or 4- to 7-membered heterocyclyl, wherein said cycloalkyl and heterocyclyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl, and C1-C4haloalkyl, and said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1- C4alkyl, and C1-C4haloalkyl; Riis selected from hydrogen and C1-C4alkyl; and L' is a direct bond, C1-C4alkylene or C1-C4haloalkylene; • R2is hydrogen, C1-C4alkyl, C1-C4haloalkyl, −L''−Z', −L''−C(O)Rz, −L''−C(O)ORz, −L''−C(O)NRiiiRz, −L''−C(O)NH2, −L''−NRiiiC(O)Rz, −L''−NRiiiC(O)ORz, −L''−NRiiiC(O)NRivRz, −L''−NRiiiC(O)C(O)NRivRz, −L''−NRiiiSO2Rz, −L''−(4- to 7- membered heterocyclyl), or −L''−(5- to 7-membered heteroaryl), wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl, and C1-C4haloalkyl, and wherein said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, and C1-C4haloalkyl; wherein Z' is selected from −OH, −ORiii, −NH2, and −NRiiiRz; Rzis C1-C6alkyl, C1-C6haloalkyl, −(C1-C3alkylene)−Z', −A−A', −(C1-C3alkylene)−A−A', −(C1-C3alkylene−O−C1-C3alkylene)−A−A', or −A−(C1-C3alkylene)−A, wherein A is phenyl, 3- to 7-membered cycloalkyl, 5- to 7-membered heteroaryl or 4- to 10-membered heterocyclyl, wherein said cycloalkyl and heterocyclyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, cyano, −ORiii, oxo, C1-C4alkyl and C1-C4haloalkyl, and said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, −N(C1-C3alkyl)2, –(C1-C3alkylene)−C(O)NRiii(C1-C3alkyl), C1-C4alkyl and C1-C4haloalkyl; A' is hydrogen, a phenyl moiety which moiety is unsubstituted or substituted with −(C1-C3alkylene)−NRiiiRiv, or a 4- to 8-membered heterocyclyl moiety which moiety is unsubstituted or substituted by one substituent selected from C1-C3alkyl, C1-C3haloalkyl, oxo, 3- to 5- membered carbocyclyl, 4- to 5-membered heterocyclyl, and −ORiii; L'' is a direct bond, C1-C3alkylene or C1-C3haloalkylene; and Riiiis selected from hydrogen and C1-C4alkyl; • G1is selected from phenyl, 4- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl, or 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, oxo, −ORGand –(C1-C3alkylene)−ORG, and wherein said phenyl, and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1- C4alkyl, C1-C4haloalkyl, −ORGand –(C1-C3alkylene)−ORG; • G2is selected from phenyl, 4- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, −LG−OH and oxo, and wherein said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, −O−(C1-C4alkyl), C1-C4alkyl and C1- C4haloalkyl; • LGis a direct bond, C1-C4alkylene or C1-C4haloalkylene; • RGis selected from hydrogen, C1-C4alkyl and C1-C4haloalkyl; • Y is linear or branched C1-C4alkylene, linear or branched C1-C4haloalkylene, or −C(O)−; • X1is C or N; and X2is selected from N, NR' and CR''; and X4is selected from N, NR' and CR'''; provided that either (a) at least one of X2and X4is NR', and X1is C, or (b) X2is selected from N and CR'' and X4is selected from N and CR''', and X1is N; wherein R' is hydrogen or C1-C4alkyl, R'' is hydrogen, C1-C4alkyl or halogen, and R''' is hydrogen, C1-C4alkyl, halogen, C1-C4haloalkyl, cyano or 3- to 5-membered carbocyclyl; • L1is −C(O)NRv−Q−, −L1'−NRv−Q−, or –(5- to 6-membered heteroarylene)−Q−, wherein Q is a direct bond, linear or branched C1-C4alkylene, or linear or branched C1-C4haloalkylene, wherein said alkylene and haloalkylene are unsubstituted; L1' is a direct bond, linear or branched C1-C2alkylene, or linear or branched C1-C2haloalkylene, or 4- to 5-membered heterocyclyene; and Rvis hydrogen or C1-C3alkyl; • Raand Rbare the same or different and are selected from C1-C4alkyl or C1-C4haloalkyl; or Raand Rbtogether with the carbon to which they are attached form a 3- to 7- membered cycloalkyl moiety or 4- to 7-membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl; • Rcand Rdare the same or different and are selected from hydrogen and C1-C4alkyl; and • Reand Rfare the same or different and are selected from hydrogen and C1-C4alkyl. In this embodiment, preferably the heterocyclic compound is a compound of formula (Ii) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: wherein • R1is −L'−Z, −L'−C(O)Ry, −L'−C(O)NRiRy, −L'−C(O)OH, −L'−C(O)ORy, −L'−NRiC(O)Ry, or −L'−Het, wherein Het is 4- to 7-membered heterocyclyl or 5- to 7-membered heteroaryl, wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4 alkyl, C1- C4haloalkyl, and −N(C1-C4alkyl)2, and said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, −N(C1-C4alkyl)2; Z is selected from −ORior −NRiRy; Ryis C1-C4alkyl, C1-C4haloalkyl, phenyl, 3- to 7-membered cycloalkyl, 5- to 7-membered heteroaryl or 4- to 7-membered heterocyclyl, wherein said cycloalkyl and heterocyclyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl, and C1-C4haloalkyl, and said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1- C4alkyl, and C1-C4haloalkyl; Riis selected from hydrogen and C1-C4alkyl; and L' is a direct bond, C1-C4alkylene or C1-C4haloalkylene; • R2is hydrogen, C1-C4alkyl, −L''−Z', −L''−C(O)Rz, −L''−C(O)NRiiiRz, −L''−NRiiiC(O)Rz, −L''−NRiiiC(O)ORz, −L''−NRiiiC(O)NRivRz, −L''−NRiiiSO2Rz, or −L''−(4- to 7-membered heterocyclyl), wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl, and C1-C4haloalkyl; wherein Z' is selected from −NH2or −NRiiiRz; Rzis C1-C6alkyl or −A−A', wherein A is phenyl, 3- to 7-membered cycloalkyl, 5- to 7-membered heteroaryl or 4- to 10-membered heterocyclyl, wherein said cycloalkyl and heterocyclyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl and C1-C4haloalkyl, and said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl; A' is hydrogen or 5- to 7-membered heterocyclyl which is unsubstituted or substituted by one C1-C3alkyl group; L'' is a direct bond, C1-C3alkylene or C1-C3haloalkylene; and Riiiis selected from hydrogen and C1-C4alkyl; • G1is selected from phenyl, 4- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl, or 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl and oxo, and wherein said phenyl, and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl; • G2is selected from phenyl, 4- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl and oxo, and wherein said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl; • Y is linear or branched C1-C4alkylene, linear or branched C1-C4haloalkylene, or −C(O)−; • X1is C or N; and X2and X4are the same or different and are selected from N, NR' and CR''; provided that either (a) at least one of X2and X4is NR', and X1is C, or (b) X2and X4are selected from N and CR'', and X1is N; wherein R' is hydrogen or C1-C4alkyl, and R'' is hydrogen, C1-C4alkyl or halogen; • L1is −C(O)NRv−Q−, or −L1'−NRv−Q− wherein Q is a direct bond, linear or branched C1-C4alkylene, or linear or branched C1-C4haloalkylene, wherein said alkylene and haloalkylene are unsubstituted; L1' is a direct bond, linear or branched C1-C2alkylene, or linear or branched C1-C2haloalkylene; and Rvis hydrogen or C1-C3alkyl; • Raand Rbare the same or different and are selected from C1-C4alkyl or C1-C4haloalkyl; or Raand Rbtogether with the carbon to which they are attached form a 3- to 7- membered cycloalkyl moiety or 4- to 7-membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl; • Rcand Rdare the same or different and are selected from hydrogen and C1-C4alkyl; and • Reand Rfare the same or different and are selected from hydrogen and C1-C4alkyl. Alternatively, in one preferred embodiment, the heterocyclic compound is a compound of formula (I'i) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: wherein • R1is C1-C4haloalkyl, −L'−Z, −L'−C(O)Ry, −L'−C(O)NRiRy, −L'−C(O)OH, −L'−C(O)ORy, −L'−NRiC(O)Ry, −L'−SO2NRiRy, or −L'−Het, wherein Het is 4- to 7-membered heterocyclyl or 5- to 7-membered heteroaryl, wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl, C1- C4haloalkyl, and −N(C1-C4alkyl)2, and said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, −N(C1-C4alkyl)2; Z is selected from −ORi, −NRiRyand −SRi; Ryis C1-C4alkyl, C1-C4haloalkyl, phenyl, 3- to 7-membered cycloalkyl, 5- to 7-membered heteroaryl or 4- to 7-membered heterocyclyl, wherein said cycloalkyl and heterocyclyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl, and C1-C4haloalkyl, and said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1- C4alkyl, and C1-C4haloalkyl; Riis selected from hydrogen and C1-C4alkyl; and L' is a direct bond, C1-C4alkylene or C1-C4haloalkylene; • R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety; • G1is selected from phenyl, 4- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl, or 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, oxo, −ORGand –(C1-C3alkylene)−ORG, and wherein said phenyl, and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1- C4alkyl, C1-C4haloalkyl, −ORGand –(C1-C3alkylene)−ORG; • G2is selected from phenyl, 4- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, −LG−OH and oxo, and wherein said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, −O−(C1-C4alkyl), C1-C4alkyl and C1- C4haloalkyl; • LGis a direct bond, C1-C4alkylene or C1-C4haloalkylene; • RGis selected from hydrogen, C1-C4alkyl and C1-C4haloalkyl; • Y is linear or branched C1-C4alkylene, linear or branched C1-C4haloalkylene, or −C(O)−; • X1is C or N; and X2is selected from N, NR' and CR''; and X4is selected from N, NR' and CR'''; provided that either (a) at least one of X2and X4is NR', and X1is C, or (b) X2is selected from N and CR'' and X4is selected from N and CR''', and X1is N; wherein R' is hydrogen or C1-C4alkyl, R'' is hydrogen, C1-C4alkyl or halogen, and R''' is hydrogen, C1-C4alkyl, halogen, C1-C4haloalkyl, cyano or 3- to 5-membered carbocyclyl; • L1is −C(O)NRv−Q−, −L1'−NRv−Q−, or –(5- to 6-membered heteroarylene)−Q−, wherein Q is a direct bond, linear or branched C1-C4alkylene, or linear or branched C1-C4haloalkylene, wherein said alkylene and haloalkylene are unsubstituted; L1' is a direct bond, linear or branched C1-C2alkylene, or linear or branched C1-C2haloalkylene, or 4- to 5-membered heterocyclyene; and Rvis hydrogen or C1-C3alkyl; • Raand Rbare the same or different and are selected from C1-C4alkyl or C1-C4haloalkyl; or Raand Rbtogether with the carbon to which they are attached form a 3- to 7- membered cycloalkyl moiety or 4- to 7-membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl; • Rcand Rdare the same or different and are selected from hydrogen and C1-C4alkyl; and • Reand Rfare the same or different and are selected from hydrogen and C1-C4alkyl. In this embodiment, preferably the heterocyclic compound is a compound of formula (Ii) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: wherein • R1is −L'−Z, −L'−C(O)Ry, −L'−C(O)NRiRy, −L'−C(O)OH, −L'−C(O)ORy, −L'−NRiC(O)Ry, or −L'−Het, wherein Het is 4- to 7-membered heterocyclyl or 5- to 7-membered heteroaryl, wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl, C1- C4haloalkyl, and −N(C1-C4alkyl)2, and said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, −N(C1-C4alkyl)2; Z is selected from −ORior −NRiRy; Ryis C1-C4alkyl, C1-C4haloalkyl, phenyl, 3- to 7-membered cycloalkyl, 5- to 7-membered heteroaryl or 4- to 7-membered heterocyclyl, wherein said cycloalkyl and heterocyclyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, oxo, C1-C4alkyl, and C1-C4haloalkyl, and said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1- C4alkyl, and C1-C4haloalkyl; Riis selected from hydrogen and C1-C4alkyl; and L' is a direct bond, C1-C4alkylene or C1-C4haloalkylene; • R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety; • G1is selected from phenyl, 4- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl, or 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl and oxo, and wherein said phenyl, and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl; • G2is selected from phenyl, 4- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl and oxo, and wherein said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl; • Y is methylene or −C(O)−, wherein said methylene is unsubstituted or substituted by C1-C4alkyl, C1-4haloalkyl, halogen or hydroxy; • X1is C or N; and X2and X4are the same or different and are selected from N, NR' and CR''; provided that either (a) at least one of X2and X4is NR', and X1is C, or (b) X2and X4are selected from N and CR'', and X1is N; wherein R' is hydrogen or C1-C4alkyl, and R'' is hydrogen, C1-C4alkyl or halogen; • L1is −C(O)NRv−Q−, or −L1'−NRv−Q− wherein Q is a direct bond, linear or branched C1-C4alkylene, or linear or branched C1-C4haloalkylene, wherein said alkylene and haloalkylene are unsubstituted; L1' is a direct bond, linear or branched C1-C2alkylene, or linear or branched C1-C2haloalkylene; and Rvis hydrogen or C1-C3alkyl; • Raand Rbare the same or different and are selected from C1-C4alkyl or C1-C4haloalkyl; or Raand Rbtogether with the carbon to which they are attached form a 3- to 7- membered cycloalkyl moiety or 4- to 7-membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl; • Rcand Rdare the same or different and are selected from hydrogen and C1-C4alkyl; and • Reand Rfare the same or different and are selected from hydrogen and C1-C4alkyl. In a more preferred embodiment, the heterocyclic compound is a compound of formula (I'ii(a)) or (I'ii(b)) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: (I'ii(b)) wherein • R1is −C1-C4haloalkyl, −SRi, –(C1-C4alkylene)−ORi, −C(O)Ry, −C(O)NRiRy, −C(O)OH, −C(O)ORy, −NRiC(O)Ry, −SO2NRiRy, or −Het, wherein Het is 4- to 6-membered heterocyclyl or 5- to 6-membered heteroaryl, wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from oxo, C1-C4alkyl, and −N(C1- C4alkyl)2, and said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from C1-C4alkyl; Ryis C1-C4alkyl, 3- to 7-membered cycloalkyl or 4- to 7-membered heterocyclyl, wherein said cycloalkyl and heterocyclyl are unsubstituted or substituted by one C1-C4alkyl group; and Riis selected from hydrogen and C1-C4alkyl; • R2is hydrogen, C1-C4alkyl, C1-C4haloalkyl, −Z', −C(O)Rz, −C(O)ORz, −C(O)NRiiiRz, −C(O)NH2, −NRiiiC(O)Rz, −NRiiiC(O)ORz, −NRiiiC(O)NRivRz, −NRiiiC(O)C(O)NRivRz, −NRiiiSO2Rz, −(4- to 7-membered heterocyclyl) which is unsubstituted or substituted by one oxo group, or −(5- to 7-membered heteroaryl) which is unsubstituted or substituted with one C1-C3alkyl group; wherein Z' is selected from −OH, −O(C1-C3alkyl), −NH2, −NRiii(C1-C3alkyl), −NRiii(C1-C3haloalkyl), a −NH−(5- to 6-membered heteroaryl) group which is unsubstituted, and a −NH−(4- to 6-membered heterocyclyl) group which is unsubstituted or substituted with one C1-C3alkyl group, or one C1-C3alkyl group and one oxo group; Rzis C1-C6alkyl, C1-C6haloalkyl, −(C1-C3alkylene)−Z', −A−A', −(C1-C3alkylene)−A−A', −(C1-C3alkylene−O−C1-C3alkylene)−A−A', or −A−(C1-C3alkylene)−A, wherein A is a phenyl moiety which is unsubstituted or substituted with one substituent selected from C1-C3alkyl, halogen, −N(C1-C3alkyl)2, and –(C1- C3alkylene)−C(O)NRiii(C1-C3alkyl), a 3- to 7-membered cycloalkyl moiety which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from C1-C3alkyl, halogen, cyano, and −ORiii, a 5- to 7-membered heteroaryl moiety which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C3 alkyl, or a 4- to 10-membered heterocyclyl moiety which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, cyano, C1-C3alkyl, and oxo; A' is hydrogen, a phenyl moiety which moiety is unsubstituted or substituted with −(C1-C3alkylene)−NRiiiRiv,or a 4- to 8-membered heterocyclyl moiety which moiety is unsubstituted or substituted by one substituent selected from C1-C3alkyl, C1-C3haloalkyl, oxo, 3- to 5- membered carbocyclyl, 4- to 5-membered heterocyclyl, and −ORiii; and Riiiis selected from hydrogen and C1-C4alkyl; • G1is selected from phenyl, 4- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl, or 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, oxo, −ORGand –(C1-C3alkylene)−ORG, and wherein said phenyl, and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1- C4 alkyl, C1-C4 haloalkyl, −ORGand –(C1-C3 alkylene)−ORG; • G2is selected from phenyl, 4- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, −LG−OH and oxo, and wherein said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, −O−(C1-C4alkyl), C1-C4alkyl and C1- C4haloalkyl; • LGis a direct bond or C1-C3alkylene; • RGis selected from hydrogen and C1-C3 alkyl; • Y is methylene or −C(O)−, wherein said methylene is unsubstituted or substituted by C1-C4alkyl, C1-4haloalkyl, halogen or hydroxy; • R''' is hydrogen, C1-C4alkyl, halogen, C1-C4haloalkyl, cyano or 3- to 5-membered carbocyclyl; • L1is −C(O)NRv−Q−, –(4-membered heterocyclylene)−NRv−Q−, −NRv−Q− or –(5- membered heteroarylene)−Q−, wherein Q is a direct bond, or unsubstituted C1-C2alkylene, and Rvis hydrogen or C1-C3alkyl; • Raand Rbare the same or different and are C1-C4alkyl; or Raand Rbtogether with the carbon to which they are attached form a 3- to 7-membered cycloalkyl moiety or 4- to 6- membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C4alkyl; • Rcand Rdare the same or different and are selected from hydrogen and methyl; and • Reand Rfare the same or different and are selected from hydrogen and methyl. In this embodiment, more preferably the heterocyclic compound is a compound of formula (Iii) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: wherein • R1is –(C1-C4alkylene)−ORi, −C(O)Ry, −C(O)NRiRy, −C(O)OH, −C(O)ORy, −NRiC(O)Ry, or −Het, wherein Het is 4- to 6-membered heterocyclyl or 5- to 6-membered heteroaryl, wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from oxo, C1-C4alkyl, and −N(C1- C4alkyl)2, and said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from C1-C4alkyl; Ryis C1-C4alkyl, 3- to 7-membered cycloalkyl or 4- to 7-membered heterocyclyl, wherein said cycloalkyl and heterocyclyl are unsubstituted or substituted by one C1-C4alkyl group; and Riis selected from hydrogen and C1-C4alkyl; • R2is hydrogen, C1-C4alkyl, −Z', −C(O)Rz, −C(O)NRiiiRz, −NRiiiC(O)Rz, −NRiiiC(O)ORz, −NRiiiC(O)NRivRz, −NRiiiSO2Rz, or −4- to 7-membered heterocyclyl which is unsubstituted or substituted by one oxo group; wherein Z' is selected from −NH2, −NRiii(C1-C3alkyl), a −NH−(5- to 6-membered heteroaryl) group which is unsubstituted, or a −NH−(4- to 6-membered heterocyclyl) group which is unsubstituted or substituted with one C1-C3alkyl group; Rzis C1-C6alkyl or −A−A', wherein A is a phenyl moiety, a 3- to 7-membered cycloalkyl moiety, a 5- to 7-membered heteroaryl moiety or a 4- to 10-membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one C1-C3alkyl group; A' is hydrogen or 5- to 7-membered heterocyclyl which is unsubstituted or substituted by one C1-C3alkyl group; and Riiiis selected from hydrogen and C1-C4alkyl; • G1is selected from a phenyl moiety, a 4- to 7-membered heterocyclyl moiety, a 5- to 7-membered heteroaryl moiety, or a 4- to 7-membered cycloalkyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl; • G2is selected from phenyl, 4- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one substituent selected from C1-C4alkyl and oxo, and wherein said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4 haloalkyl; • Y is methylene or −C(O)−, wherein said methylene is unsubstituted or substituted by C1-C4alkyl, C1-4haloalkyl, halogen or hydroxy; • R'' is hydrogen, C1-C4alkyl or halogen; • L1is −C(O)NRv−Q−, or −NRv−Q− wherein Q is a direct bond, or unsubstituted C1- C2alkylene, and Rvis hydrogen or C1-C3alkyl; • Raand Rbare the same or different and are C1-C4alkyl; or Raand Rbtogether with the carbon to which they are attached form a 4- to 6-membered cycloalkyl moiety or 4- to 6- membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C4alkyl; • Rcand Rdare the same or different and are selected from hydrogen and methyl; and • Reand Rfare the same or different and are selected from hydrogen and methyl. In a yet more preferred embodiment, the heterocyclic compound is a compound of formula (I'ii(a)) or (I'ii(b)) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof, wherein • R1is C1-C3haloalkyl, −SRi, (C1-C4alkylene)−OH, −C(O)Ry, −C(O)NRi(C1-C3alkyl), −C(O)OH, −C(O)O(C1-C3alkyl), −NRiC(O)(C1-C3alkyl), −SO2NRi(C1-C3alkyl), 4- to 5-membered heterocyclyl which is unsubstituted or substituted by one oxo group, one C1- C3alkyl group or one −N(C1-C3alkyl)2group, or which is substituted by one oxo group and one C1-C3alkyl group; or a 5-membered heteroaryl group which is unsubstituted or substituted with one or two C1-C3alkyl, wherein Ryis C1-C3alkyl, or unsubstituted 4- to 6-membered heterocyclyl; and Riis hydrogen or C1-C3alkyl; • R2is hydrogen, C1-C3alkyl, C1-C3haloalkyl, −Z', −C(O)(C1-C3alkyl), −C(O)O(C1- C4alkyl), −C(O)NRiii(C1-C3alkyl), −C(O)NRiii(−A−A'), −C(O)NH2, −NRiiiC(O)Rz, −NRiiiC(O)O(C1-C4alkyl), −NRiiiC(O)O(−A−A'), −NRiiiC(O)NRiv(C1-C3alkyl), −NRiiiC(O)C(O)NRiv(C1-C3alkyl), −NHSO2(C1-C3alkyl), 5-membered heterocyclyl which is unsubstituted or substituted with one oxo group, or 5-membered heteroaryl which is unsubstituted or substituted with one C1-C3alkyl group, wherein Z' is −NH2, −NRiii(C1-C3alkyl), −NRiii(C1-C3haloalkyl), a −NH−(6- membered heteroaryl) group which is unsubstituted, a −NH−(4-membered heterocyclyl) group which is unsubstituted or substituted with one C1-C3alkyl group, or a −NH−(6-membered heterocyclyl) group which is substituted with one C1-C3alkyl group and one oxo group; Rzis C1-C5alkyl, or 3- to 5-membered cycloalkyl which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, cyano, and −ORiii, or 4- to 10 membered heterocyclyl which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, cyano, C1-C3alkyl, and oxo, or phenyl−A' wherein said phenyl is unsubstituted or substituted with one substituent selected from C1-C3 alkyl, halogen, −N(C1-C3 alkyl)2, and –(C1-C3 alkylene)−C(O)NRiii(C1-C3 alkyl), or (5- to 6-membered heteroaryl)−A' wherein said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C3alkyl, wherein A' is hydrogen, phenyl which is substituted with −(C1-C3alkylene)−NH(CH3), a 4-membered heterocyclyl which is unsubstituted or substituted with one substituent selected from methyl, cyclopropyl, cyclobutyl, and methoxy, a 5-membered heterocyclyl which is unsubstituted or substituted with one methoxy group, a 6-membered heterocyclyl which is unsubstituted or substituted with one substituent selected from methyl, ethyl, C2haloalkyl, cyclopropyl, cyclobutyl, oxetanyl, oxo, and methoxy, or an unsubstituted 7- to 8-membered heterocyclyl, and Riiiis hydrogen or C1-C3alkyl; • G1is unsubstituted 5- to 6-membered heterocyclyl, unsubstituted 5- to 6-membered cycloalkyl, 5- to 6-membered heteroaryl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine, chlorine and C1-C3alkyl, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine, chlorine and C1-C3alkyl; • G2is 5- to 10-membered heterocyclyl which is unsubstituted or substituted with one oxo group; 5- to 6- membered cycloalkyl which is unsubstituted or substituted with one hydroxy group; 5- to 10- membered heteroaryl which is unsubstituted or substituted with one halogen group, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from halogen, −O−(C1-C3alkyl) and C1-C3alkyl; • Y is methylene or −C(O)−; • R''' is hydrogen, halogen, methyl, trifluoromethyl, cyano or 3-to 4-membered carbocyclyl; • L1is −C(O)NRv−Q−, –(oxetanylene)−NRv−Q−, or –(triazolylene)−Q−, wherein Q is a direct bond or methylene and Rvis hydrogen or C1-C3alkyl; and Raand Rbare the same or different and are C1-C3alkyl, or Raand Rbtogether with the carbon to which they are attached form an unsubstituted 4- to 6-membered heterocyclyl, or a 3- to 7-membered cycloalkyl which is unsubstituted or substituted by one or two substituents selected from fluorine and C1-C3alkyl. In this embodiment, yet more preferably the heterocyclic compound is a compound of formula (Iii) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof, wherein • R1is (C1-C4alkylene)−OH, −C(O)Ry, −C(O)NRi(C1-C3alkyl), −C(O)OH, −C(O)O(C1-C3alkyl), −NRiC(O)(C1-C3alkyl); 4- to 5-membered heterocyclyl which is unsubstituted or substituted by one oxo group, one C1-C3alkyl group or one −N(C1-C3alkyl)2group; or a 5-membered heteroaryl group which is unsubstituted or substituted with one C1-C3alkyl, wherein Ryis C1-C3alkyl, or unsubstituted 4- to 6-membered heterocyclyl; and Riis hydrogen or C1-C3alkyl; • R2is hydrogen, C1-C3alkyl, −Z', −C(O)(C1-C3alkyl), −C(O)NRiii(C1-C3alkyl), −NRiiiC(O)Rz, −NHC(O)O(C1-C4alkyl), −NHC(O)N(C1-C3alkyl)2, −NHSO2(C1-C3alkyl), or 5-membered heterocyclyl which is unsubstituted or substituted with one oxo group, wherein Z' is −NH2, −NRiii(C1-C3alkyl), a −NH−(6-membered heteroaryl) group which is unsubstituted, or a −NH−(4-membered heterocyclyl) group which is unsubstituted or substituted with one C1-C3alkyl group; Rzis C1-C5alkyl, unsubstituted 3- to 5-membered cycloalkyl, unsubstituted 6-membered heteroaryl, unsubstituted 4-membered heterocyclyl, 9- to 10-membered heterocyclyl which is unsubstituted or substituted with one C1-C3alkyl group, or phenyl−A' wherein said phenyl is unsubstituted or substituted with one C1-C3alkyl group, wherein A' is hydrogen or 6-membered heterocyclyl which is unsubstituted or substituted with one methyl group, and Riiiis hydrogen or C1-C3alkyl; • G1is unsubstituted 5- to 6-membered heterocyclyl, unsubstituted 5- to 6-membered heteroaryl, unsubstituted 5- to 6-membered cycloalkyl, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine and C1-C3alkyl; • G2is 5- to 10-membered heterocyclyl which is unsubstituted or substituted with one oxo group; unsubstituted 5- to 6- membered cycloalkyl; unsubstituted 5- to 10- membered heteroaryl, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine and C1-C3alkyl; • Y is methylene or −C(O)−; • R'' is hydrogen or fluorine; • L1is −C(O)NRv−Q−, wherein Q is a direct bond or methylene and Rvis hydrogen or C1-C3alkyl; and • Raand Rbare the same or different and are C1-C3alkyl, or Raand Rbtogether with the carbon to which they are attached form an unsubstituted 4- to 6-membered heterocyclyl, or a 4- to 6-membered cycloalkyl which is unsubstituted or substituted by two substituents selected from fluorine and C1-C3alkyl. Alternatively, in a more preferred embodiment, the heterocyclic compound is a compound of formula (I'ii(a)) or (I'ii(b)) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: (I'ii(b)) wherein • R1is −C1-C4haloalkyl, −SRi, –(C1-C4alkylene)−ORi, −C(O)Ry, −C(O)NRiRy, −C(O)OH, −C(O)ORy, −NRiC(O)Ry, −SO2NRiRy, or −Het, wherein Het is 4- to 6-membered heterocyclyl or 5- to 6-membered heteroaryl, wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from oxo, C1-C4alkyl, and −N(C1- C4alkyl)2, and said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from C1-C4alkyl; Ryis C1-C4alkyl, 3- to 7-membered cycloalkyl or 4- to 7-membered heterocyclyl, wherein said cycloalkyl and heterocyclyl are unsubstituted or substituted by one C1-C4alkyl group; and Riis selected from hydrogen and C1-C4alkyl; • R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety; • G1is selected from phenyl, 4- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl, or 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, oxo, −ORGand –(C1-C3alkylene)−ORG, and wherein said phenyl, and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1- C4alkyl, C1-C4haloalkyl, −ORGand –(C1-C3alkylene)−ORG; • G2is selected from phenyl, 4- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, −LG−OH and oxo, and wherein said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, −O−(C1-C4alkyl), C1-C4alkyl and C1- C4haloalkyl; • LGis a direct bond or C1-C3alkylene; • RGis selected from hydrogen and C1-C3alkyl; • Y is methylene or −C(O)−, wherein said methylene is unsubstituted or substituted by C1-C4alkyl, C1-4haloalkyl, halogen or hydroxy; • R''' is hydrogen, C1-C4alkyl, halogen, C1-C4haloalkyl, cyano or 3- to 5-membered carbocyclyl; • L1is −C(O)NRv−Q−, –(4-membered heterocyclylene)−NRv−Q−, −NRv−Q− or –(5- membered heteroarylene)−Q−, wherein Q is a direct bond, or unsubstituted C1-C2alkylene, and Rvis hydrogen or C1-C3alkyl; • Raand Rbare the same or different and are C1-C4alkyl; or Raand Rbtogether with the carbon to which they are attached form a 3- to 7-membered cycloalkyl moiety or 4- to 6- membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C4alkyl; • Rcand Rdare the same or different and are selected from hydrogen and methyl; and • Reand Rfare the same or different and are selected from hydrogen and methyl. In this embodiment, more preferably the heterocyclic compound is a compound of formula (Iii) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: wherein • R1is –(C1-C4alkylene)−ORi, −C(O)Ry, −C(O)NRiRy, −C(O)OH, −C(O)ORy, −NRiC(O)Ry, or −Het, wherein Het is 4- to 6-membered heterocyclyl or 5- to 6-membered heteroaryl, wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from oxo, C1-C4 alkyl, and −N(C1- C4alkyl)2, and said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from C1-C4alkyl; Ryis C1-C4alkyl, 3- to 7-membered cycloalkyl or 4- to 7-membered heterocyclyl, wherein said cycloalkyl and heterocyclyl are unsubstituted or substituted by one C1-C4alkyl group; and Riis selected from hydrogen and C1-C4alkyl; • R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety; • G1is selected from a phenyl moiety, a 4- to 7-membered heterocyclyl moiety, a 5- to 7-membered heteroaryl moiety, or a 4- to 7-membered cycloalkyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl; • G2is selected from phenyl, 4- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one substituent selected from C1-C4alkyl and oxo, and wherein said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl; • Y is methylene or −C(O)−; • R'' is hydrogen, C1-C4alkyl or halogen; • L1is −C(O)NRv−Q−, or −NRv−Q− wherein Q is a direct bond, or unsubstituted C1- C2alkylene, and Rvis hydrogen or C1-C3alkyl; • Raand Rbare the same or different and are C1-C4alkyl; or Raand Rbtogether with the carbon to which they are attached form a 4- to 6-membered cycloalkyl moiety or 4- to 6- membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C4alkyl; • Rcand Rdare the same or different and are selected from hydrogen and methyl; and • Reand Rfare the same or different and are selected from hydrogen and methyl. In this embodiment, yet more preferably the heterocyclic compound is a compound of formula (Iii) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof, wherein • R1is (C1-C4alkylene)−OH, −C(O)Ry, −C(O)NRi(C1-C3alkyl), −C(O)OH, −C(O)O(C1-C3alkyl), −NRiC(O)(C1-C3alkyl); 4- to 5-membered heterocyclyl which is unsubstituted or substituted by one oxo group, one C1-C3alkyl group or one −N(C1-C3alkyl)2group; or a 5-membered heteroaryl group which is unsubstituted or substituted with one C1-C3alkyl, wherein Ryis C1-C3alkyl, or unsubstituted 4- to 6-membered heterocyclyl; and Riis hydrogen or C1-C3alkyl; • R2is hydrogen, C1-C3alkyl, −Z', −C(O)(C1-C3alkyl), −C(O)NRiii(C1-C3alkyl), −NRiiiC(O)Rz, −NHC(O)O(C1-C4alkyl), −NHC(O)N(C1-C3alkyl)2, −NHSO2(C1-C3alkyl), or 5-membered heterocyclyl which is unsubstituted or substituted with one oxo group, wherein Z' is −NH2, −NRiii(C1-C3alkyl), a −NH−(6-membered heteroaryl) group which is unsubstituted, or a −NH−(4-membered heterocyclyl) group which is unsubstituted or substituted with one C1-C3alkyl group; Rzis C1-C5alkyl, unsubstituted 3- to 5-membered cycloalkyl, unsubstituted 6-membered heteroaryl, unsubstituted 4-membered heterocyclyl, 9- to 10-membered heterocyclyl which is unsubstituted or substituted with one C1-C3alkyl group, or phenyl−A' wherein said phenyl is unsubstituted or substituted with one C1-C3alkyl group, wherein A' is hydrogen or 6-membered heterocyclyl which is unsubstituted or substituted with one methyl group, and Riiiis hydrogen or C1-C3alkyl; • G1is unsubstituted 5- to 6-membered heterocyclyl, unsubstituted 5- to 6-membered heteroaryl, unsubstituted 5- to 6-membered cycloalkyl, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine and C1-C3alkyl; • G2is 5- to 10-membered heterocyclyl which is unsubstituted or substituted with one oxo group; unsubstituted 5- to 6- membered cycloalkyl; unsubstituted 5- to 10- membered heteroaryl, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine and C1-C3alkyl; • Y is methylene or −C(O)−; • R'' is hydrogen or fluorine; • L1is −C(O)NRv−Q−, wherein Q is a direct bond or methylene and Rvis hydrogen or C1-C3alkyl; and • Raand Rbare the same or different and are C1-C3alkyl, or Raand Rbtogether with the carbon to which they are attached form an unsubstituted 4- to 6-membered heterocyclyl, or a 4- to 6-membered cycloalkyl which is unsubstituted or substituted by two substituents selected from fluorine and C1-C3alkyl. In a yet more preferred embodiment, the heterocyclic compound is a compound of formula (I'ii(a)) or (I'ii(b)) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof, wherein • R1is C1-C3haloalkyl, −SRi, (C1-C4alkylene)−OH, −C(O)Ry, −C(O)NRi(C1-C3alkyl), −C(O)OH, −C(O)O(C1-C3alkyl), −NRiC(O)(C1-C3alkyl), −SO2NRi(C1-C3alkyl), 4- to 5-membered heterocyclyl which is unsubstituted or substituted by one oxo group, one C1- C3alkyl group or one −N(C1-C3alkyl)2group, or which is substituted by one oxo group and one C1-C3alkyl group; or a 5-membered heteroaryl group which is unsubstituted or substituted with one or two C1-C3alkyl, wherein Ryis C1-C3alkyl, or unsubstituted 4- to 6-membered heterocyclyl; and Riis hydrogen or C1-C3 alkyl; • R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety; • G1is unsubstituted 5- to 6-membered heterocyclyl, unsubstituted 5- to 6-membered cycloalkyl, 5- to 6-membered heteroaryl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine, chlorine and C1-C3alkyl, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine, chlorine and C1-C3 alkyl; • G2is 5- to 10-membered heterocyclyl which is unsubstituted or substituted with one oxo group; 5- to 6- membered cycloalkyl which is unsubstituted or substituted with one hydroxy group; 5- to 10- membered heteroaryl which is unsubstituted or substituted with one halogen group, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from halogen, −O−(C1-C3alkyl) and C1-C3alkyl; • Y is methylene or −C(O)−; • R''' is hydrogen, halogen, methyl, trifluoromethyl, cyano or 3-to 4-membered carbocyclyl; • L1is −C(O)NRv−Q−, –(oxetanylene)−NRv−Q−, or –(triazolylene)−Q−, wherein Q is a direct bond or methylene and Rvis hydrogen or C1-C3alkyl; and Ra and Rb are the same or different and are C1-C3 alkyl, or Ra and Rb together with the carbon to which they are attached form an unsubstituted 4- to 6-membered heterocyclyl, or a 3- to 7-membered cycloalkyl which is unsubstituted or substituted by one or two substituents selected from fluorine and C1-C3alkyl. In this embodiment, yet more preferably the heterocyclic compound is a compound of formula (Iii) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof, wherein • R1is (C1-C4alkylene)−OH, −C(O)Ry, −C(O)NRi(C1-C3alkyl), −C(O)OH, −C(O)O(C1-C3alkyl), −NRiC(O)(C1-C3alkyl); 4- to 5-membered heterocyclyl which is unsubstituted or substituted by one oxo group, one C1-C3alkyl group or one −N(C1-C3alkyl)2group; or a 5-membered heteroaryl group which is unsubstituted or substituted with one C1-C3alkyl, wherein Ryis C1-C3alkyl, or unsubstituted 4- to 6-membered heterocyclyl; and Riis hydrogen or C1-C3alkyl; • R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety; • G1is unsubstituted 5- to 6-membered heterocyclyl, unsubstituted 5- to 6-membered heteroaryl, unsubstituted 5- to 6-membered cycloalkyl, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine and C1-C3alkyl; • G2is 5- to 10-membered heterocyclyl which is unsubstituted or substituted with one oxo group; unsubstituted 5- to 6- membered cycloalkyl; unsubstituted 5- to 10- membered heteroaryl, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine and C1-C3alkyl; • Y is methylene or −C(O)−; • R'' is hydrogen or fluorine; • L1is −C(O)NRv−Q−, wherein Q is a direct bond or methylene and Rvis hydrogen or C1-C3alkyl; and • Raand Rbare the same or different and are C1-C3alkyl, or Raand Rbtogether with the carbon to which they are attached form an unsubstituted 4- to 6-membered heterocyclyl, or a 4- to 6-membered cycloalkyl which is unsubstituted or substituted by two substituents selected from fluorine and C1-C3alkyl. In a further preferred embodiment, the heterocyclic compound is a compound of formula (I'iii(a)) or (I'iii(b)) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: (I'iii(b)) wherein • R1is CF2CH3, −SCH3, C4 alkylene−OH, −C(O)Ry, −C(O)NHCH3, −C(O)N(CH3)2, −C(O)N(CH3)(C3alkyl), −C(O)N(CH2CH3)2,−C(O)OH, −C(O)OCH3, −NHC(O)CH3, −N(CH3)C(O)CH3, −SO2NH(CH3), or unsubstituted pyrrolidinone, or an oxetanyl moiety which is unsubstituted or substituted by one methyl group or one −N(CH3)2 group, or a triazolyl moiety which is unsubstituted, substituted with one methyl group, or substituted with one oxo group and one methyl group, or an imidazolyl moiety which is unsubstituted, substituted with one or two methyl groups, or substituted with one oxo group and one methyl group, or a pyrazolyl moiety which is unsubstituted or substituted by one methyl group, or unsubstituted oxadiazolyl, or an oxazolyl moiety which is unsubstituted or substituted by one methyl group, or a furanyl moiety which is substituted with two methyl groups, or unsubstituted tetrahydrofuranyl, or unsubstituted tetrazolyl, wherein Ryis methyl, ethyl, i-propyl, unsubstituted azetidinyl, unsubstituted pyrrolidinyl, unsubstituted piperidinyl, or unsubstituted morpholinyl; • R2is hydrogen, methyl, −CH2F, −Z', −C(O)CH3, −C(O)O(tert-butyl), −C(O)NH(CH3), −C(O)N(CH3)2, −C(O)NH(−A−A'), −C(O)NH2, −N(CH3)C(O)CH3, −NHC(O)Rz, −NHC(O)O(C3-C4alkyl), −NHC(O)O(unsubstituted phenyl), −NHC(O)N(CH3)2, −NHC(O)N(CH3)(CH2CH3), −NHC(O)NH(CH3), −NHC(O)C(O)N(CH3)2, −NHSO2(CH3), unsubstituted pyrrolidinone, unsubstituted dihydrotriazolone, unsubstituted oxadiazolone, imidazolyl which is unsubstituted or substituted with one methyl group, triazolyl which is unsubstituted or substituted with one methyl group, or unsubstituted tetrazolyl, wherein Z' is −NH2, −NH(CH3), −N(CH3)2, −NHCH2CF3, a −NH−pyridinyl group which is unsubstituted, a −NH−oxetanyl group which is unsubstituted or substituted with one methyl group, or a −NH−(unsubstituted pyrimidinone) group; Rzis methyl, tert-butyl, iso-butyl, −CH2−(tert-butyl), cyclopropyl which is unsubstituted or substituted with one halogen group, cyclobutyl which is unsubstituted or substituted with one cyano group or one methoxy group, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted cyclohexyl, oxadiazolyl which is substituted with one methyl group, unsubstituted thiazolyl, benzodioxazolyl which is unsubstituted or substituted with one or two halogen groups, oxetanyl which is unsubstituted or substituted with one methyl group, azetidinyl which is unsubstituted or substituted with one cyano group or one methoxy group, unsubstituted pyrrolidinyl, pyrimidinonyl which is unsubstituted or substituted with one methyl group, indolinyl which is unsubstituted or substituted with one methyl group, morpholinyl which is unsubstituted or substituted with one methyl group, piperidinyl which is unsubstituted or substituted with one methyl group, piperazinyl which is unsubstituted or substituted with one methyl group, tetrahydroquinoline which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and methyl, unsubstituted tetrahydrofuranyl, unsubstituted tetrahydropyranyl, tetrahydropyrazolo[1,5-a]pyrazinyl which is unsubstituted or substituted with one methyl group, tetrahydro-1H,3H-5l2-furo[3,4- c]pyrrole which is substituted with one or two methyl groups, unsubstituted oxa- azaspiroheptane, unsubstituted oxa-azaspirooctane, unsubstituted oxa- azaspirononane, unsubstituted oxa-azabicycloheptane, unsubstituted oxa- azabicycloctane, or phenyl−A' wherein said phenyl is unsubstituted or substituted with one substituent selected from methyl, propyl, halogen, −N(CH3)2, and – (ethylene)−C(O)NH(CH3), or (imidazolyl)−A' wherein said imidazolyl is unsubstituted or substituted with one methyl group, or (pyrazolyl)−A' wherein said pyrazolyl is unsubstituted or substituted with one or two methyl groups, or (pyridinyl)−A' wherein said pyridinyl is unsubstituted or substituted with one C1-C3alkyl group or one halogen group, or (pyrimidinyl)−A' wherein said pyrimidinyl is unsubstituted or substituted with one methyl group, wherein A' is hydrogen, phenyl which is substituted with −(CH2)−NH(CH3), azetidinyl which is substituted with one substituent selected from methyl, methoxy, cyclopropyl, and cyclobutyl, piperidinyl which is substituted with one substituent selected from methyl, ethyl, cyclopropyl, cyclobutyl, −CH2CH2F, −CH2CHF2, methoxy, and oxetanyl, morpholinyl which is unsubstituted or substituted with one methyl group or one oxo group, piperazinyl which is substituted with one substituent selected from methyl, cyclopropyl, and cyclobutyl, tetrahydropyridinyl which is substituted with one methyl group, pyrrolidinyl which is substituted with one methoxy group, or unsubstituted oxazaspiroheptane, unsubstituted oxazaspirooctane, or unsubstituted tetrahydropyranyl; • G1is unsubstituted piperidinyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted cyclohexyl, unsubstituted pyrimidinyl, pyridinyl which is unsubstituted or substituted with one methyl group, one fluorine group, or one chlorine group, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine, chlorine and methyl; • G2is unsubstituted piperidinyl, unsubstituted benzimidazolyl, unsubstituted pyrrolidinyl, unsubstituted tetrahydropyranyl, unsubstituted bicyclo[1.1.1]pentyl, cyclohexyl which is unsubstituted or substituted with one hydroxy group, unsubstituted indolinyl, unsubstituted oxoindolinyl, unsubstituted benzoxazolonyl, unsubstituted dihydroquinolinonyl, pyridinyl which is unsubstituted or substituted with one chlorine group, unsubstituted pyrimidinyl, unsubstituted indolyl, unsubstituted oxazolyl, unsubstituted thiazolyl, or phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine, chlorine, methoxy and methyl; • Y is methylene or −C(O)−; • R''' is hydrogen, fluorine, chlorine, bromine, methyl, trifluoromethyl, cyano, or cyclopropyl; • L1is −C(O)NRv−Q−, –(oxetanylene)−NRv−Q−, or –(triazolylene)−Q−, wherein Q is a direct bond or methylene, and Rvis hydrogen or methyl; • Rais methyl and Rbis methyl; or Raand Rbtogether with the carbon to which they are attached form unsubstituted oxetanyl, unsubstituted tetrahydrofuranyl, unsubstituted cyclopropyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or a cyclobutyl group which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl. In this embodiment, further preferably the heterocyclic compound is a compound of formula (Iiii) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: wherein • R1is C4alkylene−OH, −C(O)Ry, −C(O)NHCH3, −C(O)N(CH3)2, −C(O)N(CH3)(C3alkyl), −C(O)OH, −C(O)OCH3, −NHC(O)CH3, −N(CH3)C(O)CH3, unsubstituted pyrrolidinone, an oxetanyl moiety which is unsubstituted or substituted by one methyl group or one −N(CH3)2group, an imidazolyl or triazolyl moiety which is unsubstituted or substituted with one methyl group, or unsubstituted pyrazolyl, or unsubstituted oxadiazolyl, or unsubstituted oxazolyl, wherein Ryis i-propyl, unsubstituted azetidinyl, unsubstituted pyrrolidinyl, unsubstituted piperidinyl, or unsubstituted morpholinyl; • R2is hydrogen, methyl, −Z', −C(O)CH3, −C(O)NH(CH3), −C(O)N(CH3)2, −N(CH3)C(O)CH3, −NHC(O)Rz, −NHC(O)O(C4alkyl), −NHC(O)N(CH3)2, −NHSO2(CH3), or unsubstituted pyrrolidinone, wherein Z' is −NH2, −NH(CH3), −N(CH3)2, a −NH−pyridinyl group which is unsubstituted, or a −NH−oxetanyl group which is unsubstituted or substituted with one methyl group; Rzis methyl, tert-butyl, −CH2−(tert-butyl), unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted pyridinyl, unsubstituted oxetanyl, indolinyl which is unsubstituted or substituted with one methyl group, tetrahydropyrazolo[1,5-a]pyrazinyl which is unsubstituted or substituted with one methyl group, or phenyl−A' wherein said phenyl is unsubstituted or substituted with one propyl group, wherein A' is hydrogen, piperidinyl which is unsubstituted or substituted with one methyl group, or unsubstituted tetrahydropyranyl; • G1is unsubstituted piperidinyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted pyridinyl, or phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl; • G2is unsubstituted piperidinyl, unsubstituted benzimidazolyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted indolinyl, unsubstituted oxoindolinyl or unsubstituted pyridinyl, or phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl; • Y is methylene or −C(O)−; • R'' is hydrogen or fluorine; • L1is −C(O)NRv−Q−, wherein Q is a direct bond or methylene, and Rvis hydrogen or methyl; • Rais methyl and Rbis methyl; or Raand Rbtogether with the carbon to which they are attached form unsubstituted oxetanyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or a cyclobutyl group which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl. Alternatively, in a further preferred embodiment, the heterocyclic compound is a compound of formula (I'iii(a)) or (I'iii(b)) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: (I'iii(b)) • R1is CF2CH3, −SCH3, C4 alkylene−OH, −C(O)Ry, −C(O)NHCH3, −C(O)N(CH3)2, −C(O)N(CH3)(C3alkyl), −C(O)N(CH2CH3)2,−C(O)OH, −C(O)OCH3, −NHC(O)CH3, −N(CH3)C(O)CH3, −SO2NH(CH3), or unsubstituted pyrrolidinone, or an oxetanyl moiety which is unsubstituted or substituted by one methyl group or one −N(CH3)2group, or a triazolyl moiety which is unsubstituted, substituted with one methyl group, or substituted with one oxo group and one methyl group, or an imidazolyl moiety which is unsubstituted, substituted with one or two methyl groups, or substituted with one oxo group and one methyl group, or a pyrazolyl moiety which is unsubstituted or substituted by one methyl group, or unsubstituted oxadiazolyl, or an oxazolyl moiety which is unsubstituted or substituted by one methyl group, or a furanyl moiety which is substituted with two methyl groups, or unsubstituted tetrahydrofuranyl, or unsubstituted tetrazolyl, wherein Ryis methyl, ethyl, i-propyl, unsubstituted azetidinyl, unsubstituted pyrrolidinyl, unsubstituted piperidinyl, or unsubstituted morpholinyl; • R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety • G1is unsubstituted piperidinyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted cyclohexyl, unsubstituted pyrimidinyl, pyridinyl which is unsubstituted or substituted with one methyl group, one fluorine group, or one chlorine group, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine, chlorine and methyl; • G2is unsubstituted piperidinyl, unsubstituted benzimidazolyl, unsubstituted pyrrolidinyl, unsubstituted tetrahydropyranyl, unsubstituted bicyclo[1.1.1]pentyl, cyclohexyl which is unsubstituted or substituted with one hydroxy group, unsubstituted indolinyl, unsubstituted oxoindolinyl, unsubstituted benzoxazolonyl, unsubstituted dihydroquinolinonyl, pyridinyl which is unsubstituted or substituted with one chlorine group, unsubstituted pyrimidinyl, unsubstituted indolyl, unsubstituted oxazolyl, unsubstituted thiazolyl, or phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine, chlorine, methoxy and methyl; • Y is methylene or −C(O)−; • R''' is hydrogen, fluorine, chlorine, bromine, methyl, trifluoromethyl, cyano, or cyclopropyl; • L1is −C(O)NRv−Q−, –(oxetanylene)−NRv−Q−, or –(triazolylene)−Q−, wherein Q is a direct bond or methylene, and Rvis hydrogen or methyl; • Rais methyl and Rbis methyl; or Raand Rbtogether with the carbon to which they are attached form unsubstituted oxetanyl, unsubstituted tetrahydrofuranyl, unsubstituted cyclopropyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or a cyclobutyl group which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl. In this embodiment, further preferably the heterocyclic compound is a compound of formula (Iiii) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof:

[0004] wherein • R1is C4alkylene−OH, −C(O)Ry, −C(O)NHCH3, −C(O)N(CH3)2, −C(O)N(CH3)(C3alkyl), −C(O)OH, −C(O)OCH3, −NHC(O)CH3, −N(CH3)C(O)CH3, unsubstituted pyrrolidinone, an oxetanyl moiety which is unsubstituted or substituted by one methyl group or one −N(CH3)2group, an imidazolyl or triazolyl moiety which is unsubstituted or substituted with one methyl group, or unsubstituted pyrazolyl, or unsubstituted oxadiazolyl, or unsubstituted oxazolyl, wherein Ryis i-propyl, unsubstituted azetidinyl, unsubstituted pyrrolidinyl, unsubstituted piperidinyl, or unsubstituted morpholinyl; • R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety; • G1is unsubstituted piperidinyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted pyridinyl, or phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl; • G2is unsubstituted piperidinyl, unsubstituted benzimidazolyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted indolinyl, unsubstituted oxoindolinyl or unsubstituted pyridinyl, or phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl; • Y is methylene or −C(O)−; • R'' is hydrogen or fluorine; • L1is −C(O)NRv−Q−, wherein Q is a direct bond or methylene, and Rvis hydrogen or methyl; • Rais methyl and Rbis methyl; or Raand Rbtogether with the carbon to which they are attached form unsubstituted oxetanyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or a cyclobutyl group which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl. In a most preferred embodiment, the heterocyclic compound is a compound of formula (Iiv) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: wherein • R1is −C(O)−(unsubstituted pyrrolidinyl), −C(O)N(CH3)2, an imidazolyl or triazolyl moiety which is unsubstituted or substituted with one methyl group, or unsubstituted pyrazolyl, or unsubstituted oxadiazolyl, or unsubstituted oxazolyl; • R2is −NHC(O)Rz, −NHC(O)O(tert-butyl), or −NHC(O)N(CH3)2, wherein Rzis methyl, tert-butyl, −CH2−(tert-butyl), unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted pyridinyl, or phenyl−A' wherein said phenyl is unsubstituted and A' is hydrogen, piperidinyl which is unsubstituted or substituted with one methyl group, or unsubstituted tetrahydropyranyl; • G1is phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl; • G2is phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl; • R'' is hydrogen or fluorine; and • Raand Rbtogether with the carbon to which they are attached form a cyclobutyl group which is unsubstituted or substituted by two substituents selected from fluorine and methyl. Alternatively, in a most preferred embodiment, the heterocyclic compound is a compound of formula (Iiv) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof:

[0005] wherein • R1is −C(O)−(unsubstituted pyrrolidinyl), −C(O)N(CH3)2, an imidazolyl or triazolyl moiety which is unsubstituted or substituted with one methyl group, or unsubstituted pyrazolyl, or unsubstituted oxadiazolyl, or unsubstituted oxazolyl; • R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety; • G1is phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl; • G2is phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl; • R'' is hydrogen or fluorine; and • Raand Rbtogether with the carbon to which they are attached form a cyclobutyl group which is unsubstituted or substituted by two substituents selected from fluorine and methyl. In a yet further most preferred embodiment, the heterocyclic compound is a compound of formula (I'iv(a)) or (I'iv(b)) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: w • R1is −C(O)N(CH3)2; • R2is −NHC(O)(−A−A'), wherein A is unsubstituted phenyl or pyrazolyl which is substituted with one methyl group, and A' is piperidinyl which is substituted with one substituent selected from cyclobutyl and −CH2CHF2, or azetidinyl which is substituted with one methoxy group, or unsubstituted morpholinyl; • G1is unsubstituted phenyl; • G2is unsubstituted phenyl; • R''' is hydrogen or methyl; and • Raand Rbtogether with the carbon to which they are attached form unsubstituted oxetanyl or unsubstituted cyclobutyl. Alternatively, in a most preferred embodiment, the heterocyclic compound is a compound of formula (I'iv(a)) or (I'iv(b)) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof: w • R1is −C(O)N(CH3)2; • R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety; • G1 is unsubstituted phenyl; • G2is unsubstituted phenyl; • R''' is hydrogen or methyl; and Raand Rbtogether with the carbon to which they are attached form unsubstituted oxetanyl or unsubstituted cyclobutyl. Preferred compounds of formula (I') are: • N-(4-acetamidobenzyl)-2'-(4-(N-methylacetamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(isopropyl(methyl)carbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)-3,5-dimethylbenzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)-3-methylbenzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-((5-(dimethylcarbamoyl)pyridin-2-yl)methyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(1-methyl-1H-imidazol-2-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(4-methyl-4H-1,2,4-triazol-3-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(1,3,4-oxadiazol-2-yl)benzyl)-N-(4-acetamidobenzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(oxazol-2-yl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-((1-isobutyrylpiperidin-4-yl)methyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(1H-pyrazol-1-yl)benzyl)-N-(4-acetamidobenzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(3-methyloxetan-3-yl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • Methyl 3-((6'-((4-acetamidobenzyl)carbamoyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazin]-2'-yl)methyl)bicyclo[1.1.1]pentane- 1-carboxylate; • 3-((6'-((4-acetamidobenzyl)carbamoyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazin]-2'-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; • N-(4-acetamidobenzyl)-2'-(4-(3-(dimethylamino)oxetan-3-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-((3-(dimethylcarbamoyl)bicyclo[1.1.1]pentan-1- yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(1-hydroxy-2-methylpropyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(2-methyl-4-(1H-1,2,4-triazol-1-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-isobutyrylbenzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(methylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((2-((3R,5S)-3,5-Dimethylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5-(2- (trifluoromethyl)pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine • N-(4-acetamidobenzyl)-2'-(4-(2-oxopyrrolidin-1-yl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-(dimethylamino)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-N-methyl-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-benzyl-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((1-acetylpiperidin-4-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclopentane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclohexane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3,3-dimethyl-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(azetidine-1-carbonyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(pyrrolidine-1-carbonyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(piperidine-1-carbonyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(morpholine-4-carbonyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(methylamino)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((5-acetamidopyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamido-3-methylbenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamido-3,5-dimethylbenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(3-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamido-3-fluorobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(N-methylacetamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((2-oxoindolin-5-yl)methyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((2-methyl-1H-benzo[d]imidazol-5- yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(methylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((3-methyloxetan-3-yl)amino)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((5-(cyclopropanecarboxamido)pyridin-2-yl)methyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide; • N-((1-acetylindolin-5-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(3-acetamidophenyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidophenyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N,2'-bis(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylpiperidin-3- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide; • Tert-butyl (4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamido)methyl)phenyl)carbamate; • N-(4-aminobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-(cyclopropanecarboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-isopropylbenzamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(isonicotinamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-pivalamidobenzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-(cyclobutanecarboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-benzamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(oxetane-3-carboxamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(nicotinamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(oxetane-2-carboxamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(tetrahydro-2H-pyran-4- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-(bicyclo[1.1.1]pentane-1-carboxamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(pyridin-2-ylamino)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5- a]pyrazine-3-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-methylindoline-6-carboxamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-(3,3-dimethylbutanamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(picolinamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((5-benzamidopyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((3-aminobicyclo[1.1.1]pentan-1-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((3-acetamidobicyclo[1.1.1]pentan-1-yl)methyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-8'-fluoro-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; and • N-(4-acetamidobenzyl)-2-(4-(dimethylcarbamoyl)benzyl)-1,1-dimethyl-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide. • N-((5-acetamidopyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)-2,6- difluorobenzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]- 6'-carboxamide • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)-2-methylbenzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-acetamidobenzyl)-2'-(4-(5-methyl-1H-1,2,4-triazol-1-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-acetamidobenzyl)-2'-(4-(1-methyl-1H-1,2,4-triazol-5-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-acetamidobenzyl)-2'-(2-chloro-4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(methylcarbamoyl)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-acetamidobenzyl)-2'-(4-(5-methyl-1H-pyrazol-1-yl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-((3-chloro-5-(dimethylcarbamoyl)pyridin-2-yl)methyl)-N-(4-(3,3- dimethylureido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-(1H-imidazol-2-yl)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(4H-1,2,4-triazol-3-yl)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((1-(methylcarbamoyl)piperidin-4-yl)methyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-((4-acetamidophenyl)methyl-d2)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-carbamoylbenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • isopropyl (4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamido)methyl)phenyl)carbamate • N-(4-((2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamido)methyl)phenyl)morpholine-4-carboxamide • N-(4-acetamidobenzyl)-7'-(4-(dimethylcarbamoyl)benzyl)-1'-methyl-6',7'-dihydro- 5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-1'-methyl-N-(4-(methylcarbamoyl)benzyl)-6',7'- dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7'-(4-(dimethylcarbamoyl)benzyl)-N-methyl-6',7'-dihydro- 5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-acetamidobenzyl)-2'-(4-(isoxazol-3-yl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-acetamidobenzyl)-2'-((4-(dimethylcarbamoyl)phenyl)methyl-d2)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclopropane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-((5-(dimethylcarbamoyl)-3-fluoropyridin-2-yl)methyl)-N-(4-(3,3- dimethylureido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-((5-(dimethylcarbamoyl)-3-fluoropyridin-2-yl)methyl)-N-(4-(4- morpholinobenzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-((5-(3,3-dimethylureido)pyridin- 2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-N-((5-(3,3-dimethylureido)pyridin-2- yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • N-(4-carbamoylbenzyl)-2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-N-(4-(5-methyl-1-(1-methylpiperidin-4- yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-N-(4-(oxetane-3-carboxamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-3,3-difluoro-N-(4- (methylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-((5-(3,3-dimethylureido)pyridin- 2-yl)methyl)-3,3-difluoro-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-((5-acetamidopyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)-2,6- difluorobenzyl)-3,3-difluoro-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(3,3-dimethylureido)benzyl)- 3,3-difluoro-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-3,3-difluoro-N-(4-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-N-((5-(3,3-dimethylureido)pyridin-2- yl)methyl)-3,3-difluoro-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-N-(4-(3,3-dimethylureido)benzyl)-3,3- difluoro-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • N-((5-(cyclopropanecarboxamido)pyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)- 2-fluorobenzyl)-3,3-difluoro-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-3,3-difluoro-N-((5-(1-methyl-1H- pyrazole-4-carboxamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-3,3-difluoro-N-((5-(1-methyl-1H- imidazole-4-carboxamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(3,3-dimethylureido)benzyl)- 3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H- spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-3',4'-dihydro- 2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((1S,2S)-2-fluorocyclopropane-1- carboxamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-((5-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)pyridin-2-yl)methyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 7'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(4- morpholinobenzamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'- imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-6',7'-dihydro- 5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-6',7'-dihydro- 5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-((1S,2S)-2- fluorocyclopropane-1-carboxamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane- 1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(2-fluoro-4-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 1-chloro-7-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(3,3- dimethylureido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • 7''-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)-6'',7''- dihydro-5''H-dispiro[cyclobutane-1,1'-cyclobutane-3',8''-imidazo[1,5-a]pyrazine]- 3''-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)-6',7'- dihydro-5'H-spiro[cyclopropane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-8'-methyl-N-(4-(5-methyl-1-(1-methylpiperidin- 4-yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-((1S,2S)-2-fluorocyclopropane-1- carboxamido)benzyl)-1-methyl-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • N-(4-(1-(1-(2,2-difluoroethyl)piperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7-(4-(dimethylcarbamoyl)benzyl)-6,7-dihydro-5H- spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(7-fluoro-1-methyl-1,2,3,4- tetrahydroquinoline-6-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-methoxypropanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(2-cyclopropylacetamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((1R,2R)-2-fluorocyclopropane-1- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-methyl-1H-imidazole-4- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-(methylamino)-3- oxopropyl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-methyl-1H-pyrazole-4- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-methyl-1H-pyrazole-3- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((1S,2S)-2-fluorocyclopropane-1- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(2'-((methylamino)methyl)-[1,1'-biphenyl]- 4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-(4-(4-cyclopropylpiperazin-1-yl)benzamido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-hydroxypropanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-methyl-1-(1-methylpiperidin-4-yl)-1H- pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(1-ethylpiperidin-4-yl)-5-methyl-1H- pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-methyl-1-(1-(oxetan-3-yl)piperidin-4- yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(1-(1-(2,2-difluoroethyl)piperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(1-(2-fluoroethyl)piperidin-4-yl)-5- methyl-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(1-methylpiperidin-4-yl)-1H-pyrazole- 4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-methyl-1-(1-methylazetidin-3-yl)-1H- pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(1,5-dimethyl-1H-pyrazole-4-carboxamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-(1H-pyrazole-3-carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-((1r,3r)-3-cyanocyclobutane-1-carboxamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-((1s,3s)-3-cyanocyclobutane-1-carboxamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • (1R,4R)-N-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-2- oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide • (1R,5S)-N-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-3- oxa-8-azabicyclo[3.2.1]octane-8-carboxamide • N-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-2-oxa-6- azaspiro[3.4]octane-6-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-methylureido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-2-oxa-7- azaspiro[3.5]nonane-7-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(tetrahydrofuran-2-carboxamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • (S)-2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylpiperidin-3- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • (R)-2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylpiperidin-3- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)morpholine-4-carboxamide • N-(4-(cyclohexanecarboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(pyrrolidine-1-carboxamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(azetidine-1-carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-ethyl-3-methylureido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(3-cyanoazetidine-1-carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-methoxyazetidine-1- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((1s,3s)-3-methoxycyclobutane-1- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • isobutyl (4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamido)methyl)phenyl)carbamate • N-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-2-oxa-6- azaspiro[3.3]heptane-6-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(4-methylpiperazin-1- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylazetidin-3- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methyl-1,2,5,6-tetrahydropyridin-3- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylpiperidin-4- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-(4-(4-cyclobutylpiperazin-1-yl)benzamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-(4-(1-cyclobutylpiperidin-4-yl)benzamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((5-(3,3-dimethylureido)pyridin-2-yl)methyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((5-(4-(4-methylpiperazin-1- yl)benzamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((5-(4-morpholinobenzamido)pyridin-2- yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • N-((5-(4-(1-cyclobutylpiperidin-4-yl)benzamido)pyridin-2-yl)methyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-((5-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)pyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((5-(5-methyl-1-(1-methylpiperidin-4-yl)-1H- pyrazole-4-carboxamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(2-fluoro-4-(4-(1-methylpiperidin-4- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(2-fluoro-4-(5-methyl-1-(1-methylpiperidin-4- yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(oxetane-3- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)-6',7'- dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-(4-(4-cyclobutylpiperazin-1-yl)benzamido)benzyl)-7'-(4- (dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(6-morpholinonicotinamido)benzyl)-6',7'- dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-morpholinobenzamido)benzyl)-6',7'- dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylpiperidin-4- yl)benzamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • N-(4-(4-(4-cyclopropylpiperazin-1-yl)benzamido)benzyl)-7'-(4- (dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • N1-(4-((7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane- 1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamido)methyl)phenyl)-N2,N2- dimethyloxalamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-methoxyazetidin-1- yl)benzamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • isobutyl (4-((7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'- carboxamido)methyl)phenyl)carbamate • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(2-morpholinopyrimidine-5- carboxamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-methoxypyrrolidin-1- yl)benzamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • N-(4-(1-(1-(2,2-difluoroethyl)piperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-(oxetan-3-yl)piperidin-4- yl)benzamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • N-(4-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-methoxyazetidin-1- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]- 6'-carboxamide • N-(4-(1-(1-cyclopropylazetidin-3-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 1-chloro-7-(4-(dimethylcarbamoyl)benzyl)-N-(4-((1S,2S)-2-fluorocyclopropane-1- carboxamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]- 3-carboxamide • 4-((7'-(4-acetamidobenzyl)-6'-oxo-3',4',6',7',8',9'-hexahydro-2'H-spiro[cyclobutane- 1,1'-pyrido[4',3':4,5]pyrrolo[1,2-a]pyrazin]-2'-yl)methyl)-N,N-dimethylbenzamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-((5-(4-(4-methylpiperazin-1- yl)benzamido)pyridin-2-yl)methyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'- imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-((5-(4-morpholinobenzamido)pyridin-2- yl)methyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'- carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-N-((5-(4-(4-methylpiperazin-1- yl)benzamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-((5-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)pyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-((5-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)pyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-N-((5-(1-methyl-1H-pyrazole-4- carboxamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-N-((5-(1-methyl-1H-imidazole-4- carboxamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-N-((5-(4- morpholinobenzamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-N-(4-(1-methyl-1H-imidazole-4- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-(cyclopropanecarboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3,3- difluoro-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)-3,3-difluoro- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-N-(4-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-N-(4-(4-(1-methylpiperidin-4- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)-3',4'- dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(4-(4-cyclopropylpiperazin-1-yl)benzamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylpiperidin-4- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]- 6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(4-methylpiperazin-1- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]- 6'-carboxamide • N-(4-(4-(4-cyclobutylpiperazin-1-yl)benzamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(2-fluoro-4- morpholinobenzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-(oxetan-3-yl)piperidin-4- yl)benzamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]- 3-carboxamide • N-(4-(4-(4-cyclopropylpiperazin-1-yl)benzamido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-1-methyl-6,7-dihydro-5H-spiro[imidazo[1,5- a]pyrazine-8,3'-oxetane]-3-carboxamide • N-(4-(1-(1-cyclopropylazetidin-3-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7-(4-(dimethylcarbamoyl)benzyl)-6,7-dihydro-5H- spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • N-(4-(4-(1-(2,2-difluoroethyl)piperidin-4-yl)benzamido)benzyl)-7'-(4- (dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-N-(4-(4- morpholinobenzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 7-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(3,3-dimethylureido)benzyl)- 6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 7-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(4- morpholinobenzamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • N-(4-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-6,7-dihydro- 5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-methyl-1-(1-methylpiperidin-4-yl)-1H- pyrazole-4-carboxamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine- 8,3'-oxetane]-3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(4-methylpiperazin-1- yl)benzamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]- 3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)-6,7- dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylpiperidin-4- yl)benzamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]- 3-carboxamide • N-(4-(4-(4-cyclobutylpiperazin-1-yl)benzamido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-morpholinobenzamido)benzyl)-6,7- dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • N-(4-(3-(4-cyclopropylpiperazin-1-yl)benzamido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(2-fluoro-4-morpholinobenzamido)benzyl)- 6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-methoxyazetidin-1- yl)benzamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]- 3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(4-methoxypiperidin-1- yl)benzamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]- 3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-oxomorpholino)benzamido)benzyl)- 6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-methylindoline-5-carboxamido)benzyl)- 6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-(oxetan-3-yl)piperidin-4- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]- 6'-carboxamide • N-(4-(4-(1-(2,2-difluoroethyl)piperidin-4-yl)benzamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-(1-(1-cyclobutylazetidin-3-yl)-5-methyl-1H-pyrazole-4-carboxamido)benzyl)- 7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'- imidazo[1,5-a]pyrazine]-3'-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(1-(2-fluoroethyl)piperidin-4-yl)-5- methyl-1H-pyrazole-4-carboxamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5- a]pyrazine-8,3'-oxetane]-3-carboxamide • 1-chloro-7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)- 6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • N-(4-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7-(4-(dimethylcarbamoyl)benzyl)-6,7-dihydro-5H- spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-8'-methyl-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 1'-chloro-7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)- 6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • tert-butyl (4-((1'-bromo-7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'- carboxamido)methyl)phenyl)carbamate • 1'-bromo-7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)- 6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 1-chloro-7-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-((1S,2S)-2- fluorocyclopropane-1-carboxamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5- a]pyrazine-8,3'-oxetane]-3-carboxamide • 1-chloro-7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)- 6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 1-chloro-7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)-6,7- dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 1-chloro-N-(3-chloro-4-(3,3-dimethylureido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • N-(4-(3-chloro-4-(3-methoxyazetidin-1-yl)benzamido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • N-(4-(1-(1-cyclopropylazetidin-3-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N2,N2- dimethyloxalamide • 7-(4-(dimethylcarbamoyl)benzyl)-1-methyl-N-(4-(4- morpholinobenzamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • 7'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(2-methoxy-4-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((4-morpholinophenyl)carbamoyl)benzyl)- 6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-((1-(1-cyclopropylpiperidin-4-yl)-1H-imidazol-4-yl)carbamoyl)benzyl)-7'-(4- (dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)-7'-fluoro-3',4'- dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(4-(4-cyclopropylpiperazin-1-yl)benzamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-8'-methyl-3',4'-dihydro-2'H-spiro[oxetane-3,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-((5-(4-(3-methoxyazetidin-1- yl)benzamido)pyridin-2-yl)methyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'- imidazo[1,5-a]pyrazine]-3'-carboxamide • 1'-chloro-7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-methyl-4,5,6,7- tetrahydropyrazolo[1,5-a]pyrazine-3-carboxamido)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-1'-methyl-N-(4-(5-methyl-4,5,6,7- tetrahydropyrazolo[1,5-a]pyrazine-3-carboxamido)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((1S,2S)-2-fluorocyclopropane-1- carboxamido)benzyl)-1'-methyl-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'- imidazo[1,5-a]pyrazine]-3'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-methylindoline-5-carboxamido)benzyl)- 3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-8'-methyl-N-(4-(4- morpholinobenzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-8'-methyl-N-((5-(4- morpholinobenzamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(4-(4-cyclobutyl-2-oxopiperazin-1-yl)benzamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-8'-methyl-3',4'-dihydro-2'H-spiro[oxetane-3,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-8'-methyl-N-(4-(4-(3- oxomorpholino)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)-1- (trifluoromethyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3- carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)-1- (trifluoromethyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3- carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-methoxyazetidin-1- yl)benzamido)benzyl)-1-methyl-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • N-(4-(4-(4-cyclobutylpiperazin-1-yl)benzamido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-1-methyl-6,7-dihydro-5H-spiro[imidazo[1,5- a]pyrazine-8,3'-oxetane]-3-carboxamide • N-(4-(1-(1-(2,2-difluoroethyl)piperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7-(4-(dimethylcarbamoyl)benzyl)-1-methyl-6,7-dihydro-5H- spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • N-(4-(4-(1-cyclopropylazetidin-3-yl)benzamido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-1-methyl-6,7-dihydro-5H-spiro[imidazo[1,5- a]pyrazine-8,3'-oxetane]-3-carboxamide • 1-chloro-N-(4-(1-(1-(2,2-difluoroethyl)piperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7-(4-(dimethylcarbamoyl)benzyl)-6,7-dihydro-5H- spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide. • Preferred compounds of formula (I) are: • N-(4-acetamidobenzyl)-2'-(4-(N-methylacetamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(isopropyl(methyl)carbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)-3,5-dimethylbenzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)-3-methylbenzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-((5-(dimethylcarbamoyl)pyridin-2-yl)methyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(1-methyl-1H-imidazol-2-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(4-methyl-4H-1,2,4-triazol-3-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(1,3,4-oxadiazol-2-yl)benzyl)-N-(4-acetamidobenzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(oxazol-2-yl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-((1-isobutyrylpiperidin-4-yl)methyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(1H-pyrazol-1-yl)benzyl)-N-(4-acetamidobenzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(3-methyloxetan-3-yl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • Methyl 3-((6'-((4-acetamidobenzyl)carbamoyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazin]-2'-yl)methyl)bicyclo[1.1.1]pentane- 1-carboxylate; • 3-((6'-((4-acetamidobenzyl)carbamoyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazin]-2'-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; • N-(4-acetamidobenzyl)-2'-(4-(3-(dimethylamino)oxetan-3-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-((3-(dimethylcarbamoyl)bicyclo[1.1.1]pentan-1- yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(1-hydroxy-2-methylpropyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(2-methyl-4-(1H-1,2,4-triazol-1-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-isobutyrylbenzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(methylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((2-((3R,5S)-3,5-Dimethylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5-(2- (trifluoromethyl)pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine • N-(4-acetamidobenzyl)-2'-(4-(2-oxopyrrolidin-1-yl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-(dimethylamino)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-N-methyl-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-benzyl-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((1-acetylpiperidin-4-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclopentane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclohexane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3,3-dimethyl-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(azetidine-1-carbonyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(pyrrolidine-1-carbonyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(piperidine-1-carbonyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(morpholine-4-carbonyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(methylamino)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((5-acetamidopyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamido-3-methylbenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamido-3,5-dimethylbenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(3-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamido-3-fluorobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(N-methylacetamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((2-oxoindolin-5-yl)methyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((2-methyl-1H-benzo[d]imidazol-5- yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(methylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((3-methyloxetan-3-yl)amino)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((5-(cyclopropanecarboxamido)pyridin-2-yl)methyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide; • N-((1-acetylindolin-5-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(3-acetamidophenyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidophenyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N,2'-bis(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylpiperidin-3- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide; • Tert-butyl (4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamido)methyl)phenyl)carbamate; • N-(4-aminobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-(cyclopropanecarboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-isopropylbenzamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(isonicotinamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-pivalamidobenzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-(cyclobutanecarboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-benzamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(oxetane-3-carboxamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(nicotinamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(oxetane-2-carboxamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(tetrahydro-2H-pyran-4- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-(bicyclo[1.1.1]pentane-1-carboxamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(pyridin-2-ylamino)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5- a]pyrazine-3-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-methylindoline-6-carboxamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-(3,3-dimethylbutanamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(picolinamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((5-benzamidopyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((3-aminobicyclo[1.1.1]pentan-1-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((3-acetamidobicyclo[1.1.1]pentan-1-yl)methyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-8'-fluoro-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; and • N-(4-acetamidobenzyl)-2-(4-(dimethylcarbamoyl)benzyl)-1,1-dimethyl-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide. Preferred compounds of formula (I') and formula (I) where R2is −L2−LBM are: • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)nonanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N9-((S)-1-((2S,4R)-4- hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1- yl)-3,3-dimethyl-1-oxobutan-2-yl)nonanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-amido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(6-(4-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzoyl)piperazin-1-yl)hexanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((S)-15-((2S,4R)-4-hydroxy-2-((4-(4- methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-16,16-dimethyl-13- oxo-4,7,10-trioxa-14-azaheptadecanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecan-18-amido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(7-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)piperazin-1-yl)heptanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5- yl)phenoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4- (4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan- 2-yl)amino)-2-oxoethyl)piperazin-1-yl)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-(4-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzoyl)piperazin-1-yl)pentanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)piperazin-1-yl)hexanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)pentanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(10-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)decanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)- 1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4- (4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan- 2-yl)amino)-3-oxopropyl)piperazin-1-yl)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N5-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)glutaramide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(6-(((S)-1-((2S,4R)-4-hydroxy-2- (((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)piperazin-1- yl)propanamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(4-(((S)-1-((2S,4R)-4-hydroxy-2-((4- (4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan- 2-yl)amino)-4-oxobutyl)piperazin-1-yl)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylphenyl)-1-oxo-5,8,11,14-tetraoxa-2-azaheptadecan-17- amido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(6-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)hexanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N8-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)octanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)ethoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)pentanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N10-((S)-1-((2S,4R)- 4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)decanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)hexanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)piperazin-1-yl)pentanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N5-((S)-1-((2S,4R)-4- hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1- yl)-3,3-dimethyl-1-oxobutan-2-yl)glutaramide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(9-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)nonanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)-3,6,9,12,15,18- hexaoxahenicosan-21-amido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)-3,6,9,12- tetraoxapentadecan-15-amido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N9-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)nonanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(10-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)decanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N4-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)succinamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N4-((S)-1-((2S,4R)-4- hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1- yl)-3,3-dimethyl-1-oxobutan-2-yl)succinamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(3-(((S)-1-((2S,4R)-4-hydroxy-2- (((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)piperazin-1- yl)propanamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • rac-2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-(2-(((2R,4S)-4-hydroxy-1-(3- methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamido)methyl)-5- (4-methylthiazol-5-yl)phenoxy)ethoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)heptanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(11-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)amino)undecanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N15-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N1-(2-(2,6- dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-6,9,12-trioxa-3- azapentadecanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(4-(((S)-1-((2S,4R)-4-hydroxy-2- (((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)amino)-4-oxobutyl)piperazin-1-yl)propanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-((2-((2-(2,6-dioxopiperidin-3-yl)- 1,3-dioxoisoindolin-4-yl)amino)-2- oxoethyl)amino)ethoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(7-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)heptanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N11-((S)-1-((2S,4R)- 4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1- yl)-3,3-dimethyl-1-oxobutan-2-yl)undecanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(10-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)amino)decanamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(2-(4-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzoyl)piperazin-1-yl)acetamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4- (4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan- 2-yl)amino)-3-oxopropoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N6-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)adipamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(8-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)octanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N6-((S)-1-((2S,4R)-4- hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1- yl)-3,3-dimethyl-1-oxobutan-2-yl)adipamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(7-(4-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzoyl)piperazin-1-yl)heptanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzoyl)piperazin-1-yl)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)undecanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)amino)propanamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N21-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N1-(2-(2,6- dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-6,9,12,15,18-pentaoxa-3- azahenicosanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)butanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N8-((S)-1-((2S,4R)-4- hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1- yl)-3,3-dimethyl-1-oxobutan-2-yl)octanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(4-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzoyl)piperazin-1-yl)butanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(7-(((S)-1-((2S,4R)-4-hydroxy-2-((4- (4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan- 2-yl)amino)-7-oxoheptyl)piperazin-1-yl)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(11-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)undecanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(5-(((S)-1-((2S,4R)-4-hydroxy-2- (((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)piperazin-1- yl)propanamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(3-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)- 1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl- 1-oxobutan-2-yl)amino)-3-oxopropoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(7-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)heptanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4- methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2- yl)amino)-3-oxopropoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(2-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)piperazin-1-yl)acetamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(8-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)amino)octanamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylphenyl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-amido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-(2-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5- yl)phenoxy)ethoxy)ethoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(7-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)amino)heptanamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(8-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)octanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylphenyl)-1-oxo-5,8,11,14,17-pentaoxa-2-azaicosan-20- amido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(2-(((S)-1-((2S,4R)-4-hydroxy-2- (((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)amino)-2-oxoethyl)piperazin-1-yl)propanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)-3,6,9,12,15- pentaoxaoctadecan-18-amido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • rac-2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-(((2R,4S)-4-hydroxy-1-(3- methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamido)methyl)-5- (4-methylthiazol-5-yl)phenoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(6-(((S)-1-((2S,4R)-4-hydroxy-2-((4- (4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan- 2-yl)amino)-6-oxohexyl)piperazin-1-yl)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5- yl)phenoxy)ethoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)piperazin-1-yl)propanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N7-((S)-1-((2S,4R)-4- hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1- yl)-3,3-dimethyl-1-oxobutan-2-yl)heptanediamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N12-((S)-1-((2S,4R)- 4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)dodecanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(11-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)undecanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)butanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)pentanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N7-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)heptanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)octanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide. Uses and Methods Compounds of the invention as described herein are inhibitors of STAT6. Preferably, the heterocyclic compound of the invention has an IC50against STAT6 of no more than 10,000 nM, more preferably no more than 1,000 nM, or no more than 100 nM, or no more than 10 nM. Most preferably, the heterocyclic compound of the invention has an IC50against STAT6 of no more than 5 nM. The compounds of the present invention may be used in the treatment of a condition or disease susceptible to amelioration by inhibition of STAT6. Said condition or disease susceptible to amelioration by inhibition of STAT6 includes an atopic disease, an allergic disease, an inflammatory disease and lymphoma. For instance, the condition or disease can be selected from atopic dermatitis, eczema, nummular eczema, allergic contact dermatitis, chronic hand eczema, hand and foot dermatitis, bullous pemphigoid, chronic spontaneous urticaria, cholinergic urticaria, chronic cold-induced urticaria, prurigo nodularis, chronic pruritus, Netherton syndrome, alopecia areata, lichen sclerosus, asthma, allergic rhinitis, chronic rhinosinusitis, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic chronic sinusitis, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis, eosinophilic gastritis, ulcerative colitis, chronic hepatic pruritus, food allergies, atopic keratoconjunctivitis, localized scleroderma, fibrotic diseases, keloids, systemic sclerosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, liver fibrosis, eosinophilic fasciitis, eosinophilic otitis media, solid tumors and hematological cancers including cutaneous cell lymphoma (CTCL), Sezary syndrome (SS), Hodgkin lymphomas, primary mediastinal and primary central nervous system lymphoma, follicular and T cell lymphomas. Preferably, the condition or disease is selected from atopic dermatitis, asthma, chronic spontaneous urticaria and purigo nodularis. The invention therefore provides a method of treating a subject, the method comprising administering to said subject a therapeutically effective amount of a heterocyclic compound of the invention, or a pharmaceutical composition of the invention. The invention therefore provides a method of treating a condition or disease selected from an atopic disease, an allergic disease, an inflammatory disease or lymphoma in a subject, the method comprising administering to said subject a therapeutically effective amount of a heterocyclic compound of the invention, or a pharmaceutical composition of the invention. For instance, the condition or disease can be selected from atopic dermatitis, eczema, nummular eczema, allergic contact dermatitis, chronic hand eczema, hand and foot dermatitis, bullous pemphigoid, chronic spontaneous urticaria, cholinergic urticaria, chronic cold-induced urticaria, prurigo nodularis, chronic pruritus, Netherton syndrome, alopecia areata, lichen sclerosus, asthma, allergic rhinitis, chronic rhinosinusitis, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic chronic sinusitis, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis, eosinophilic gastritis, ulcerative colitis, chronic hepatic pruritus, food allergies, atopic keratoconjunctivitis, localized scleroderma, fibrotic diseases, keloids, systemic sclerosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, liver fibrosis, eosinophilic fasciitis, eosinophilic otitis media, solid tumors and hematological cancers including cutaneous cell lymphoma (CTCL), Sezary syndrome (SS), Hodgkin lymphomas, primary mediastinal and primary central nervous system lymphoma, follicular and T cell lymphomas. Preferably, the condition or disease is selected from atopic dermatitis, asthma, chronic spontaneous urticaria and purigo nodularis. The invention also provides the use of a heterocyclic compound of the invention, or a pharmaceutical composition of the invention, for the manufacture of a medicament. The invention also provides the use of a heterocyclic compound of the invention, or a pharmaceutical composition of the invention, for the manufacture of a medicament for treating a condition or disease selected from atopic dermatitis, eczema, nummular eczema, allergic contact dermatitis, chronic hand eczema, hand and foot dermatitis, bullous pemphigoid, chronic spontaneous urticaria, cholinergic urticaria, chronic cold-induced urticaria, prurigo nodularis, chronic pruritus, Netherton syndrome, alopecia areata, lichen sclerosus, asthma, allergic rhinitis, chronic rhinosinusitis, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic chronic sinusitis, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis, eosinophilic gastritis, ulcerative colitis, chronic hepatic pruritus, food allergies, atopic keratoconjunctivitis, localized scleroderma, fibrotic diseases, keloids, systemic sclerosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, liver fibrosis, eosinophilic fasciitis, eosinophilic otitis media, solid tumors and hematological cancers including cutaneous cell lymphoma (CTCL), Sezary syndrome (SS), Hodgkin lymphomas, primary mediastinal and primary central nervous system lymphoma, follicular and T cell lymphomas. Preferably, the condition or disease is selected from atopic dermatitis, asthma, chronic spontaneous urticaria and purigo nodularis. Pharmaceutical compositions, dosage and formulation The compounds of the invention, when used in a method of treatment, can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. Thus, preferably, the compounds of the present invention can be included in a pharmaceutical composition. Preferably the pharmaceutical composition is suitable for oral administration. Said pharmaceutical composition typically contains up to 85 wt% of a compound of the invention. More typically, it contains up to 50 wt% of a compound of the invention. One exemplary such pharmaceutical composition is a solid dosage form suitable for oral administration (e.g., a tablet, capsule (each of which includes a sustained release or timed release formulation), pill, powder, or granule). Another exemplary such pharmaceutical composition is a liquid dosage form suitable for oral administration (e.g., an elixir, tincture, suspension, syrup, solution or emulsion). However, the compounds of the invention may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. The dosage regimen for the compounds of the invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired. A physician or veterinarian can determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the thromboembolic disorder. By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg / kg of body weight, preferably between about 0.01 to 100 mg / kg of body weight per day, and most preferably between about 1.0 to 20 mg / kg / day. Intravenously, the most preferred doses will range from about 1 to about 10 mg / kg / minute during a constant rate infusion. Compounds of the invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily. Compounds of the invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches. When administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. The compounds are typically administered alongside suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices. For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, com sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like. Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field. General synthetic schemes Reagents, starting materials, and solvents were purchased from commercial suppliers and used as received. Commercial intermediates are referred to in the experimental section by their IUPAC name. Ether refers to diethyl ether, unless otherwise specified. Concentration or evaporation refer to evaporation under vacuum using a Büchi rotatory evaporator. Standard synthetic methods are described the first time they are used. Compounds synthesized with similar methods are referred to only by their starting materials, without full experimental detail. Slight modifications to the general experimental methods used are permitted in these cases. Specific synthetic transformations already described in the literature are referred to only by their bibliographical reference. Other specific methods are also described in full. The compounds of the invention can be prepared using the methods and procedures described herein or using similar methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. Processes for preparing compounds of the invention are provided as further embodiments of the invention and are illustrated by the procedures below. In the following Schemes 1-15, compounds are depicted where L1 is −C(O)NH−CH2−. For compounds where L1is another embodiment of −C(O)NRv−Q−, or is −L1'−NRv−Q− or −Het'−Q− as defined herein, analogous synthetic processes can be used which are well-known to the person skilled in the art. In the following Schemes 1-7, compounds are depicted where m is 0, n is 1, X1is N and X2, X4are CR''. According to one embodiment of the present invention, compounds of Formula Ia may be prepared by the following a 5 steps synthetic route as illustrated in Scheme 1:

[0006] Scheme 1 Pictet-Spengler condensation of ethan-1-amines of Formula IIa with ketones of Formula II, in a solvent such as ethanol or dichloromethane, in the presence of an acid such as p-toluene sulphonic acid or trifluoroacetic acid, at temperatures ranging from 25-80 ºC gives rise to dihydro-pyrrolopyrazines of Formula III. Treatment of the protected amine of Formula IV with 2,2,2-trichloroacetyl chloride in the presence of triethylamine in a solvent such as dichloromethane, at temperatures ranging from 0-25 ºC, gives rise to carboxylic acids of Formula V after treatment with a base such as NaOH, in a solvent such as tetrahydrofuran or water, at room temperature. Reaction with amines of Formula VI, in the presence of 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate or N,N,N′,N′-tetramethylchloroformamidinium hexafluorophosphate / N-methylimidazole as coupling reagent, in the presence of a base such as diisopropylethylamine, in a solvent such as N,N-dimethylformamide at room temperature furnishes amides of Formula VII, after deprotection of the corresponding amine. Compounds of Formula Ia are obtained from amines of Formula VII by reductive amination with aldehydes of Formula VIII, in a solvent such as dichloromethane or dichloroethane, in the presence of a reductive reagent such as sodium triacetoxyborohydride, in the presence of an acid such as acetic acid, at room temperature. Alternatively, compounds of Formula Ia can be obtained by treatment with alkylating agents of Formula VIIIa, in a solvent such as acetonitrile, in the presence of a base such as diisopropylethylamine at 60ºC. In the particular case where R1in Scheme 1 is a carboxylic acid, compounds of Formula Ib may be prepared by the following a 2-step synthetic route as illustrated in Scheme 2: Compounds of Formula X are obtained from amines of Formula VII by reductive amination with aldehydes of Formula IX, in a solvent such as dichloromethane or dichloroethane, in the presence of a reductive reagent such as sodium triacetoxyborohydride, in the presence of an acid such as acetic acid, at room temperature. Treatment of the resulting acids with amines of Formula XI in the presence of 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3- tetramethyl uronium hexafluorophosphate as a coupling reagent, in the presence of a base such as diisopropylethylamine, in a solvent such as N,N-dimethylformamide at room temperature gives rise to compounds of Formula Ib. In the particular case where carboxylic acids of Formula XIII are substituted on nitrogen, compounds of Formula Ic may be prepared as illustrated in Scheme 3:

[0007] Compounds of Formula XII are obtained from amines of Formula III by reductive amination with aldehydes of Formula VIII, in a solvent such as dichloromethane or dichloroethane, in the presence of a reductive reagent such as sodium triacetoxyborohydride, in the presence of an acid such as acetic acid, at room temperature. Treatment of compounds of Formula XII with 2,2,2-trichloroacetyl chloride in the presence of triethylamine in a solvent such as dichloromethane, at temperatures ranging from 0-25 ºC, gives rise to trichloroacetyl derivatives of Formula XIIa, that give rise to carboxylic acids of Formula XIII after treatment with a base such as NaOH, in a solvent such as tetrahydrofuran or water, at room temperature. Alternatively, carboxylic acids of Formula XIII can be obtained directly from compounds of Formula XII in a one pot reaction. Compounds of Formula Ic may be prepared directly by amide coupling of acids of Formula XIII with amines of Formula VI, in the presence of 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate or N,N,N′,N′-tetramethylchloroformamidinium hexafluorophosphate / N-methylimidazole as coupling reagent, in the presence of a base such as diisopropylethylamine, in a solvent such as N,N-dimethylformamide at room temperature. Alternatively, compounds of Formula Ic can be obtained directly from compounds of Formula XII by treatment with 2,2,2-trichloroacetyl chloride in the presence of a base such as triethylamine in a solvent such as dichloromethane, at 0 ºC, followed by treatment of with amines of Formula VI in the presence of a base such as triethylamine, in a solvent such as dicholoromethane at room temperature. Finally, compounds of Formula Ic can be also obtained from compounds of Formula XIIa in a one pot reaction by treatment of with amines of Formula VI in the presence of a base such as triethylamine, in a solvent such as dicholoromethane at room temperature. Alternatively, compounds of Formula XII can be obtained by treatment of ethan-1- amines of Formula IIa with ketones of Formula VIII, in a solvent such as methanol, in the presence palladium on carbon as a catalyst by treatment with hydrogen under pressure (15 psi), at room temperature, followed by Pictet-Spengler reaction by treatment with a ketone of Formula II in a solvent such as ethanol or dichloromethane, in the presence of an acid such as p-toluene sulphonic acid or trifluoroacetic acid, at temperatures ranging from 25- 80ºC. Through synthetic processes well-known to the person skilled in the art, further derivatization of compounds of formula XII may lead to the final compounds of Formula Ic as described in Scheme 3b. Scheme 3b In the particular case where compounds of Formula XIII are coupled with amines of Formula XIV where A is as defined herein, compounds of Formula Id may be prepared as illustrated in Scheme 4:

[0008] Scheme 4 Compounds of Formula XV may be prepared by amide coupling of acids of Formula XIII with amines of Formula XIV, in the presence of 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3- tetramethyl uronium hexafluorophosphate or N,N,N′,N′-tetramethylchloroformamidinium hexafluorophosphate and N-methylimidazole as coupling reagent, in the presence of a base such as diisopropylethylamine, in a solvent such as N,N-dimethylformamide at room temperature. Compounds of Formula Id may be prepared from halides of Formula XV by reaction with boronic acids or boronic esters of Formula XVI under Suzuki–Miyaura reaction conditions (Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457). In the Formula XVI, the B’ group represents a boronic acid or a boronic ester. Such reactions may be catalyzed by a suitable palladium catalyst such as [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex or tris(dibenzylideneacetone)dipalladium (0) in a solvent such as dioxane, dimethoxyethane, toluene or N,N’-dimethylformamide with or without water as a cosolvent, in the presence of a base such as cesium carbonate, potassium carbonate, sodium carbonate or potassium phosphate, at temperatures ranging from 80-120 ºC with or without the use of microwave irradiation. In the particular case where carboxylic acids of Formula XIII are coupled with amines of Formula VI where R2 is NH-PG compounds of Formula Ie may be prepared as illustrated in Scheme 5:

[0009] Compounds of Formula XVII may be prepared by amide coupling of acids of Formula XIII with amines of Formula VI, in the presence of 2-(1H-7-azabenzotriazol-1-yl)- 1,1,3,3-tetramethyl uronium hexafluorophosphate or N,N,N′,N′- tetramethylchloroformamidinium hexafluorophosphate and N-methylimidazole as coupling reagent, in the presence of a base such as diisopropylethylamine, in a solvent such as N,N- dimethylformamide at room temperature, after deprotection of the corresponding amine. Compound of Formula Ie may be prepared by treatment with compound of Formula XVIII where R5can be OH or Cl and Rzis as defined herein. In the particular case where R5is OH, compounds of Formula Ie may be prepared by amide coupling by treatment with amines of Formula XVII and carboxylic acids of Formula XVIII, in the presence of 2-(1H-7- azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate or N,N,N′,N′- tetramethylchloroformamidinium hexafluorophosphate and N-methylimidazole as coupling reagent, in the presence of a base such as diisopropylethylamine, in a solvent such as N,N- dimethylformamide at room temperature. In the particular case where R5is Cl, compounds of Formula Ie may be prepared by amide fomation by treatment with amines of Formula XVII and acyl chlorides of Formula XVIII, in the presence of a suitable base such as diisopropylethylamine in a solvent such as dichloromethane at temperatures ranging from 0 to 25ºC. In the particular case where X4is CR''' (in particular where R''' is not hydrogen, for example, C1-4alkyl or halogen) compounds of Formula If may be prepared as illustrated in Scheme 6:

[0010] Scheme 6 Compounds of Formula XX may be prepared by treatment of compounds of Formula XIX with 2-bromoacetamide, in the presence of a suitable base such as cesium carbonate, in a solvent such as N,N-dimethylformamide at room temperature. Treatment of compounds of Formula XX with ketones of Formula II in the presence of a suitable condensation agent such as Eaton’s reagent at 85ºC, gives rise to compounds of Formula XXI. Compounds of Formula XXII may be prepared by reaction of compounds of Formula XXI with a suitable reducing agent such as borane dimethylsulfide, in a suitable solvent such as tetrahydrofuran at temperatures ranging from 0-80ºC. Reductive amination of amines of Formula XXII with aldehydes of Formula VIII, in a suitable solvent such as dichloromethane or dichloroethane, in the presence of a suitable reductive reagent such as sodium triacetoxyborohydride, in the presence of a suitable acid such as acetic acid, at room temperature gives rise to compounds of Formula XXIII. Compounds of Formula If may be prepared by hydrolysis of compounds of Formula XXIII in the presence of a suitable base such as lithium hydroxide, in a suitable solvent such as tetrahydrofuran or methanol, at room temperature, followed by amide coupling of the resultant acids of Formula XIV with amines of Formula VI, in the presence of 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate as coupling reagent, in the presence of a suitable base such as diisopropylethylamine, in a suitable solvent such as N,N-dimethylformamide at room temperature. In the particular case where Y is C(=O) compounds of Formula Ig may be prepared as illustrated in Scheme 7: Scheme 7 Compounds of Formula XXVI may be prepared by amide coupling of methyl 3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxylate 2,2,2- trifuoroacetic acid with carboxcylic acids of Formula XXV, in the 7- azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate as a reagent, in the presence of a suitable base such as diisopropylethylamine, in a suitable solvent such as N,N-dimethylformamide at room temperature, followed by hydrolysis of the resulting ester in the presence of a suitable base such as sodium hydroxide, in a suitable solvent such as tetrahydrofuran or methanol, at room temperature. Compounds of Formula Ig may be prepared by amide coupling of compounds of Formula XXVI with amines of Formula VI, in the presence of 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate as coupling reagent, in the presence of a suitable base such as diisopropylethylamine, in a suitable solvent such as N,N-dimethylformamide at room temperature. In the particular case where X1and X4are N, compounds of Formula Ih may be prepared as illustrated in Scheme 8:

[0011] Scheme 8 Compounds of Formula XXVIII may be prepared by Dess-Martin oxidation of amino alcohols of Formula XXVII by treatment with Dess Martin reagent in a suitable solvent such as dichloromethane at room temperature. Cyclisation of the resulting aldehyde by treatment with oxoaldehyde in the presence of an aqueous solution of ammonia in a suitable solvent such as methanol at room temperature gives rise to compounds of Formula XXIX. Compounds of Formula XXX may be prepared by treatment of the resulting imidazole with methyl chloroacetate, in the presence of a suitable base such as potassium carbonate, in a suitable solvent such as N,N-dimethylformamide at room temperature. Condensation of the resulting amino ester in the presence of a suitable acid such as trifluoroacetic acid in a suitable solvent such as dichloromethane at room temperature gives rise to bicycles of Formula XXXI. Compounds of Formula XXXII may be prepared by reduction by treatment with borane dimethyl sulfide, in a suitable solvent such as tetrahydrofuran, at temperatures ranging from 0-20ºC. Reductive amination of the resulting amine with aldehydes of Formula VIII, in a suitable solvent such as dichloromethane or dichloroethane, in the presence of a suitable reductive reagent such as sodium triacetoxyborohydride, in the presence of a suitable acid such as acetic acid, at room temperature gives rise to compounds of Formula XXXIII. Compounds of Formula XXXIV may be prepared by bromination of compounds of Formula XXXIII by treatment with N-bromosuccinimide in a suitable solvent such as dichloromethane at room temperature. Compounds of Formula XXXV may be prepared by treatment of the corresponding bromo derivative with carbon monoxide, in the presence of a suitable catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), in the presence of a suitable base such as triethylamine, in a suitable solvent such as methanol or N,N-dimethylformamide at temperatures ranging from 60-80ºC. Compounds of Formula Ih may be prepared by hydrolysis of compounds of Formula XXXV in the presence of a suitable base such as sodium hydroxide, in a suitable solvent such as tetrahydrofuran or methanol, at room temperature, followed by amide coupling of the resultant acids of Formula XXXVI with amines of Formula VI, in the presence of 2-(1H-7-azabenzotriazol-1-yl)- 1,1,3,3-tetramethyl uronium hexafluorophosphate as coupling reagent, in the presence of a suitable base such as diisopropylethylamine, in a suitable solvent such as N,N- dimethylformamide at room temperature. In the particular case where X1and X2are N, compounds of Formula Ii may be prepared as illustrated in Scheme 9: Scheme 9 Compounds of Formula XXXIX may be prepared by Grignard reaction of imidazoles of Formula XXXVII with sulfinamides of Formula XXXVIII, in the presence of a suitable Grignard reagent such as ethylmagnesium bromide, in a suitable solvent such as dichloromethane, at temperature ranging from 0-20ºC, followed by deprotection of the corresponding protecting group. Treatment of the resulting imidazole with methyl 2- chloroacetate, in a suitable solvent such as N,N-dimethylformamide, in the presence of a suitable base such as potassium carbonate, at room temperature, gives rise to compounds of Formula XL. Compounds of Formula XLI may be prepared by condensation in the presence of a suitable acid such as trifluoroacetic acid, in a suitable solvent such as dichloromethane, at room temperature. Through synthetic processes well-known to the person skilled in the art, further derivatization of compounds of formula XLI may lead to the final compounds of Formula Ii. In the particular case where m and n are 1 and X1is C, compounds of Formula Ij may be prepared as illustrated in Scheme 10. Compounds of Formula XLIII may be prepared by condensation of compounds of Formula XLII with ketones of Formula II, in a suitable solvent such as ethanol or dichloromethane, in the presence of a suitable acid such as p-toluene sulphonic acid or trifluoroacetic acid, at temperatures ranging from 25-80 ºC. Through synthetic processes well-known to the person skilled in art, further derivatization of compounds of formula XLIII may lead to the final compounds of Formula Ij. In the particular case where X1is C and X2is N compounds of Formula Ik may be prepared as illustrated in Scheme 11.

[0012] Scheme 11 Compounds of Formula XLV may be prepared by reaction with 1,3,2-dioxathiolane 2,2-dioxide, in a suitable solvent such as tetrahydrofuran, in the presence of a suitable base such as lithium diisopropylamide, at temperatures ranging from -78-20ºC, followed by treatment with a suitable acid such as hydrochloric acid at temperatures ranging from 0-20ºC and further protection of the resulting alcohol. Compounds of Formula XLVI may be prepared by Grignard reaction with sulfinamides of Formula XXXVIII, in the presence of a suitable Grignard reagent such as ethylmagnesium bromide, in a suitable solvent such as dichloromethane, at temperature ranging from 0-20ºC, followed by deprotection of the corresponding protecting group. Compounds of Formula XLVII may be prepared by ciclyzation of compounds of Formula XLVI. Through synthetic processes well-known to the person skilled in art, further derivatization of compounds of formula XLVII may lead to the final compounds of Formula Ik. In the particular case where m is 1 and n is 0 and X1is C, compounds of Formula Il may be prepared as illustrated in Scheme 12.

[0013] Scheme 12 Compounds of Formula XLIX may be prepared by Grignard reaction of compounds of Formula XLVIII with sulfinamides of Formula XXXVIII, in the presence of a suitable Grignard reagent such as isopropylmagnesium choride, in a suitable solvent such as tetrahydrofuran, at temperature ranging from 0-20ºC. Compounds of Formula L may be prepared by treatment of the corresponding bromo derivative with carbon monoxide, in the presence of a suitable base such as triethylamine, in the presence of a suitable catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), in a suitable solvent such as methanol or N,N-dimethylformamide at temperatures ranging from 60-80ºC. Compounds of Formula LI may be prepared by cyclization of compounds of Formula L, in the presence of a suitable acid such as hydrochloric acid. Through synthetic processes well-known to the person skilled in art, further derivatization of compounds of Formula LI may lead to the final compounds of Formula Il. In the particular case where R'' is a halogen compounds of Formula Im may also be prepared as illustrated in Scheme 13:

[0014] Scheme 13 Compounds of Formula LIII may be prepared by a one pot reaction by treatment of compounds of Formula XII with 2,2,2-trichloroacetyl chloride in the presence of a base such as triethylamine in a solvent such as dichloromethane, at 0 ºC, followed by treatment of with amines of Formula LII having a Boc protected amino group in the presence of a base such as triethylamine, in a solvent such as dicholoromethane at room temperature. Halogenated compounds of Formula LV may be prepared by treatment of compounds of Formula LIII with the corresponding N-halogenated succinimide reagents in a solvent such as acetone at room temperature, followed by Boc group deprotection by treatment of resulting compounds of Formula LIV with an acid such as trifluoroacetic acid or hydrochloric acid in a solvent such as dichloromethane or dioxane at room temperature. Compounds of Formula Im may be prepared by amide coupling by treatment of amines of Formula LV with carboxylic acids of Formula LVI, in the presence of 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate or N,N,N′,N′-tetramethylchloroformamidinium hexafluorophosphate and N-methylimidazole as coupling reagent, in the presence of a base such as diisopropylethylamine, in a solvent such as N,N-dimethylformamide at room temperature. In the particular case where R'' is C1-4alkyl, C1-4haloalkyl or 3- to 5-membered carbocyclyl, compounds of Formula In may also be prepared as illustrated in Scheme 14: Scheme 14 Compounds of Formula LIX may be prepared by Suzuki coupling of halogenated compounds of Formula LVII with a boronated reagent of Formula LVIII in the presence of a base such as cesium carbonate and a palladium catalyst such as [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex in a solvent such as dioxane at 120ºC. Through synthetic processes well-known to the person skilled in art, further derivatization of compounds of Formula LIX may lead to the final compounds of Formula Im. Compounds of formula (I’) or formula (I) wherein R2is L2-LBM may be prepared following the synthetic pathway described in Scheme 15: Scheme 15 For compounds where m, n, and X1-X4define alternative heterocyclic cores, analogous synthetic processes can be used which are well-known to the person skilled in the art. Specific synthetic processes not covered by Schemes 1-15 are described in detail in the experimental section. In any step of the synthetic sequences described above, any reactant and intermediate can be used in a protected form to prevent certain functional groups from undergoing undesired reactions. In these cases, standard methods for the introduction and subsequent removal of these protecting groups can be used at any suitable step of the synthesis. Numerous protecting groups, their introduction and their removal are described in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York, 1999, and references cited therein. The syntheses of the compounds of the invention are illustrated by the following Examples (1 to 322) and PROTAC Examples (1 to 88) including Intermediates (1 to 153), and are given in order to provide a person skilled in the art with a sufficiently clear and complete explanation of the present invention, but should not be considered as limiting of the essential aspects of its subject, as set out in the preceding portions of this description. Starting compounds are commercially available or may be obtained following the conventional synthetic methods already known in the art. Examples The syntheses of the compounds of the invention are illustrated by the following Examples which do not limit the scope of the invention in any way. Preparative Examples Abbreviations: Ac2O Acetic anhydride ACN Acetonitrile AcOH Acetic acid Al2O3Aluminium oxide BH3-Me2S Borane dimethylsulfide bb Broad band Boc2O Di-tert-butyl decarbonate BOP (Benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate) BrettPhos Pd G3 [(2-Di-cyclohexylphosphino-3,6-dimethoxy-2′,4′,6′- triisopropyl- 1,1′-biphenyl)-2-(2′-amino-1,1′ -biphenyl)]palladium(II) methanesulfonate methanesulfonate br Broad BuOH Buthanol CAN Cerium ammonium nitrate CCl4Carbon tetrachloride CDCl3Deuterated chloroform CHCl3Chloroform CO Carbon monoxide Cs2CO3Cesium carbonate CuI Copper iodide d Doublet dd Doublet of doublets DCM Dichloromethane DIEA Diisopropylethylamine DMA Dimethylacetamide DMAP Dimethylaminopyridine DMC·HCl 2-Chloro-1,3-dimethyl-4,5-dihydroimidazol-1-ium chloride DME Dimethoxyethane DMEDA N,N′-dimethylethylenediamine DMF N,N-dimethylformamide DMSO Dimethylsulfoxide DMSO-d6Deuterated Dimethylsulfoxide dtbbpy 4-Tert-butyl-2-(4-tert-butyl-2-pyridyl)pyridine EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide EtOAc Ethyl acetate EtOH Ethanol h Hour H2Hydrogen HATU 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate HCHO Formaldehyde HCl Hydrochloric acid IPA Isopropanol (Ir(dF(CF3)ppy)2(dtbbpy))PF6: Bis[3,5-difluoro-2-[5-(trifluoromethyl)-2- pyridyl]phenyl]iridium(1+);4-tert-butyl-2-(4-tert-butyl-2- pyridyl)pyridine;hexafluorophosphate K2CO3Potassium carbonate KOH Potassium hydroxide KPNH Amine Functionalized Stationary Phase LRMS Low Resolution Mass Spectrometry LC Liquid Chromatography m Multiplet MeI Iodomethane MeOH Methanol MeOD Deuterated methanol MgSO4Magnesium sulfate min Minutes MPLC Medium Pressure Liquid Chromatography MS Mass Spectrometry MsCl Methanesulfonyl chloride mw Microwave N2Nitrogen NaBH4Sodium borohydride NaBH3CN Sodium cyanoborohydride NaBH(OAc)3Sodium triacetoxyborohydride NaCN Sodium cyanide NaH Sodium Hydride NaHCO3Sodium bicarbonate Na2CO3Sodium carbonate NaOH Sodium hydroxide Na2SO4Sodium sulfate NBS N-bromosuccinimide NCS N-Chlorosuccinimide NH3Ammonia NH4Cl Ammonium Chloride NH2-NH2·H2O Hydrazine hydrate NiCl2glyme dichloronickel;1,2-dimethoxyethane Ni Raney Nickel Raney NMI N-methylimidazole NMR Nuclear magnetic resonance PBr3Phosphorus tribromide PCy3Tricyclohexylphosphine Pd2(dba)3Tris(dibenzylideneacetone)dipalladium(0) Pd(dppf)Cl2.CH2Cl2[1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex Pd(OAc)2Palladium acetate Pd(PPh3)4Tetrakis(triphenylphosphine)palladium(0) p-TsOH para-Toluenesulfonic acid q Quartet r.t. Room temperature Ru Ruthenium s Singlet SiO2Silicon dioxide SOCl2Thionyl chloride t Triplet T4P 2,4,6-Tributyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide Tª Temperature TBAF Tetrabuthylammonium floride tBu Tert-butyl TCFH N,N,N′,N′-tetramethylchloroformamidinium hexafluorophosphate td Triple doublet TFA Trifluoroacetic acid TEA Triethylamine THF Tetrahydrofuran TLC Thin Layer Chromatography TMSOK Potassium trimethylsilanolateTTMSS Tris(trimethylsilyl)silane UPLC Ultra Pressure Liquid Chromatography XPhos 2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl XPhos Pd G3 Methanesulfonato(2-dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'- biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) dichloromethane adduct Analytical methods: LCMS method 1, LCMS (1) Apparatus: Waters Acquity UPLC I-Class system; Bin. Pump: BSM, SM with SO; PDA; TQD; ESI, pos / neg 160-900; column: Waters Acquity UPLC BEH C-18, 50x2.1mm, 1.7µm, Temp: 50ºC, Flow rate: 0.65 mL / min, Gradient: from 5% B to 95% B, Run time: 5 min, Eluent A: 0.05% formic acid + 0.0125% ammonia in water, Eluent B: 0.04% formic acid + 0.01% ammonia in ACN / MeOH (1:1). Sample concentration: 1 mM in DMSO. Injection volume: 0.5 µL. Chromatograms were processed at 210 nm. LCMS methods 2 Detection methods are Evaporarive Light-scattering detector (ELSD) and diode array (DAD). MS mode was positive and negative electrospray ionization. MS range was 50-2000. Chromatograms were processed at 210 and 254 nm. LCMS method 2a, LCMS (2a) Apparatus: Agilent 1200 HPLC, MSD:6120 single quadrupole MSD, pos 50-2000; column: Halo C183.0*30 mm, 5 µm, Temp: 40ºC, Flow rate: 0.2 mL / min, Gradient: 10-100% B in 0.90 min, Eluent A: 0.04% TFA in water, Eluent B: 0.02% TFA in HPLC grade ACN. LCMS method 2b, LCMS (2b) Apparatus: Agilent 1200 HPLC, MSD:6120 single quadrupole MSD, pos / neg 50-2000; column: Xtimate C182.1*30mm, 5 μm, Temp: 40ºC, Flow rate: 1.5 mL / min, Gradient: 10- 100% B in 0.5 min and holding at 100% for 0.4 min, Eluent A: 10 mM NH4HCO3in water, Eluent B: HPLC grade ACN. LCMS method 2c, LCMS (2c) Apparatus: Agilent 1200 HPLC, MSD:6120 single quadrupole MSD, pos / neg 50-2000; column: XBridge C182.1*30mm, 5 μm, Temp: 40ºC, Flow rate: 1.2 mL / min, Gradient: 5%- 95% B in 1.5 min and holding at 95% B for 0.50 min, Eluent A: 10 mM NH4HCO3in water, Eluent B: HPLC grade ACN. LCMS method 2d, LCMS (2d) Apparatus: Agilent 1200 HPLC, MSD:6120 single quadrupole MSD, pos 50-2000; column: Luna C1830*2.0 mm, 3 μm, Temp: 40ºC, Flow rate: 1.2 mL / min, Gradient: 5%-95% B in 3.5 min, Eluent A: 0.04% TFA in water, Eluent B: 0.02% TFA in HPLC grade ACN. LCMS method 2e, LCMS (2e) Apparatus: Agilent 1200 HPLC, MSD:6120 single quadrupole MSD, pos 100-1000; column: Xbridge C182.1*50 mm column, 5 μm, Temp: 40ºC, Flow rate: 0.8 mL / min, Gradient: 5- 95% B at 0.40-5.50 min, and then 95-100% B at 5.50-7.00 min, Eluent A: 10 mM NH4HCO3in water, Eluent B: HPLC grade ACN. LCMS method 2f, LCMS (2f) Apparatus: Agilent 1200 HPLC, MSD:6120 single quadrupole MSD, pos 100-1000; column: Xbridge C182.1*50 mm column, 5 μm, Temp: 40ºC, Flow rate: 0.8 mL / min, Gradient: 25%- 65% B in 8 min, Eluent A: 10 mM NH4HCO3in water, Eluent B: HPLC grade ACN. LCMS method 2g, LCMS (2g) Apparatus: Agilent 1200 HPLC, MSD:6120 single quadrupole MSD, pos 100-1000; column: Xbridge C182.1*50 mm column, 5 μm, Temp: 40ºC, Flow rate: 1.2 mL / min, Gradient: 0%- 60% B in 1.5 min and holding at 60% B for 0.50 min, Eluent A: 10 mM NH4HCO3in water, Eluent B: HPLC grade ACN. LCMS method 2h, LCMS (2h) Apparatus: Agilent 1200 HPLC, MSD:6120 single quadrupole MSD, pos 100-1000; column: Xbridge C182.1*30 mm column, 5 μm, Temp: 40ºC, Flow rate: 1.2 mL / min, Gradient: 0- 30% B in 1.5 min, 30-90% B in 0.5 min , 90-0% B in 0.01 min , and then hold at 0% B for 0.49 min, Eluent A: 10 mM NH4HCO3in water, Eluent B: HPLC grade ACN. LCMS method 2i, LCMS (2i) Apparatus: Agilent 1200 HPLC, MSD:6120 single quadrupole MSD, pos 100-1000; column: Xtimate C182.1*30mm, 5μm, Temp: 40ºC, Flow rate: 1.5 mL / min, Gradient: 10-100% B in 0.90 min .10% B in 0.01 min, 10-100% B (0.01-0.50 min) with a hold at 100% B for 0.40 min, Eluent A: 10 mM NH4HCO3in water, Eluent B: HPLC grade ACN. LCMS method 2j, LCMS (2j) Apparatus: Agilent 1200 HPLC, MSD:6120 single quadrupole MSD, pos 100-1000; column: Luna C1850*2.0mm, 5 μm, Temp: 40ºC, Flow rate: 1.0 mL / min, Gradient: 5%B in 0.40 min and 5-95% B in 2.60 min, hold on 95% B in 1.00 min, and then 95-5%B in 0.01 min, Eluent A: 0.04% TFA in water, Eluent B: 0.02% TFA in HPLC grade ACN. LCMS method 3, LCMS (3) Apparatus: Agilent 1290 Infinity II; Bin. Pump: 1290 High speed Pump, 1290 Multisampler; 1290 DAD WR; LC / MSD IQ; ESI, pos / neg 100-1000; column: Infinitylab Poroshell 120 EC-C18 2,1X50mm, 50x2.1mm, 1.9µm, Temp column: 50ºC, Flow rate: 0.65 mL / min, Gradient: from 4% B to 98% B, Run time: 3 min, Eluent A: 0.05% formic acid + 0.0125% ammonia in water, Eluent B: 0.04% formic acid + 0.01% ammonia in ACN / MeOH (1:1). LCMS method 4a, LCMS (4a) Apparatus: Waters ACQUITYTM UPLCTM system; Bin. Pump: Waters ACQUITY TM Quaternary Solvent manager; PDA; Waters ACQUITY™ PDA detector; Waters QDa mass detector; ESI, pos / neg 100-1000; column: Waters UPLCTM BEHTM C182.1x50mm, 1.7 µm, Temp: 40ºC, Flow rate: 0.9 mL / min, Gradient: from 5% B to 100% B, Run time: 1.1 min, Eluent A: 0.1% formic acid in water, Eluent B: 0.1% formic acid in ACN / MeOH (1:1). Sample concentration: 1 mM. Injection volume: 1 µL. Chromatograms were processed at 215 nm. LCMS method 4b, LCMS (4b) Apparatus: Waters ACQUITYTM UPLCTM system; Bin. Pump: Waters ACQUITY TM Quaternary Solvent manager; Waters H Class Sample Manager and Organiser; PDA; Waters ACQUITY™ PDA detector; Waters SQDa mass detector; ESI, pos / neg 100-1000; column: Phenomenex Kinetex® Evo C18 column 2.1 mm × 50 mm, 1.7 µm, Temp: 40ºC, Flow rate: 1.0 mL / min, Gradient: from 1% B to 100% B then 100% B for 0.25 min, Run time: 1.1 min, Eluent A: water + 0.2% ammonium hydroxide, Eluent B: HPLC grade ACN. Sample concentration: 1 mM. Injection volume: 1 µL. Chromatograms were processed at 215 nm. LCMS method 4c, LCMS (4c) Apparatus: Waters ACQUITYTM UPLCTM system; Bin. Pump: Waters ACQUITY TM Quaternary Solvent manager; Waters H Class Sample Manager and Organiser; PDA; Waters ACQUITY™ PDA detector; Waters SQDa mass detector; ESI, pos / neg 100-1000; column: Phenomenex Kinetex® Evo C18 column 2...

Claims

CLAIMS 1. A heterocyclic compound, which heterocyclic compound is a compound of formula (I') or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof, for use as a medicamentwherein • R1is C1-C6haloalkyl, −L'−Z, −L'−C(O)Ry, −L'−C(O)NRiRy, −L'−C(O)OH, −L'−C(O)ORy, −L'−NRiC(O)Ry, −L'−SO2NRiRy, or −L'−Het, wherein Het is 4- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl, wherein said heterocyclyl is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, oxo, C1- C6alkyl, C1-C6haloalkyl, −L'−ORiand −L'−NRiRii, and said heteroaryl is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, −L'−ORiand −L'−NRiRii; Z is selected from −ORi, −NRiRyand −SRi; Ryis C1-C6alkyl, C1-C6haloalkyl, phenyl, 3- to 7-membered carbocyclyl, 5- to 7-membered heteroaryl or 4- to 7-membered heterocyclyl, wherein said carbocyclyl and heterocyclyl are unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, oxo, C1- C6 alkyl, C1-C6 haloalkyl, −L'−ORiand −L'−NRiRii, and said phenyl and heteroaryl are unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, C1-C6alkyl, C1-C6haloalkyl, −L'−ORiand −L'−NRiRii;Riand Riiare the same or different and are selected from hydrogen, C1-C6alkyl and C1-C6haloalkyl; and L' is a direct bond, C1-C6alkylene or C1-C6haloalkylene; • R2is hydrogen, C1-C6alkyl, C1-C6haloalkyl, −L''−Z', −L''−C(O)Rz, −L''−C(O)ORz, −L''−C(O)NRiiiRz, −L''−C(O)NH2, −L''−NRiiiC(O)Rz, −L''−NRiiiC(O)ORz, −L''−NRiiiC(O)NRivRz, −L''−NRiiiC(O)C(O)NRivRz, −L''−NRiiiSO2Rz, −L''−(4- to 10- membered heterocyclyl), or −L''−(5- to 7-membered heteroaryl), wherein said heterocyclyl is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, oxo, C1-C6alkyl, C1-C6haloalkyl, −L''−ORiiiand −L''−NRiiiRiv, and wherein said heteroaryl is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, C1-C6alkyl, C1- C6haloalkyl, −L''−ORiiiand −L''−NRiiiRiv; wherein Z' is selected from −OH, −ORiii, −NH2, −NRiiiRzand −SRiii; Rzis C1-C6alkyl, C1-C6haloalkyl, −Q''−Z', −A−A', −Q'−A−A', or −A−Q''−A, wherein A is phenyl, 3- to 7-membered carbocyclyl, 5- to 7-membered heteroaryl or 4- to 10-membered heterocyclyl, wherein said carbocyclyl and heterocyclyl are unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, oxo, cyano, C1-C6alkyl, C1-C6haloalkyl, −L''−ORiii, −L''−NRiiiRiv, and −L''−C(O)NRiiiRiv, and said phenyl and heteroaryl are unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, −L''−ORiii, −L''−NRiiiRiv, −L''−C(O)NRiiiRiv; A' is hydrogen, phenyl or 4- to 8-membered heterocyclyl, wherein said phenyl is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, C1-C6alkyl, C1-C6haloalkyl, 3- to 7-membered carbocyclyl, 4- to 7-membered heterocyclyl, −L''−ORiii, and −L''−NRiiiRiv, and said heterocyclyl is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, oxo, C1-C6alkyl, C1-C6haloalkyl, 3- to 7-membered carbocyclyl, 4- to 7-membered heterocyclyl, −L''−ORiii, −L''−NRiiiRiv; Q' is C1-C6alkylene, C1-C6haloalkylene, or −Q''−O−L''−;Q'' is C1-C6alkylene or C1-C6haloalkylene; L'' is a direct bond, C1-C6alkylene or C1-C6haloalkylene; Riiiand Rivare the same or different and are selected from hydrogen, C1-C6alkyl and C1-C6haloalkyl; or R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety; and • G1and G2are the same or different and are selected from phenyl, naphthyl, 4- to 10- membered heterocyclyl, 5- to 10-membered heteroaryl, or 4- to 10-membered carbocyclyl, wherein said heterocyclyl and carbocyclyl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1- C4haloalkyl, oxo, and −LG−ORG, and wherein said phenyl, naphthyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl, C1-C4haloalkyl, and −LG−ORG, wherein LGis a direct bond, C1-C6 alkylene or C1-C6 haloalkylene; and RGis selected from hydrogen, C1-C6alkyl and C1-C6haloalkyl; • Y is methylene or −C(O)−, wherein said methylene is unsubstituted or substituted by C1-C4 alkyl, C1-4 haloalkyl, halogen or hydroxy; • X1is C or N; m is 0 or 1; X2, and X3are the same or different and are selected from N, NR' and CR'', and X4is selected from N, NR' and CR'''; provided that when m is 0, either (a) at least one of X2 and X4 is NR', and X1 is C, or (b) X2 is selected from N and CR'' and X4is selected from N and CR''', and X1is N; and when m is 1, X1is C, X2and X3are the same or different and are selected from N and CR'', and X4is selected from N and CR'''; wherein R' is hydrogen or C1-C4alkyl, R'' is hydrogen, C1-C4alkyl or halogen, and R''' is hydrogen, C1-C4alkyl, halogen, C1-C4haloalkyl, cyano or 3- to 5-membered carbocyclyl; • L1is −C(O)NRv−Q−, −L1'−NRv−Q−, or −Het'−Q−, wherein Q is a direct bond, linear or branched C1-C6alkylene, or linear or branched C1-C6haloalkylene, wherein said alkylene and haloalkylene are unsubstituted or substituted by a hydroxy group; L1' is a direct bond, linear or branched C1-C2alkylene, linear or branched C1- C2haloalkylene or 4- to 6-membered heterocyclylene; Het' is a 4- to 6-membered heterocyclylene group or a 5- to 6-membered heteroarylene group, which group is unsubstituted or substituted by one, two or three C1-C3alkyl groups which are the same or different; and Rvis hydrogen or C1-C3alkyl;• Raand Rbare the same or different and are selected from C1-C4alkyl or C1-C4haloalkyl; or Raand Rbtogether with the carbon to which they are attached form a 3- to 7- membered carbocyclyl moiety or 4- to 7-membered heterocyclyl moiety, which moiety is unsubstituted or substituted by one, two or three substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl; • Rcand Rdare the same or different and are selected from hydrogen and C1-C4alkyl, or Rcand Rdtogether are oxo; • Reand Rfare the same or different and are selected from hydrogen, halogen, C1-C4alkyl and C1-C4haloalkyl; and • n is 0 or 1.

2. A heterocyclic compound for use according to claim 1, wherein the heterocyclic compound is a compound of formula (I') or a pharmaceutically acceptable salt, or a solvate, or a tautomer, or a stereoisomer thereof.

3. A heterocyclic compound for use according to claim 1 or claim 2, wherein R1is −C1- C4haloalkyl, −SRi, –(C1-C4alkylene)−ORi, −C(O)Ry, −C(O)NRiRy, −C(O)OH, −C(O)ORy, −NRiC(O)Ry, −SO2NRiRy, or −Het.

4. A heterocyclic compound for use according to any one of the preceding claims, wherein Het is 4- to 6-membered heterocyclyl or 5- to 6-membered heteroaryl, wherein said heterocyclyl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from oxo, C1-C4alkyl, and −N(C1-C4alkyl)2, and said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from C1-C4alkyl.

5. A heterocyclic compound for use according to any one of the preceding claims, wherein Het is 4- to 5-membered heterocyclyl which is unsubstituted or substituted by one oxo group, one C1-C3alkyl group or one −N(C1-C3alkyl)2group, or which is substituted by one oxo group and one C1-C3alkyl group; or a 5-membered heteroaryl group which is unsubstituted or substituted with one or two C1-C3alkyl.

6. A heterocyclic compound for use according to any one of the preceding claims, wherein Ryis C1-C4alkyl, 3- to 7-membered cycloalkyl or 4- to 7-membered heterocyclyl,wherein said cycloalkyl and heterocyclyl are unsubstituted or substituted by one C1-C4alkyl group.

7. A heterocyclic compound for use according to any one of the preceding claims, wherein Ryis C1-C3alkyl, or unsubstituted 4- to 6-membered heterocyclyl.

8. A heterocyclic compound for use according to any one of the preceding claims, wherein Riis selected from hydrogen and C1-C4alkyl.

9. A heterocyclic compound for use according to any one of the preceding claims, wherein R1is −C(O)NRi(C1-C3alkyl).

10. A heterocyclic compound for use according to any one of the preceding claims, wherein R1is −C(O)N(CH3)2.

11. A heterocyclic compound for use according to any one of the preceding claims, wherein R2is hydrogen, C1-C4alkyl, C1-C4haloalkyl, −Z', −C(O)Rz, −C(O)ORz, −C(O)NRiiiRz, −C(O)NH2, −NRiiiC(O)Rz, −NRiiiC(O)ORz, −NRiiiC(O)NRivRz, −NRiiiC(O)C(O)NRivRz, −NRiiiSO2Rz, −(4- to 7-membered heterocyclyl) which is unsubstituted or substituted by one oxo group, or −(5- to 7-membered heteroaryl) which is unsubstituted or substituted with one C1-C3alkyl group; or R2is −L2-LBM, wherein L2is a linker and LBM is a ligase binding moiety.

12. A heterocyclic compound for use according to any one of the preceding claims, wherein R2is hydrogen, C1-C3alkyl, C1-C3haloalkyl, −Z', −C(O)(C1-C3alkyl), −C(O)O(C1- C4alkyl), −C(O)NRiii(C1-C3alkyl), −C(O)NRiii(−A−A'), −C(O)NH2, −NRiiiC(O)Rz, −NRiiiC(O)O(C1-C4alkyl), −NRiiiC(O)O(−A−A'), −NRiiiC(O)NRiv(C1-C3alkyl), −NRiiiC(O)C(O)NRiv(C1-C3alkyl), −NHSO2(C1-C3alkyl), 5-membered heterocyclyl which is unsubstituted or substituted with one oxo group, or 5-membered heteroaryl which is unsubstituted or substituted with one C1-C3alkyl group.

13. A heterocyclic compound for use according to any one of the preceding claims, wherein Z' is selected from −OH, −O(C1-C3alkyl), −NH2, −NRiii(C1-C3alkyl), −NRiii(C1-C3haloalkyl), a −NH−(5- to 6-membered heteroaryl) group which is unsubstituted, and a−NH−(4- to 6-membered heterocyclyl) group which is unsubstituted or substituted with one C1-C3alkyl group, or one C1-C3alkyl group and one oxo group.

14. A heterocyclic compound for use according to any one of the preceding claims, wherein Rzis C1-C6alkyl, C1-C6haloalkyl, −(C1-C3alkylene)−Z', −A−A', −(C1-C3alkylene)−A−A', −(C1-C3alkylene−O−C1-C3alkylene)−A−A', or −A−(C1-C3alkylene)−A, wherein A is a phenyl moiety which is unsubstituted or substituted with one substituent selected from C1-C3alkyl, halogen, −N(C1-C3alkyl)2, and –(C1-C3alkylene)−C(O)NRiii(C1- C3alkyl), a 3- to 7-membered cycloalkyl moiety which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from C1-C3alkyl, halogen, cyano, and −ORiii, a 5- to 7-membered heteroaryl moiety which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C3alkyl, or a 4- to 10-membered heterocyclyl moiety which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, cyano, C1-C3alkyl, and oxo; and A' is hydrogen, a phenyl moiety which moiety is unsubstituted or substituted with −(C1-C3alkylene)−NRiiiRiv,or a 4- to 8-membered heterocyclyl moiety which moiety is unsubstituted or substituted by one substituent selected from C1-C3alkyl, C1-C3haloalkyl, oxo, 3- to 5-membered carbocyclyl, 4- to 5-membered heterocyclyl, and −ORiii.

15. A heterocyclic compound for use according to any one of the preceding claims, wherein Rzis phenyl−A' wherein said phenyl is unsubstituted or substituted with one substituent selected from C1-C3alkyl, halogen, −N(C1-C3alkyl)2, and –(C1-C3alkylene)−C(O)NRiii(C1-C3alkyl), or (5- to 6-membered heteroaryl)−A' wherein said heteroaryl is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and C1-C3alkyl, wherein A' is a 4- to 8-membered heterocyclyl moiety which moiety is unsubstituted or substituted by one substituent selected from C1-C3alkyl, C1-C3haloalkyl, oxo, 3- to 5-membered carbocyclyl, 4- to 5-membered heterocyclyl, and −ORiii.

16. A heterocyclic compound for use according to any one of the preceding claims, wherein Rzis (unsubstituted phenyl)−A', or (pyrazolyl)−A' wherein said pyrazolyl is substituted with one methyl group, and wherein A' is piperidinyl which is substituted withone substituent selected from cyclobutyl and −CH2CHF2, or azetidinyl which is substituted with one methoxy group, or unsubstituted morpholinyl.

17. A heterocyclic compound for use according to any one of the preceding claims, wherein Riiiis selected from hydrogen and C1-C4alkyl.

18. A heterocyclic compound for use according to any one of the preceding claims, wherein G1is selected from a phenyl moiety, a 5- to 7-membered heterocyclyl moiety, a 5- to 7-membered heteroaryl moiety, or a 5- to 7-membered cycloalkyl moiety, which moiety is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, C1-C4alkyl and C1-C4haloalkyl.

19. A heterocyclic compound for use according to any one of the preceding claims, wherein G1is phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine, chlorine and C1-C3alkyl.

20. A heterocyclic compound for use according to any one of the preceding claims, wherein G2is selected from phenyl, 4- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or 4- to 7-membered cycloalkyl, wherein said heterocyclyl and cycloalkyl are unsubstituted or substituted by one substituent selected from C1-C4alkyl, −(C1-C4alkylene)−OH and oxo, and wherein said phenyl and heteroaryl are unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen, −O−(C1-C4alkyl), C1-C4alkyl and C1-C4haloalkyl.

21. A heterocyclic compound for use according to any one of the preceding claims, wherein G2is phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from halogen, −O−(C1-C3alkyl) and C1-C3alkyl.

22. A heterocyclic compound for use according to any one of the preceding claims, wherein Y is methylene.

23. A heterocyclic compound for use according to any one of the preceding claims, wherein m is 0.

24. A heterocyclic compound for use according to claim 23, wherein X1is N, X2is N or CR'', and X4is CR'''.

25. A heterocyclic compound for use according to claim 24, wherein: (a) m is 0, X1is N, X2is CH and X4is CH; or (b) m is 0, X1is N, X2is N and X4is CH or C(CH3).

26. A heterocyclic compound for use according to any one of the preceding claims, wherein L1is −C(O)NRv−Q−, –(4-membered heterocyclylene)−NRv−Q−, −NRv−Q− or –(5- membered heteroarylene)−Q−, wherein Q is a direct bond, or unsubstituted C1-C2alkylene, and Rvis hydrogen or C1-C3alkyl.

27. A heterocyclic compound for use according to any one of the preceding claims, wherein L1is −C(O)NRv−Q−, wherein Q is methylene and Rvis hydrogen.

28. A heterocyclic compound for use according to any one of the preceding claims, wherein Raand Rbare the same or different and are C1-C3alkyl, or Raand Rbtogether with the carbon to which they are attached form an unsubstituted 4- to 6-membered heterocyclyl, or a 3- to 7-membered cycloalkyl which is unsubstituted or substituted by one or two substituents selected from fluorine and C1-C3alkyl.

29. A heterocyclic compound for use according to any one of the preceding claims, wherein Raand Rbtogether with the carbon to which they are attached form an unsubstituted 4-membered heterocyclyl, or an unsubstituted 4-membered cycloalkyl.

30. A heterocyclic compound for use according to any one of the preceding claims, wherein Rcand Rdare hydrogen.

31. A heterocyclic compound for use according to any one of the preceding claims, wherein Reand Rfare hydrogen.

32. A heterocyclic compound for use according to any one of the preceding claims, wherein n is 1.

33. A heterocyclic compound for use according to any one of the preceding claims, wherein R1, G1, G2, Y, X1, X2, X3, X4, L1, Ra, Rb, Rc, Rd, Re, Rf, m and n are as defined in any one of the preceding claims, and R2is −L2-LBM.

34. A heterocyclic compound for use according to any one of the preceding claims which is a compound of formula (I'iii(a)) or (I'iii(b)) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof:(I'iii(b)) wherein • R1is CF2CH3, −SCH3, C4 alkylene−OH, −C(O)Ry, −C(O)NHCH3, −C(O)N(CH3)2, −C(O)N(CH3)(C3alkyl), −C(O)N(CH2CH3)2,−C(O)OH, −C(O)OCH3, −NHC(O)CH3, −N(CH3)C(O)CH3, −SO2NH(CH3), or unsubstituted pyrrolidinone, or an oxetanyl moiety which is unsubstituted or substituted by one methyl group or one −N(CH3)2group, or a triazolyl moiety which is unsubstituted, substituted with one methyl group, or substituted with one oxo group and one methyl group, or an imidazolyl moiety which is unsubstituted, substituted with one or two methyl groups, or substituted with one oxo group and one methyl group, or a pyrazolyl moiety which is unsubstituted or substituted by one methyl group, orunsubstituted oxadiazolyl, or an oxazolyl moiety which is unsubstituted or substituted by one methyl group, or a furanyl moiety which is substituted with two methyl groups, or unsubstituted tetrahydrofuranyl, or unsubstituted tetrazolyl, wherein Ryis methyl, ethyl, i-propyl, unsubstituted azetidinyl, unsubstituted pyrrolidinyl, unsubstituted piperidinyl, or unsubstituted morpholinyl; • R2is hydrogen, methyl, −CH2F, −Z', −C(O)CH3, −C(O)O(tert-butyl), −C(O)NH(CH3), −C(O)N(CH3)2, −C(O)NH(−A−A'), −C(O)NH2, −N(CH3)C(O)CH3, −NHC(O)Rz, −NHC(O)O(C3-C4alkyl), −NHC(O)O(unsubstituted phenyl), −NHC(O)N(CH3)2, −NHC(O)N(CH3)(CH2CH3), −NHC(O)NH(CH3),−NHC(O)C(O)N(CH3)2, −NHSO2(CH3), unsubstituted pyrrolidinone, unsubstituted dihydrotriazolone, unsubstituted oxadiazolone, imidazolyl which is unsubstituted or substituted with one methyl group, triazolyl which is unsubstituted or substituted with one methyl group, or unsubstituted tetrazolyl, wherein Z' is −NH2, −NH(CH3), −N(CH3)2, −NHCH2CF3, a −NH−pyridinyl group which is unsubstituted, a −NH−oxetanyl group which is unsubstituted or substituted with one methyl group, or a −NH−(unsubstituted pyrimidinone) group; Rzis methyl, tert-butyl, iso-butyl, −CH2−(tert-butyl), cyclopropyl which is unsubstituted or substituted with one halogen group, cyclobutyl which is unsubstituted or substituted with one cyano group or one methoxy group, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted cyclohexyl, oxadiazolyl which is substituted with one methyl group, unsubstituted thiazolyl, benzodioxazolyl which is unsubstituted or substituted with one or two halogen groups, oxetanyl which is unsubstituted or substituted with one methyl group, azetidinyl which is unsubstituted or substituted with one cyano group or one methoxy group, unsubstituted pyrrolidinyl, pyrimidinonyl which is unsubstituted or substituted with one methyl group, indolinyl which is unsubstituted or substituted with one methyl group, morpholinyl which is unsubstituted or substituted with one methyl group, piperidinyl which is unsubstituted or substituted with one methyl group, piperazinyl which is unsubstituted or substituted with one methyl group, tetrahydroquinoline which is unsubstituted or substituted by one or two substituents which are the same or different and are selected from halogen and methyl, unsubstituted tetrahydrofuranyl, unsubstituted tetrahydropyranyl, tetrahydropyrazolo[1,5-a]pyrazinyl which is unsubstituted or substituted with one methyl group, tetrahydro-1H,3H-5l2-furo[3,4- c]pyrrole which is substituted with one or two methyl groups, unsubstituted oxa-azaspiroheptane, unsubstituted oxa-azaspirooctane, unsubstituted oxa- azaspirononane, unsubstituted oxa-azabicycloheptane, unsubstituted oxa- azabicycloctane, or phenyl−A' wherein said phenyl is unsubstituted or substituted with one substituent selected from methyl, propyl, halogen, −N(CH3)2, and – (ethylene)−C(O)NH(CH3), or (imidazolyl)−A' wherein said imidazolyl is unsubstituted or substituted with one methyl group, or (pyrazolyl)−A' wherein said pyrazolyl is unsubstituted or substituted with one or two methyl groups, or (pyridinyl)−A' wherein said pyridinyl is unsubstituted or substituted with one C1-C3alkyl group or one halogen group, or (pyrimidinyl)−A' wherein said pyrimidinyl is unsubstituted or substituted with one methyl group, wherein A' is hydrogen, phenyl which is substituted with −(CH2)−NH(CH3), azetidinyl which is substituted with one substituent selected from methyl, methoxy, cyclopropyl, and cyclobutyl, piperidinyl which is substituted with one substituent selected from methyl, ethyl, cyclopropyl, cyclobutyl, −CH2CH2F, −CH2CHF2, methoxy, and oxetanyl, morpholinyl which is unsubstituted or substituted with one methyl group or one oxo group, piperazinyl which is substituted with one substituent selected from methyl, cyclopropyl, and cyclobutyl, tetrahydropyridinyl which is substituted with one methyl group, pyrrolidinyl which is substituted with one methoxy group, or unsubstituted oxazaspiroheptane, unsubstituted oxazaspirooctane, or unsubstituted tetrahydropyranyl; • G1is unsubstituted piperidinyl, unsubstituted bicyclo[1.1.1]pentyl, unsubstituted cyclohexyl, unsubstituted pyrimidinyl, pyridinyl which is unsubstituted or substituted with one methyl group, one fluorine group, or one chlorine group, or phenyl which is unsubstituted or substituted with one or two substituents which are the same or different and are selected from fluorine, chlorine and methyl; • G2is unsubstituted piperidinyl, unsubstituted benzimidazolyl, unsubstituted pyrrolidinyl, unsubstituted tetrahydropyranyl, unsubstituted bicyclo[1.1.1]pentyl, cyclohexyl which is unsubstituted or substituted with one hydroxy group, unsubstituted indolinyl, unsubstituted oxoindolinyl, unsubstituted benzoxazolonyl, unsubstituted dihydroquinolinonyl, pyridinyl which is unsubstituted or substituted with one chlorine group, unsubstituted pyrimidinyl, unsubstituted indolyl, unsubstituted oxazolyl, unsubstituted thiazolyl, or phenyl which is unsubstituted or substituted with one or two substituents selected from fluorine, chlorine, methoxy and methyl;• Y is methylene or −C(O)−; • R''' is hydrogen, fluorine, chlorine, bromine, methyl, trifluoromethyl, cyano, or cyclopropyl; • L1is −C(O)NRv−Q−, –(oxetanylene)−NRv−Q−, or –(triazolylene)−Q−, wherein Q is a direct bond or methylene, and Rvis hydrogen or methyl; • Rais methyl and Rbis methyl; or Raand Rbtogether with the carbon to which they are attached form unsubstituted oxetanyl, unsubstituted tetrahydrofuranyl, unsubstituted cyclopropyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or a cyclobutyl group which is unsubstituted or substituted with one or two substituents selected from fluorine and methyl.

35. A heterocyclic compound for use according to any one of the preceding claims which is a compound of formula (I'iv(a)) or (I'iv(b)) or a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative thereof:wherein • R1is −C(O)N(CH3)2; • R2is −NHC(O)(−A−A'), wherein A is unsubstituted phenyl or pyrazolyl which is substituted with one methyl group, and A' is piperidinyl which is substituted with onesubstituent selected from cyclobutyl and −CH2CHF2, or azetidinyl which is substituted with one methoxy group, or unsubstituted morpholinyl; • G1is unsubstituted phenyl; • G2is unsubstituted phenyl; • R''' is hydrogen or methyl; and Raand Rbtogether with the carbon to which they are attached form unsubstituted oxetanyl or unsubstituted cyclobutyl.

36. A heterocyclic compound for use according to any one of the preceding claims, wherein the heterocyclic compound has an IC50of no more than 10,000 nM against STAT6.

37. A heterocyclic compound for use according to any one of the preceding claims, wherein the heterocyclic compound is one of: • N-(4-acetamidobenzyl)-2'-(4-(N-methylacetamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(isopropyl(methyl)carbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)-3,5-dimethylbenzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)-3-methylbenzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-((5-(dimethylcarbamoyl)pyridin-2-yl)methyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(1-methyl-1H-imidazol-2-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(4-methyl-4H-1,2,4-triazol-3-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(1,3,4-oxadiazol-2-yl)benzyl)-N-(4-acetamidobenzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(oxazol-2-yl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-((1-isobutyrylpiperidin-4-yl)methyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide;• 2'-(4-(1H-pyrazol-1-yl)benzyl)-N-(4-acetamidobenzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(3-methyloxetan-3-yl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • Methyl 3-((6'-((4-acetamidobenzyl)carbamoyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazin]-2'-yl)methyl)bicyclo[1.1.1]pentane- 1-carboxylate; • 3-((6'-((4-acetamidobenzyl)carbamoyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazin]-2'-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; • N-(4-acetamidobenzyl)-2'-(4-(3-(dimethylamino)oxetan-3-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-((3-(dimethylcarbamoyl)bicyclo[1.1.1]pentan-1- yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(1-hydroxy-2-methylpropyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(2-methyl-4-(1H-1,2,4-triazol-1-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-isobutyrylbenzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(methylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((2-((3R,5S)-3,5-Dimethylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5-(2- (trifluoromethyl)pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine • N-(4-acetamidobenzyl)-2'-(4-(2-oxopyrrolidin-1-yl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-(dimethylamino)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-N-methyl-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide;• N-benzyl-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((1-acetylpiperidin-4-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclopentane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclohexane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3,3-dimethyl-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(azetidine-1-carbonyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(pyrrolidine-1-carbonyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(piperidine-1-carbonyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(morpholine-4-carbonyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(methylamino)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((5-acetamidopyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamido-3-methylbenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide;• N-(4-acetamido-3,5-dimethylbenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(3-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamido-3-fluorobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(N-methylacetamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((2-oxoindolin-5-yl)methyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((2-methyl-1H-benzo[d]imidazol-5- yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(methylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((3-methyloxetan-3-yl)amino)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((5-(cyclopropanecarboxamido)pyridin-2-yl)methyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide; • N-((1-acetylindolin-5-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(3-acetamidophenyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-acetamidophenyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N,2'-bis(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylpiperidin-3- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide;• Tert-butyl (4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamido)methyl)phenyl)carbamate; • N-(4-aminobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-(cyclopropanecarboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-isopropylbenzamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(isonicotinamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-pivalamidobenzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-(cyclobutanecarboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-benzamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(oxetane-3-carboxamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(nicotinamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(oxetane-2-carboxamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(tetrahydro-2H-pyran-4- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-(bicyclo[1.1.1]pentane-1-carboxamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(pyridin-2-ylamino)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide;• 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5- a]pyrazine-3-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-methylindoline-6-carboxamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-(4-(3,3-dimethylbutanamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(picolinamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((5-benzamidopyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((3-aminobicyclo[1.1.1]pentan-1-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; • N-((3-acetamidobicyclo[1.1.1]pentan-1-yl)methyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide; • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-8'-fluoro-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide; and • N-(4-acetamidobenzyl)-2-(4-(dimethylcarbamoyl)benzyl)-1,1-dimethyl-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide. • N-((5-acetamidopyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)-2,6- difluorobenzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]- 6'-carboxamide • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)-2-methylbenzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-acetamidobenzyl)-2'-(4-(5-methyl-1H-1,2,4-triazol-1-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-acetamidobenzyl)-2'-(4-(1-methyl-1H-1,2,4-triazol-5-yl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-acetamidobenzyl)-2'-(2-chloro-4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(methylcarbamoyl)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide• N-(4-acetamidobenzyl)-2'-(4-(5-methyl-1H-pyrazol-1-yl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-((3-chloro-5-(dimethylcarbamoyl)pyridin-2-yl)methyl)-N-(4-(3,3- dimethylureido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-(1H-imidazol-2-yl)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(4H-1,2,4-triazol-3-yl)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((1-(methylcarbamoyl)piperidin-4-yl)methyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-((4-acetamidophenyl)methyl-d2)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-carbamoylbenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • isopropyl (4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamido)methyl)phenyl)carbamate • N-(4-((2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamido)methyl)phenyl)morpholine-4-carboxamide • N-(4-acetamidobenzyl)-7'-(4-(dimethylcarbamoyl)benzyl)-1'-methyl-6',7'-dihydro- 5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-1'-methyl-N-(4-(methylcarbamoyl)benzyl)-6',7'- dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7'-(4-(dimethylcarbamoyl)benzyl)-N-methyl-6',7'-dihydro- 5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-acetamidobenzyl)-2'-(4-(isoxazol-3-yl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-acetamidobenzyl)-2'-((4-(dimethylcarbamoyl)phenyl)methyl-d2)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide• N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclopropane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-((5-(dimethylcarbamoyl)-3-fluoropyridin-2-yl)methyl)-N-(4-(3,3- dimethylureido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-((5-(dimethylcarbamoyl)-3-fluoropyridin-2-yl)methyl)-N-(4-(4- morpholinobenzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-((5-(3,3-dimethylureido)pyridin- 2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-N-((5-(3,3-dimethylureido)pyridin-2- yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • N-(4-carbamoylbenzyl)-2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-N-(4-(5-methyl-1-(1-methylpiperidin-4- yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-N-(4-(oxetane-3-carboxamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-3,3-difluoro-N-(4- (methylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-((5-(3,3-dimethylureido)pyridin- 2-yl)methyl)-3,3-difluoro-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-((5-acetamidopyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)-2,6- difluorobenzyl)-3,3-difluoro-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide• 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(3,3-dimethylureido)benzyl)- 3,3-difluoro-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-3,3-difluoro-N-(4-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-N-((5-(3,3-dimethylureido)pyridin-2- yl)methyl)-3,3-difluoro-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-N-(4-(3,3-dimethylureido)benzyl)-3,3- difluoro-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • N-((5-(cyclopropanecarboxamido)pyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)- 2-fluorobenzyl)-3,3-difluoro-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-3,3-difluoro-N-((5-(1-methyl-1H- pyrazole-4-carboxamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-3,3-difluoro-N-((5-(1-methyl-1H- imidazole-4-carboxamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(3,3-dimethylureido)benzyl)- 3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H- spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-3',4'-dihydro- 2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((1S,2S)-2-fluorocyclopropane-1- carboxamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide• 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-((5-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)pyridin-2-yl)methyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 7'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(4- morpholinobenzamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'- imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-6',7'-dihydro- 5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-6',7'-dihydro- 5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-((1S,2S)-2- fluorocyclopropane-1-carboxamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane- 1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(2-fluoro-4-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 1-chloro-7-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(3,3- dimethylureido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • 7''-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)-6'',7''- dihydro-5''H-dispiro[cyclobutane-1,1'-cyclobutane-3',8''-imidazo[1,5-a]pyrazine]- 3''-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)-6',7'- dihydro-5'H-spiro[cyclopropane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-8'-methyl-N-(4-(5-methyl-1-(1-methylpiperidin- 4-yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-((1S,2S)-2-fluorocyclopropane-1- carboxamido)benzyl)-1-methyl-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide• N-(4-(1-(1-(2,2-difluoroethyl)piperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7-(4-(dimethylcarbamoyl)benzyl)-6,7-dihydro-5H- spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(7-fluoro-1-methyl-1,2,3,4- tetrahydroquinoline-6-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-methoxypropanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(2-cyclopropylacetamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((1R,2R)-2-fluorocyclopropane-1- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-methyl-1H-imidazole-4- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-(methylamino)-3- oxopropyl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-methyl-1H-pyrazole-4- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-methyl-1H-pyrazole-3- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((1S,2S)-2-fluorocyclopropane-1- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(2'-((methylamino)methyl)-[1,1'-biphenyl]- 4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide• N-(4-(4-(4-cyclopropylpiperazin-1-yl)benzamido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-hydroxypropanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-methyl-1-(1-methylpiperidin-4-yl)-1H- pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(1-ethylpiperidin-4-yl)-5-methyl-1H- pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-methyl-1-(1-(oxetan-3-yl)piperidin-4- yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(1-(1-(2,2-difluoroethyl)piperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(1-(2-fluoroethyl)piperidin-4-yl)-5- methyl-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(1-methylpiperidin-4-yl)-1H-pyrazole- 4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-methyl-1-(1-methylazetidin-3-yl)-1H- pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide• N-(4-(1,5-dimethyl-1H-pyrazole-4-carboxamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-(1H-pyrazole-3-carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-((1r,3r)-3-cyanocyclobutane-1-carboxamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-((1s,3s)-3-cyanocyclobutane-1-carboxamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • (1R,4R)-N-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-2- oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide • (1R,5S)-N-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-3- oxa-8-azabicyclo[3.2.1]octane-8-carboxamide • N-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-2-oxa-6- azaspiro[3.4]octane-6-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-methylureido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-2-oxa-7- azaspiro[3.5]nonane-7-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(tetrahydrofuran-2-carboxamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • (S)-2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylpiperidin-3- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • (R)-2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylpiperidin-3- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide• N-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)morpholine-4-carboxamide • N-(4-(cyclohexanecarboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(pyrrolidine-1-carboxamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(azetidine-1-carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-ethyl-3-methylureido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(3-cyanoazetidine-1-carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-methoxyazetidine-1- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((1s,3s)-3-methoxycyclobutane-1- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • isobutyl (4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamido)methyl)phenyl)carbamate • N-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-2-oxa-6- azaspiro[3.3]heptane-6-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(4-methylpiperazin-1- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylazetidin-3- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide• 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methyl-1,2,5,6-tetrahydropyridin-3- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylpiperidin-4- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-(4-(4-cyclobutylpiperazin-1-yl)benzamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-(4-(1-cyclobutylpiperidin-4-yl)benzamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((5-(3,3-dimethylureido)pyridin-2-yl)methyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((5-(4-(4-methylpiperazin-1- yl)benzamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((5-(4-morpholinobenzamido)pyridin-2- yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • N-((5-(4-(1-cyclobutylpiperidin-4-yl)benzamido)pyridin-2-yl)methyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-((5-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)pyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-((5-(5-methyl-1-(1-methylpiperidin-4-yl)-1H- pyrazole-4-carboxamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(2-fluoro-4-(4-(1-methylpiperidin-4- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide• 2'-(4-(dimethylcarbamoyl)benzyl)-N-(2-fluoro-4-(5-methyl-1-(1-methylpiperidin-4- yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(oxetane-3- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)-6',7'- dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-(4-(4-cyclobutylpiperazin-1-yl)benzamido)benzyl)-7'-(4- (dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(6-morpholinonicotinamido)benzyl)-6',7'- dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-morpholinobenzamido)benzyl)-6',7'- dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylpiperidin-4- yl)benzamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • N-(4-(4-(4-cyclopropylpiperazin-1-yl)benzamido)benzyl)-7'-(4- (dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • N1-(4-((7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane- 1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamido)methyl)phenyl)-N2,N2- dimethyloxalamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-methoxyazetidin-1- yl)benzamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide• isobutyl (4-((7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'- carboxamido)methyl)phenyl)carbamate • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(2-morpholinopyrimidine-5- carboxamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-methoxypyrrolidin-1- yl)benzamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • N-(4-(1-(1-(2,2-difluoroethyl)piperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-(oxetan-3-yl)piperidin-4- yl)benzamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • N-(4-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-methoxyazetidin-1- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]- 6'-carboxamide • N-(4-(1-(1-cyclopropylazetidin-3-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 1-chloro-7-(4-(dimethylcarbamoyl)benzyl)-N-(4-((1S,2S)-2-fluorocyclopropane-1- carboxamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]- 3-carboxamide • 4-((7'-(4-acetamidobenzyl)-6'-oxo-3',4',6',7',8',9'-hexahydro-2'H-spiro[cyclobutane- 1,1'-pyrido[4',3':4,5]pyrrolo[1,2-a]pyrazin]-2'-yl)methyl)-N,N-dimethylbenzamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-((5-(4-(4-methylpiperazin-1- yl)benzamido)pyridin-2-yl)methyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'- imidazo[1,5-a]pyrazine]-3'-carboxamide• 7'-(4-(dimethylcarbamoyl)benzyl)-N-((5-(4-morpholinobenzamido)pyridin-2- yl)methyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'- carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-N-((5-(4-(4-methylpiperazin-1- yl)benzamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-((5-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)pyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-((5-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)pyridin-2-yl)methyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-N-((5-(1-methyl-1H-pyrazole-4- carboxamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-N-((5-(1-methyl-1H-imidazole-4- carboxamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-N-((5-(4- morpholinobenzamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-N-(4-(1-methyl-1H-imidazole-4- carboxamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-(cyclopropanecarboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3,3- difluoro-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)-3,3-difluoro- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-N-(4-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide• 2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-N-(4-(4-(1-methylpiperidin-4- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)-3',4'- dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(4-(4-cyclopropylpiperazin-1-yl)benzamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylpiperidin-4- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]- 6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(4-methylpiperazin-1- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]- 6'-carboxamide • N-(4-(4-(4-cyclobutylpiperazin-1-yl)benzamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(2-fluoro-4- morpholinobenzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-(oxetan-3-yl)piperidin-4- yl)benzamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]- 3-carboxamide • N-(4-(4-(4-cyclopropylpiperazin-1-yl)benzamido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-1-methyl-6,7-dihydro-5H-spiro[imidazo[1,5- a]pyrazine-8,3'-oxetane]-3-carboxamide • N-(4-(1-(1-cyclopropylazetidin-3-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7-(4-(dimethylcarbamoyl)benzyl)-6,7-dihydro-5H- spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide• N-(4-(4-(1-(2,2-difluoroethyl)piperidin-4-yl)benzamido)benzyl)-7'-(4- (dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • 2'-(4-(dimethylcarbamoyl)-2-fluorobenzyl)-N-(4-(4- morpholinobenzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 7-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(3,3-dimethylureido)benzyl)- 6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 7-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(4- morpholinobenzamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • N-(4-(1-(1-cyclobutylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-6,7-dihydro- 5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-methyl-1-(1-methylpiperidin-4-yl)-1H- pyrazole-4-carboxamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine- 8,3'-oxetane]-3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(4-methylpiperazin-1- yl)benzamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]- 3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)-6,7- dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-methylpiperidin-4- yl)benzamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]- 3-carboxamide • N-(4-(4-(4-cyclobutylpiperazin-1-yl)benzamido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-morpholinobenzamido)benzyl)-6,7- dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • N-(4-(3-(4-cyclopropylpiperazin-1-yl)benzamido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide• 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(2-fluoro-4-morpholinobenzamido)benzyl)- 6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-methoxyazetidin-1- yl)benzamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]- 3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(4-methoxypiperidin-1- yl)benzamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]- 3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-oxomorpholino)benzamido)benzyl)- 6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-methylindoline-5-carboxamido)benzyl)- 6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(1-(oxetan-3-yl)piperidin-4- yl)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]- 6'-carboxamide • N-(4-(4-(1-(2,2-difluoroethyl)piperidin-4-yl)benzamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • N-(4-(1-(1-cyclobutylazetidin-3-yl)-5-methyl-1H-pyrazole-4-carboxamido)benzyl)- 7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'- imidazo[1,5-a]pyrazine]-3'-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(1-(2-fluoroethyl)piperidin-4-yl)-5- methyl-1H-pyrazole-4-carboxamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5- a]pyrazine-8,3'-oxetane]-3-carboxamide • 1-chloro-7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)- 6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • N-(4-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7-(4-(dimethylcarbamoyl)benzyl)-6,7-dihydro-5H- spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • N-(4-acetamidobenzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-8'-methyl-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 1'-chloro-7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)- 6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide• tert-butyl (4-((1'-bromo-7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'- carboxamido)methyl)phenyl)carbamate • 1'-bromo-7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)- 6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 1-chloro-7-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-((1S,2S)-2- fluorocyclopropane-1-carboxamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5- a]pyrazine-8,3'-oxetane]-3-carboxamide • 1-chloro-7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)- 6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 1-chloro-7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)-6,7- dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 1-chloro-N-(3-chloro-4-(3,3-dimethylureido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • N-(4-(3-chloro-4-(3-methoxyazetidin-1-yl)benzamido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • N-(4-(1-(1-cyclopropylazetidin-3-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N2,N2- dimethyloxalamide • 7-(4-(dimethylcarbamoyl)benzyl)-1-methyl-N-(4-(4- morpholinobenzamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • 7'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(2-methoxy-4-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-(1-(1-cyclopropylpiperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H- spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide• 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((4-morpholinophenyl)carbamoyl)benzyl)- 6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-((1-(1-cyclopropylpiperidin-4-yl)-1H-imidazol-4-yl)carbamoyl)benzyl)-7'-(4- (dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)-7'-fluoro-3',4'- dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(4-(4-cyclopropylpiperazin-1-yl)benzamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-8'-methyl-3',4'-dihydro-2'H-spiro[oxetane-3,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-((5-(4-(3-methoxyazetidin-1- yl)benzamido)pyridin-2-yl)methyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'- imidazo[1,5-a]pyrazine]-3'-carboxamide • 1'-chloro-7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-methyl-4,5,6,7- tetrahydropyrazolo[1,5-a]pyrazine-3-carboxamido)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-1'-methyl-N-(4-(5-methyl-4,5,6,7- tetrahydropyrazolo[1,5-a]pyrazine-3-carboxamido)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((1S,2S)-2-fluorocyclopropane-1- carboxamido)benzyl)-1'-methyl-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'- imidazo[1,5-a]pyrazine]-3'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-methylindoline-5-carboxamido)benzyl)- 3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-8'-methyl-N-(4-(4- morpholinobenzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-8'-methyl-N-((5-(4- morpholinobenzamido)pyridin-2-yl)methyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N-(4-(4-(4-cyclobutyl-2-oxopiperazin-1-yl)benzamido)benzyl)-2'-(4- (dimethylcarbamoyl)benzyl)-8'-methyl-3',4'-dihydro-2'H-spiro[oxetane-3,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide• 2'-(4-(dimethylcarbamoyl)benzyl)-8'-methyl-N-(4-(4-(3- oxomorpholino)benzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)-1- (trifluoromethyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3- carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)-1- (trifluoromethyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3- carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-methoxyazetidin-1- yl)benzamido)benzyl)-1-methyl-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • N-(4-(4-(4-cyclobutylpiperazin-1-yl)benzamido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-1-methyl-6,7-dihydro-5H-spiro[imidazo[1,5- a]pyrazine-8,3'-oxetane]-3-carboxamide • N-(4-(1-(1-(2,2-difluoroethyl)piperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7-(4-(dimethylcarbamoyl)benzyl)-1-methyl-6,7-dihydro-5H- spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • N-(4-(4-(1-cyclopropylazetidin-3-yl)benzamido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-1-methyl-6,7-dihydro-5H-spiro[imidazo[1,5- a]pyrazine-8,3'-oxetane]-3-carboxamide • 1-chloro-N-(4-(1-(1-(2,2-difluoroethyl)piperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7-(4-(dimethylcarbamoyl)benzyl)-6,7-dihydro-5H- spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 1-chloro-7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-methoxyazetidin-1- yl)benzamido)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]- 3-carboxamide • N-(4-(1-(1-(2,2-difluoroethyl)piperidin-4-yl)-5-methyl-1H-pyrazole-4- carboxamido)benzyl)-7'-(4-(dimethylcarbamoyl)benzyl)-1'-methyl-6',7'-dihydro- 5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 8'-bromo-2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)-7'- fluoro-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide• N-(4-acetamidobenzyl)-7'-(4-(dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H- spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N-((5-(cyclopropanecarboxamido)pyridin-2-yl)methyl)-2'-(4- (dimethylcarbamoyl)benzyl)-3,3-difluoro-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-3,3-difluoro-N-((5-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)pyridin-2-yl)methyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 7-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(3,3-dimethylureido)benzyl)- 1-methyl-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3- carboxamide • N-(4-(4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)benzamido)benzyl)-7'-(4- (dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • N-(4-(4-(2-oxa-6-azaspiro[3.4]octan-6-yl)benzamido)benzyl)-7'-(4- (dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-methyl-1H-pyrazole-4- carboxamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • 2'-((5-(dimethylcarbamoyl)-3-methylpyridin-2-yl)methyl)-N-(4-(5-methyl-1-(1- methylpiperidin-4-yl)-1H-pyrazole-4-carboxamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 7-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3,3-dimethylureido)benzyl)-1-methyl-6,7- dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'-oxetane]-3-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-methyl-1-(1-methylpiperidin-4-yl)-1H- pyrazole-4-carboxamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'- imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(4-methylpiperazin-1- yl)benzamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide• 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-methyl-4- morpholinobenzamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'- imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-(4-(dimethylamino)benzamido)benzyl)-7'-(4-(dimethylcarbamoyl)benzyl)- 6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-methylindoline-5-carboxamido)benzyl)- 6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • (R)-7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3- methylmorpholino)benzamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'- imidazo[1,5-a]pyrazine]-3'-carboxamide • (S)-7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3- methylmorpholino)benzamido)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'- imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(morpholinomethyl)benzamido)benzyl)- 6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(6-morpholinopicolinamido)benzyl)-6',7'- dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5-a]pyrazine]-3'-carboxamide • N-(4-(benzo[d][1,3]dioxole-5-carboxamido)benzyl)-7'-(4- (dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • N-(4-(2,2-difluorobenzo[d][1,3]dioxole-5-carboxamido)benzyl)-7'-(4- (dimethylcarbamoyl)benzyl)-6',7'-dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,5- a]pyrazine]-3'-carboxamide • N,N-dimethyl-4-((6'-(1-(4-(methylcarbamoyl)benzyl)-1H-1,2,3-triazol-4-yl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazin]-2'-yl)methyl)benzamide • N-(4-(4-(4-cyclopropylpiperazin-1-yl)-2-fluorobenzamido)benzyl)-7-(4- (dimethylcarbamoyl)benzyl)-6,7-dihydro-5H-spiro[imidazo[1,5-a]pyrazine-8,3'- oxetane]-3-carboxamide • 2'-(4-(dimethylcarbamoyl)-2,6-difluorobenzyl)-N-(4-(4- morpholinobenzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide• 2'-(4-(dimethylcarbamoyl)benzyl)-7'-fluoro-N-(4-(4- morpholinobenzamido)benzyl)-3',4'-dihydro-2'H-spiro[oxetane-3,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 7'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-morpholinobenzamido)benzyl)-6',7'- dihydro-5'H-spiro[cyclobutane-1,8'-imidazo[1,2-a]pyrazine]-3'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)nonanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N9-((S)-1-((2S,4R)-4- hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1- yl)-3,3-dimethyl-1-oxobutan-2-yl)nonanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-amido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(6-(4-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzoyl)piperazin-1-yl)hexanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-((S)-15-((2S,4R)-4-hydroxy-2-((4-(4- methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-16,16-dimethyl-13- oxo-4,7,10-trioxa-14-azaheptadecanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecan-18-amido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(7-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)piperazin-1-yl)heptanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5- yl)phenoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4- (4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan- 2-yl)amino)-2-oxoethyl)piperazin-1-yl)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-(4-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzoyl)piperazin-1-yl)pentanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)piperazin-1-yl)hexanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)pentanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(10-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)decanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)- 1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4- (4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan- 2-yl)amino)-3-oxopropyl)piperazin-1-yl)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N5-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)glutaramide• 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(6-(((S)-1-((2S,4R)-4-hydroxy-2- (((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)piperazin-1- yl)propanamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(4-(((S)-1-((2S,4R)-4-hydroxy-2-((4- (4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan- 2-yl)amino)-4-oxobutyl)piperazin-1-yl)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylphenyl)-1-oxo-5,8,11,14-tetraoxa-2-azaheptadecan-17- amido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(6-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)hexanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N8-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)octanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)ethoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)pentanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide• N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N10-((S)-1-((2S,4R)- 4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)decanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)hexanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)piperazin-1-yl)pentanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N5-((S)-1-((2S,4R)-4- hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1- yl)-3,3-dimethyl-1-oxobutan-2-yl)glutaramide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(9-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)nonanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)-3,6,9,12,15,18- hexaoxahenicosan-21-amido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)-3,6,9,12- tetraoxapentadecan-15-amido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N9-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)nonanediamide• 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(10-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)decanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N4-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)succinamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N4-((S)-1-((2S,4R)-4- hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1- yl)-3,3-dimethyl-1-oxobutan-2-yl)succinamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(3-(((S)-1-((2S,4R)-4-hydroxy-2- (((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)piperazin-1- yl)propanamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • rac-2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-(2-(((2R,4S)-4-hydroxy-1-(3- methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamido)methyl)-5- (4-methylthiazol-5-yl)phenoxy)ethoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)heptanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(11-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)amino)undecanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N15-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N1-(2-(2,6- dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-6,9,12-trioxa-3- azapentadecanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(4-(((S)-1-((2S,4R)-4-hydroxy-2- (((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutyl)piperazin-1-yl)propanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-((2-((2-(2,6-dioxopiperidin-3-yl)- 1,3-dioxoisoindolin-4-yl)amino)-2- oxoethyl)amino)ethoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(7-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)heptanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N11-((S)-1-((2S,4R)- 4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1- yl)-3,3-dimethyl-1-oxobutan-2-yl)undecanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(10-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)amino)decanamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(2-(4-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzoyl)piperazin-1-yl)acetamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4- (4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan- 2-yl)amino)-3-oxopropoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N6-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)adipamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(8-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)octanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N6-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1- yl)-3,3-dimethyl-1-oxobutan-2-yl)adipamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(7-(4-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzoyl)piperazin-1-yl)heptanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzoyl)piperazin-1-yl)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)undecanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)amino)propanamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N21-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N1-(2-(2,6- dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-6,9,12,15,18-pentaoxa-3- azahenicosanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)butanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N8-((S)-1-((2S,4R)-4- hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1- yl)-3,3-dimethyl-1-oxobutan-2-yl)octanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(4-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzoyl)piperazin-1-yl)butanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(7-(((S)-1-((2S,4R)-4-hydroxy-2-((4- (4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan- 2-yl)amino)-7-oxoheptyl)piperazin-1-yl)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide• 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(11-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)undecanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(5-(((S)-1-((2S,4R)-4-hydroxy-2- (((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)piperazin-1- yl)propanamido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2- a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(3-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)- 1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl- 1-oxobutan-2-yl)amino)-3-oxopropoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(7-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)heptanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4- methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2- yl)amino)-3-oxopropoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(2-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)piperazin-1-yl)acetamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(8-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)amino)octanamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylphenyl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-amido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-(2-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5- yl)phenoxy)ethoxy)ethoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(7-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)amino)heptanamido)benzyl)-3',4'-dihydro- 2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(8-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)octanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylphenyl)-1-oxo-5,8,11,14,17-pentaoxa-2-azaicosan-20- amido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'- carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(2-(((S)-1-((2S,4R)-4-hydroxy-2- (((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)amino)-2-oxoethyl)piperazin-1-yl)propanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(1-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)-3,6,9,12,15- pentaoxaoctadecan-18-amido)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane-1,1'- pyrrolo[1,2-a]pyrazine]-6'-carboxamide • rac-2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-(((2R,4S)-4-hydroxy-1-(3- methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamido)methyl)-5- (4-methylthiazol-5-yl)phenoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(6-(((S)-1-((2S,4R)-4-hydroxy-2-((4- (4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)piperazin-1-yl)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(2-(2-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5- yl)phenoxy)ethoxy)ethoxy)propanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(3-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)-2-oxoethyl)piperazin-1-yl)propanamido)benzyl)-3',4'- dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N7-((S)-1-((2S,4R)-4- hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1- yl)-3,3-dimethyl-1-oxobutan-2-yl)heptanediamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N12-((S)-1-((2S,4R)- 4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)dodecanediamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(11-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)undecanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(4-(2-(((2S,4R)-1-((S)-2-(1- fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine- 2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)butanamido)benzyl)- 3',4'-dihydro-2'H-spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(5-(3-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)-4-methylbenzamido)pentanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide • N1-(4-((2'-(4-(dimethylcarbamoyl)benzyl)-3',4'-dihydro-2'H-spiro[cyclobutane- 1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamido)methyl)phenyl)-N7-((S)-1-((2S,4R)-4- hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)heptanediamide• 2'-(4-(dimethylcarbamoyl)benzyl)-N-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)octanamido)benzyl)-3',4'-dihydro-2'H- spiro[cyclobutane-1,1'-pyrrolo[1,2-a]pyrazine]-6'-carboxamide 38. A pharmaceutical composition comprising a heterocyclic compound as defined in any one of the preceding claims, and a pharmaceutically acceptable carrier or diluent.

39. A pharmaceutical composition according to claim 38, for use as a medicament.

40. A heterocyclic compound for use according to any one of claims 1 to 37, or the composition for use of claim 39, wherein the heterocyclic compound or composition is for use in a method of treating a condition or disease selected from atopic dermatitis, eczema, nummular eczema, allergic contact dermatitis, chronic hand eczema, hand and foot dermatitis, bullous pemphigoid, chronic spontaneous urticaria, cholinergic urticaria, chronic cold-induced urticaria, prurigo nodularis, chronic pruritus, Netherton syndrome, alopecia areata, lichen sclerosus, asthma, allergic rhinitis, chronic rhinosinusitis, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic chronic sinusitis, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis, eosinophilic gastritis, ulcerative colitis, chronic hepatic pruritus, food allergies, atopic keratoconjunctivitis, localized scleroderma, fibrotic diseases, keloids, systemic sclerosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, liver fibrosis, eosinophilic fasciitis, eosinophilic otitis media, solid tumors and hematological cancers including cutaneous cell lymphoma (CTCL), Sezary syndrome (SS), Hodgkin lymphomas, primary mediastinal and primary central nervous system lymphoma, follicular and T cell lymphomas, preferably, the condition or disease is selected from atopic dermatitis, asthma, chronic spontaneous urticaria and purigo nodularis.

41. Use of a heterocyclic compound as defined in any one of claims 1 to 37, or the composition as defined in claim 38, in the manufacture of a medicament for treating a condition or disease selected from atopic dermatitis, eczema, nummular eczema, allergic contact dermatitis, chronic hand eczema, hand and foot dermatitis, bullous pemphigoid, chronic spontaneous urticaria, cholinergic urticaria, chronic cold-induced urticaria, prurigo nodularis, chronic pruritus, Netherton syndrome, alopecia areata, lichen sclerosus, asthma, allergic rhinitis, chronic rhinosinusitis, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic chronic sinusitis, chronic obstructive pulmonary disease (COPD), eosinophilicesophagitis, eosinophilic gastritis, ulcerative colitis, chronic hepatic pruritus, food allergies, atopic keratoconjunctivitis, localized scleroderma, fibrotic diseases, keloids, systemic sclerosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, liver fibrosis, eosinophilic fasciitis, eosinophilic otitis media, solid tumors and hematological cancers including cutaneous cell lymphoma (CTCL), Sezary syndrome (SS), Hodgkin lymphomas, primary mediastinal and primary central nervous system lymphoma, follicular and T cell lymphomas, preferably, the condition or disease is selected from atopic dermatitis, asthma, chronic spontaneous urticaria and purigo nodularis.

42. A method of treating a condition or disease selected from atopic dermatitis, eczema, nummular eczema, allergic contact dermatitis, chronic hand eczema, hand and foot dermatitis, bullous pemphigoid, chronic spontaneous urticaria, cholinergic urticaria, chronic cold-induced urticaria, prurigo nodularis, chronic pruritus, Netherton syndrome, alopecia areata, lichen sclerosus, asthma, allergic rhinitis, chronic rhinosinusitis, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic chronic sinusitis, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis, eosinophilic gastritis, ulcerative colitis, chronic hepatic pruritus, food allergies, atopic keratoconjunctivitis, localized scleroderma, fibrotic diseases, keloids, systemic sclerosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, liver fibrosis, eosinophilic fasciitis, eosinophilic otitis media, solid tumors and hematological cancers including cutaneous cell lymphoma (CTCL), Sezary syndrome (SS), Hodgkin lymphomas, primary mediastinal and primary central nervous system lymphoma, follicular and T cell lymphomas, in a subject, the method comprising administering to said subject a therapeutically effective amount of a heterocyclic compound as defined in any one of claims 1 to 37, or the composition of claim 38, preferably, the condition or disease is selected from atopic dermatitis, asthma, chronic spontaneous urticaria and purigo nodularis.

43. A compound which compound is (a) a heterocyclic compound of formula (I'), wherein R1, R2, G1, G2, Y, X1, X2, X3, X4, L1, Ra, Rb, Rc, Rd, Re, Rf, m and n are as defined in any one of claims 1 to 37; or (b) a pharmaceutically acceptable salt, or a solvate, or a N-oxide, or a tautomer, or a stereoisomer, or an isotopically-labelled derivative of said heterocyclic compound,provided that said compound is not: [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5- fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol- 5(1H)-yl]methanone; [3-[[5-Fluoro-2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[(2-Ethyl-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1-piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1-piperazinyl]methanone; [3-[(2-Ethyl-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(2-methoxyethyl)-2,5-dimethyl-1-piperazinyl]methanone; [3-[[5-Fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(2- ethyl-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol- 5(1H)-yl]methanone;[(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[[5- fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(2- ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol- 5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[[2- (ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl][3-[(2-ethoxy- 5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl][3-[[2- (ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [4,6-Dihydro-6,6-dimethyl-3-[[4-(trifluoromethyl)-2-pyrimidinyl]amino]pyrrolo [3,4-c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1- piperazinyl]methanone; [4,6-Dihydro-6,6-dimethyl-3-[(4-methyl-2-pyrimidinyl)amino]pyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1- piperazinyl]methanone; [4,6-Dihydro-6,6-dimethyl-3-[(4-methyl-2-pyrimidinyl)amino]pyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1- piperazinyl]methanone; [4,6-Dihydro-3-[(4-methoxy-2-pyrimidinyl)amino]-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1- piperazinyl]methanone; [3-[[2-(Ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[[2-(Ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethyl pyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5S)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]methanone;[3-[(5-Fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo [3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-hydroxypropyl)-2,5-dimethyl-1-piperazinyl] methanone; [3-[(5-Fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo [3,4-c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl] methanone; [3-[(5-Fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[[2-(Ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(2-methoxyethyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[(4-Ethoxy-2-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1-piperazinyl]methanone; [3-[(5-Fluoro-2-methoxy-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[(5-Fluoro-2-methoxy-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[[5-Fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[[5-Fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl]methanone;[(2S,5R)-2,5-Dimethyl-4-(3,3,3-trifluoropropyl)-1-piperazinyl][3-[(2-ethyl-5- fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][1-(3,3,3-trifluoropropyl)-4-piperidinyl]methanone; [(2S,5R)-2,5-Dimethyl-4-(3,3,3-trifluoropropyl)-1-piperazinyl][3-[[2-(ethylamino)- 5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(3,3,3-trifluoropropyl)-1-piperazinyl][3-[(2-ethoxy-5- fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl][3-[(5-fluoro-2- methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; Methanone, bis[3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]-, hydrate (1:1); Methanone, bis[3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]-, with 2-propanol (1:1); [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-1- piperazinyl][3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-1- piperazinyl][3-[(2-ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [3-[(4,6-Dimethyl-2-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1- piperazinyl]methanone; [4,6-Dihydro-3-[(4-methoxy-2-pyrimidinyl)amino]-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1- piperazinyl]methanone; Methanone, [3-[[2-(ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]-, acetate (1:1);[3-[(2-Ethoxy-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1-piperazinyl]methanone; [2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5-fluoro-2- methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; Methanone, [3-[(2,5-difluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl pyrrolo[3,4-c]pyrazol-5(1H)-yl][(2R,5S)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4- yl)methyl]-1-piperazinyl]-, relative stereochemistry; Bis[3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo [3,4- c]pyrazol-5(1H)-yl]methanone; or [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S)-2-methyl-4-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-1- piperazinyl]methanone.

44. A compound according to claim 43, wherein said heterocyclic compound is other than: [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5- fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol- 5(1H)-yl]methanone; [3-[[5-Fluoro-2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[(2-Ethyl-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1-piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1-piperazinyl]methanone; [3-[(2-Ethyl-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(2-methoxyethyl)-2,5-dimethyl-1-piperazinyl]methanone; [3-[[5-Fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone;[3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(2- ethyl-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol- 5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[[5- fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(2- ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol- 5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[[2- (ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl][3-[(2-ethoxy- 5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl][3-[[2- (ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [4,6-Dihydro-6,6-dimethyl-3-[[4-(trifluoromethyl)-2-pyrimidinyl]amino]pyrrolo [3,4-c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1- piperazinyl]methanone; [4,6-Dihydro-6,6-dimethyl-3-[(4-methyl-2-pyrimidinyl)amino]pyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1- piperazinyl]methanone; [4,6-Dihydro-6,6-dimethyl-3-[(4-methyl-2-pyrimidinyl)amino]pyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1- piperazinyl]methanone; [4,6-Dihydro-3-[(4-methoxy-2-pyrimidinyl)amino]-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1- piperazinyl]methanone;[3-[[2-(Ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[[2-(Ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethyl pyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5S)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[(5-Fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo [3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-hydroxypropyl)-2,5-dimethyl-1-piperazinyl] methanone; [3-[(5-Fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo [3,4-c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl] methanone; [3-[(5-Fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[[2-(Ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-4-(2-methoxyethyl)-2,5-dimethyl-1- piperazinyl]methanone; [3-[(4-Ethoxy-2-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1-piperazinyl]methanone; [3-[(5-Fluoro-2-methoxy-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[(5-Fluoro-2-methoxy-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[[5-Fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[[5-Fluoro-2-(methoxymethyl)-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4-dimethyl-1- piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl]methanone;[3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5S)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-5-(2-hydroxyethyl)-2,4-dimethyl-1-piperazinyl]methanone; [(2S,5R)-2,5-Dimethyl-4-(3,3,3-trifluoropropyl)-1-piperazinyl][3-[(2-ethyl-5- fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][1-(3,3,3-trifluoropropyl)-4-piperidinyl]methanone; [(2S,5R)-2,5-Dimethyl-4-(3,3,3-trifluoropropyl)-1-piperazinyl][3-[[2-(ethylamino)- 5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(3,3,3-trifluoropropyl)-1-piperazinyl][3-[(2-ethoxy-5- fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; [(2S,5R)-2,5-Dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl][3-[(5-fluoro-2- methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; Methanone, bis[3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]-, hydrate (1:1); Methanone, bis[3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]-, with 2-propanol (1:1); [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-1- piperazinyl][3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-1- piperazinyl][3-[(2-ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl]methanone; [3-[(4,6-Dimethyl-2-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1- piperazinyl]methanone; [4,6-Dihydro-3-[(4-methoxy-2-pyrimidinyl)amino]-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1- piperazinyl]methanone;Methanone, [3-[[2-(ethylamino)-5-fluoro-4-pyrimidinyl]amino]-4,6-dihydro-6,6- dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1- piperazinyl]-, acetate (1:1); [3-[(2-Ethoxy-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S,5R)-4-(3-methoxypropyl)-2,5-dimethyl-1-piperazinyl]methanone; [2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5-fluoro-2- methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)- yl]methanone; Methanone, [3-[(2,5-difluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl pyrrolo[3,4-c]pyrazol-5(1H)-yl][(2R,5S)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4- yl)methyl]-1-piperazinyl]-, relative stereochemistry; Bis[3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo [3,4- c]pyrazol-5(1H)-yl]methanone; or [3-[(2-Ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4- c]pyrazol-5(1H)-yl][(2S)-2-methyl-4-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-1- piperazinyl]methanone.

Images